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INTRODUCTION 
Overview of Kir channels in humans 
Potassium channels represent an important and evolutionary conserved family of ion 
channels expressed in all living cells. Inward rectifier potassium (Kir) channels are a class of 
potassium channels expressed in a variety of excitable and non-excitable cells. They play 
essential roles in the regulation of various physiological processes ranging from maintaining the 
resting membrane potential, cardiac and neuronal excitability, epithelial transport, metabolic 
homeostasis, muscle contraction, and cellular signaling [1-4]. Given the important physiological 
roles of Kir channels and genetic evidences that disease-causing mutations affecting these 
channels cause numerous diseases [3,5], Kir channel have emerged as important therapeutic 
targets. Here, we will briefly describe some features of human Kir channel subtypes focusing on 
their molecular characteristics, functions and pharmacology. 
 
Molecular structure and functions of Kir channels 
The inward rectifier family of potassium (Kir) channels encoded by the KCNJx genes is 
comprised of at least sixteen members, which play essential physiological roles in modulating 
the functions of most organ systems [1,3,4]. This gene family is further subdivided in seven 
groups (Kir1.x to Kir7.x) based on amino acid sequence homology. High-resolution X-ray 
crystal structures reveal that Kir channels exhibit a simple structural topology characterized by 
N- and C-terminus cytoplasmic domains, two transmembrane-spanning domains (TM1 and 
TM2), and a pore-forming loop containing the conserved K+ selectivity filter (SF) sequence—
GYG [1,6,7] (Fig. 1A). With the exception of ATP-sensitive Kir (KATP) channels, which form 
2!!
octomeric complexes of Kir6.x and sulfonylurea receptors (SURx) [8], Kir channels generally 
assemble as tetrameric complexes constituted of identical (homomers) or different (heteromers) 
Kir subunits. This tetrameric assembly of Kir channels creates a water-filled pore permitting the 
movement of K+ ions down their electrochemical gradient and across the cell membrane (Fig. 
1A, B). In other terms, under physiological conditions, Kir channels conduct K+ ions from the 
inside to the outside of cell as result of the difference between intracellular and extracellular 
concentration of K+ ions. 
Unlike voltage-gated potassium (Kv) channels, Kir channels do not possess a voltage-
sensing domain, but exhibit a voltage-dependent decrease in currents. By convention, the 
movement of K+ ions inside a cell generates an inward current, whereas K+ ions efflux generates 
an outward current. The voltage-dependent decrease in outward current is called “rectification” 
and results from a physical block of Kir channels by intracellular divalent cations such as 
magnesium and polyamines (e.g. putrescine, spermine and spermidine) [9]; thus, the term 
“inward rectification” (Fig. 1C). Because of the physical property of inward rectification, Kir 
channels exhibit typically larger inward currents at hyperpolarized potentials (more negative than 
the Nerst potential for potassium, EK) as compared to outward currents. Furthermore, Kir 
channels display various degrees of inward rectification between family members, which are 
broadly classified as “strong” or “weak” rectification. This unique rectification property of Kir 
channels contributes to potassium homeostasis in different tissues and organ systems (Fig. 1C). 
In general, strong inward rectifiers are expressed in excitable cells such as neurons and muscle 
cells, whereas weak inward rectifiers are expressed in epithelial and other non-excitable cell 
types [1]. The physiological importance of Kir channel rectification in humans will be explored 
next. 
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“Strong” inward rectifier Kir channels 
Inward rectifier Kir channels exhibiting strong rectification include Kir2.x and G-protein 
coupled inward rectifier (GIRK) channels. Strong rectifiers are primarily expressed in excitable 
cells, such as the heart or neurons where they play essential roles in modulating cell excitability. 
The Kir2.x family is comprised of Kir2.1 (KCNJ2), Kir2.2 (KCNJ12), Kir2.3 (KCNJ4), Kir2.4 
(KCNJ14) and Kir2.6 (KCNJ18) subunits. Kir2.x channels are expressed primarily in excitable 
cells such as the cardiac, neuronal and skeletal muscle cells, with lesser expression reported in 
the kidney and smooth muscle cells [1]. In cardiac myocytes, Kir2.x underlies constitutively 
active currents also known as cardiac inward rectifying current (IK1), which contributes to setting 
the resting membrane and shaping the cardiac action potential—notably, the initial 
depolarization and final repolarization phases [1,10,11].  While Kir2.1 and Kir2.2 are the major 
forms in the ventricular cardiomyocytes [12], atrial cardiomyocytes are enriched with Kir2.3 
subunits. GIRK channels are expressed predominantly in the heart and nervous system, and 
comprised of Kir3.1 (KCNJ3), Kir3.2 (KCNJ6), Kir3.3 (KCNJ9) and Kir3.4 (KCNJ5) subunits 
[1]. In the heart, GIRK channels are expressed predominantly as heteromeric complexes 
composed of Kir3.1and Kir3.4 subunits, which are localized primarily in atrial myocytes [13,14].  
In the nervous system, heteromeric GIRK channels are primarily formed by Kir3.1 and Kir3.2 
subunits. In the absence of agonists, GIRK channels are in a “closed state” and therefore, 
contribute little to the resting membrane potassium conductance and potential of cells. However, 
the activation of G-protein coupled receptors by various neurotransmitters (e.g. acetylcholine, 
dopamine) induced through a pertussis toxin-sensitive pathway causes the opening of GIRK 
channels via the G!" of the heterotrimeric G-proteins.  In the heart, M2 muscarinic receptors 
activation following the release of acetylcholine upon sympathetic stimulation leads to opening 
4!!
of GIRK channels, resulting in potassium efflux, membrane hyperpolarization and consequently 
bradycardia. Defects in Kir channel functions affecting Kir2.x and GIRK channels cause various 
forms of cardiac arrhythmias, such as Anderson-Tawil syndrome and atrial fibrillation, as well as 
neurological disorders such as epilepsy and addiction [1,15]. Therefore, strong rectifiers are 
putative drug targets for the development of novel therapeutics for these pathological conditions. 
In particular, an emerging body of evidences suggests that Kir2.3 and Kir3.1/3.4, which are 
involved in atrial fibrillation, represent attractive targets for developing antiarrhythmic therapies 
without the ventricular side effects commonly associated with current therapeutics [16,17]. We 
have begun to investigate this possibility by identifying novel modulators of Kir2.3 and GIRK 
channels (see Chapter III). 
 
“Weak” inward rectifier Kir channels 
Inward rectifying Kir channels exhibiting weak rectification include members of the 
Kir1.1, Kir4.x, Kir5.1, Kir6.x and Kir7.1 families. As opposed to strong rectifiers, weak 
rectifiers display a high channel open probability across a wide range of membrane potentials. 
Consequently, weak rectifiers exhibit a relatively large current in both the inward and outward 
directions as compared to strong rectifiers (Fig. 1C).  
Kir1.1: The founding member of the Kir channel family Kir1.1 (KCNJ1) is 
predominantly expressed in the kidney, although it is also reported in the brain (i.e. cortex and 
hippocampus) [1,18]. Kir1.1 plays a crucial role in the kidney by regulating salt and water 
balance, and thus blood pressure. Disease-causing mutations affecting this channel, such as 
autosomal recessive mutations, lead to Bartter syndrome, a condition characterized by Na+ and 
K+ salt wasting, excessive urination, low to normal blood pressure and metabolic alkalosis [19]. 
5!!
Kir1.1 represents a novel diuretic target, which has prompted the development of novel small-
molecule modulators by our laboratory and others [20-22].  
Kir4.x/Kir5.1: The Kir4.x family is comprised of Kir4.1 (KCNJ10) and Kir4.2 (KCNJ15) 
subunits.  Kir4.1 is expressed predominantly in brain and spinal cord astrocytes, retinal Müller 
glia, stria vascularis and glia of the inner ear, and renal tubule epithelial cells. Consistent with its 
localization, targeted deletion of KCNJ10 in mice produces severe motor impairment, deafness, 
and premature death [23-27]. In the central nervous system, Kir 4.1 functions contribute to 
spatial buffering (clearance) of K+ ions in the astrocytes as the result of neuronal activity. Kir4.1 
is important for Na+ reabsorption in the distal convoluted tubule of the kidney [4]. Similarly to 
Kir4.1, Kir4.2 encoded by KCNJ15 is also found in the brain and kidney. The recent discovery 
[28,29] of loss-of-function mutations in KCNJ10 in patients with SeSAME (Seizures, 
Sensorineural deafness, Ataxia, Mental impairment, Electrolyte imbalance) or EAST (Epilepsy, 
Ataxia, Sensorineural deafness, salt-wasting Tubulopathy) syndrome suggests that Kir4.1 may 
represent a new target for the development of novel therapeutic approaches for neurological and 
hypertensive abnormalities. The development of in vitro assays to identify novel modulators of 
Kir4.1 is discussed in Chapter IV.   Kir5.1 encoded by KCNJ16 assembles only with Kir4.x 
subunits to form functional channels. It is expressed primarily in the brain and kidney. 
Kir6.x:  The Kir6.x family is comprised of Kir6.1 (KCNJ8) and Kir6.2 (KCNJ11) 
subunits. Kir6.1 and Kir6.2 form adenosine triphosphate (ATP)–sensitive Kir (KATP) channels, 
which modulate important functions in nerve, muscle, epithelial, and endocrine tissue physiology 
by integrating cellular metabolism and membrane excitability [30]. KATP channels assemble in 
octomeric complexes of four pore-forming Kir6.x inward rectifier K+ (Kir) channel subunits and 
four regulatory SURx sulfonylurea receptor subunits [8]. SUR1 is encoded by ABCC8, while 
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SUR2A and SUR2B (ABCC9) are splice variants of the same gene. The three major channel 
subtypes created by different subunit combinations exhibit distinctive biophysical, regulatory, 
and pharmacological properties, as well as cell type-specific expression [1,31,32].  KATP 
channels are validated targets for disorder of glucose homeostasis, such as neonatal and adult-
onset diabetes and hyperinsulemia, hypertension and cardiac arrhythmias [1,2]. We discussed in 
Chapter V, the discovery of a new modulator of KATP channels that could lead to the 
development of new therapeutics for glucose disorders, which would lack side-effects associated 
with common treatments. 
Kir7.1: Kir7.1 encoded by KCNJ13 is expressed in various organ systems including, the 
brain, eyes, thyroid, the gut and kidney [1]. As opposed to most Kir channels, Kir7.1 exhibits a 
low single channel conductance in the order of femtosiemens (i.e. ~50 fS). Kir7.1 channels 
dysfunction is associated with instance of snowflake vitreoretinal degeneration [1,3]. While our 
knowledge on Kir7.1 channel functions remains limited, recent evidence suggests that it could 
represent a novel target for post-partum hemorrhage (Jerod Denton, personal communication).  
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Figure 1. Overall Kir channel structure and characteristic currents.! (A) Left panel. 
Schematic of a Kir channel subunit indicating the cytoplasmic N- and C-terminus domains, two 
transmembrane-spanning domains (TM1 and TM2) and the pore-forming loop with selectivity 
filter (SF). Right panel. Schematic of the tetrameric complex formed between homomeric Kir 
channel subunits. Potassium ions passing through the pore is indicated in red. (B) Homology 
model of the Kir1.1 channel. Two of the subunits are removed for clarity. Key strucutres are 
indicated as TM1 and TM2, SF and the G-loop. Adapted from Bhave et al., Future Med Chem. 
2010 May;2(5):757-74. (C) Representative current-voltage relationships of Kir channel depicting 
currents generated by strong (red) and weak (blue) rectifiers. A schematic illustrating various 
stages of Kir channel current is shown as (1) inward current, (2) outward current and (3) pore 
block by divalent cations or polyamines.! !
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Figure 2. Tissue distribution of Kir channel subunits.! The tissue-specific distribution of the 
Kir channels suggests that they play an important role in ion homeostasis and disease. Kir 
channel subunits are indicated by light blue within the membrane structure. All other possible 
associated channels, transporters and regulatory molecules are also shown in the membrane that 
controls cellular physiology. Kir channel tissue distribution along with their respective 
physiopathology is color-coded (Kir1.1 — orange; Kir2.1 — blue; Kir4.1 — purple; Kir6.2 — 
green and Kir7.1 — red). Abbreviations: Kir, inwardly rectifying potassium channel; SUR, 
regulatory sulfonylurea receptor subunit; ATP, adenosine tri-phosphate; ADP, adenosine di-
phosphate; RPE, retinal pigment epithelium; PIP2, phosphatidylinositol (4,5)-bisphosphate; TAL, 
thick ascending limb. From Pattnaik, BR et al., Mol Genet Metab. 2012 Jan;105(1):64-72. 
Reproduced with authorization from Elsevier Science. License Number: 3363801001931.!!
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Pharmacology of Kir channels 
  While Kir channels have been suggested to represent important targets to for the 
development of novel therapeutics associated with channel dysfunction, pharmacological tools to 
investigate their functions and druggability are still limited. Indeed, the small-molecule 
pharmacology around the Kir channel family is largely comprised of weak and non-selective 
modulators. Shown in Table 1 is reviewed a list, which is not exhaustive, of few modulators of 
Kir channels mostly representative of cardiovascular and neurological targets—exhibiting weak 
potency and non-tissue specific effects, as well as recently discovered small-molecules which 
result from high-throughput screening efforts. 
 !  
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Table 1. Kir channel modulators. Listed alphabetically with structure as indicated. IC50 or EC50 
values accompanied by percent maximal inhibition/activation observed in parentheses. * 
indicates results obtained with heterologous expression in Xenopus oocytes which have been 
reported by some authors to yield significantly higher IC50 values when compared to mammalian 
cells [33].**indicates results obtained from thallium flux experiments. Adapted from Bhave G. et 
al., Future Med Chem.2010 May: 2(5): 757-74. 
Compound Structure Kir Target IC50/EC50 
(Max) 
Selectivity Refs. 
30 ! Kir1.1 30-49a nM 
> Kir 2.1, 2.3 
>> Kir4.1, 
Kir7.1 
Known hERG 
blocker 
[34] 
Amiodarone ! IKACh 
1.8-2.4 µM 
(100%) 
 
Known 
voltage gated 
Na, K, and Ca 
channel 
blocker 
[35] 
AVE0118 ! IKACh 
4.5 µM 
(100%) 
 
Known 
voltage gated 
K channel 
blocker 
[36] 
Bupivicaine ! Kir3 
22-170* 
µM 
G!" & 
voltage 
dependent 
(100%) 
> Kir 1.1, 2.1 
Known 
voltage gated 
Na & K 
channel 
blocker 
[37] 
Chloroethylclonid
ine ! Kir2.1 37 µM (100%) Known #2 adrenergic agonist [38] 
Chloroquine ! Kir2.1 
8.7 µM; 
voltage 
dependent 
(100%) 
Unknown [39] 
Diazoxide 
(Kir activator) ! Kir6.2/SUR1 31 µM (100%) >Kir6.2/SUR2B, Kir6.2/SUR2A [40] 
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Diphenhydramine ! Kir2.3 689 µM* (~80%) 
> Kir 2.1 
Known anti-
histamine 
[41] 
Dronedarone 
!
IKACh 
 
10-63 nM 
(100%) 
Known 
voltage gated 
Na, K, and Ca 
channel 
blocker 
[42] 
Ethosuximide ! Kir3 0.4-3.5* mM  (61-76%) 
> Kir 1.1, 2.1 
Known 
voltage gated 
Ca & Na 
channel 
blocker 
[43] 
Flecainide 
(Kir activator) !
Kir2.1 0.8 µM (22%) 
>Kir2.2, 
Kir2.3, 
Kir2.1/2.2, 
Kir2.1/2.3 
[44] 
Fluoxetine 
 !
Kir3 
 
Kir4.1 
7-13* µM 
(58-74%) 
15.2 µM 
(100%) 
> Kir 1.1, Kir 
2.1 
Known SSRI 
[45,
46] 
Halothane ! Kir3 60 µM* (100%) Unknown [47] 
JTV-519 ! IKACh 0.1-2.5 µM (100%) 
Known 
voltage gated 
Ca, Na, and K 
channel 
blocker 
[48] 
ML297 
(Kir activator) !
Kir3.1/3.2 0.54 µM 
(100%) 
>Kir3.1/3.4>
>Kir3.2/3.3, 
Kir2.1 
[49] 
ML133 ! Kir2.1 0.3b-1.9µM (100%) > Kir2.6, 2.2, 2.3, 6.2 >>4.1, 7.1, 1.1 (>300) [50] 
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Mepyramine !
Kir2.3 
Kir3.4 
306 µM* 
(~80%) 
< 300 µM* 
(Unknown) 
> Kir 2.1 
Known anti-
histamine 
[41] 
Nicorandil 
(Kir activator) ! Kir6.2/SUR2B 10 µM (100%) >Kir6.2/SUR2A [51] 
NIP-142 ! Kir3.1/3.4 0.64 µM (100%) 
Unknown 
Blocks Kv1.5 
with similar 
potency 
[33] 
NIP-151 Structure unavailable Kir3.1/3.4 1.6 nM 
(100%) 
Unknown 
HERG IC50 
58 µM 
[52] 
NN414 
(Kir activator) ! Kir6.2/SUR1 0.45 µM (100%) >SUR2-containing KATP [40] 
Nortriptyline ! Kir4.1 38 µM > Kir 1.1, 2.1 [53] 
P1075 
(Kir activator) !
Kir6.1-
6.2/SUR2B 
+ 
Kir6.2/SUR2
B 
0.16 µM 
(100%) 
>Kir6.1/SUR
2A, 
Kir6.2/SUR1 
>>Kir6.1/SU
R1 
[54] 
PNU-37883A 
(Kir activator) !
 
Kir6.1/SUR2
B 
Kir6.2/SUR2
B 
6 µM 
(60%) 
 
15 µM 
(80%) 
>Kir6.2/SUR
1, 
Kir6.2/SUR2
A 
[55] 
Pentamidine ! Kir2.1 0.2 µM (100%) >Kir2.2, Kir2.3 [56] 
Pinacidil 
(Kir activator) !
Kir6.2/SUR2
A 
Kir6.2/SUR2
B 
~2 µM 
(100%) 
 
~10 µM 
(100%) 
> SUR1-
containing 
KATP 
[51] 
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Pregnenolone 
sulfate 
(Kir activator) ! Kir2.3 16 µM
* 
(80%) 
> Kir1.1, 2.1, 
3.1/3.2 [43] 
SCH23390 ! Kir3 0.3-8 µM (100%) Known D1 receptor antagonist [57] 
Tamoxifen 
!
Kir2 0.3-0.9 µM 
(100%) 
Unknown 
Known 
estrogen 
receptor 
antagonist 
[58] 
Tenidap 
(Kir activator) !
Kir2.3 1.3 µM 
(100%) 
> Kir 2.1 
 
[59] 
Thioridazine ! Kir3 
58 µM 
(92%) 
 
Unknown 
Known anti-
psychotic 
[60] 
Tricyclic 
Antidepressants 
(Nortriptyline) !
Kir3 
 
Kir4.1 
18-71* µM 
(53-76%) 
 
16-38 µM; 
voltage 
dependent 
(100%) 
> Kir 1.1, 2.1 [53,61] 
U50488H ! Kir3 70 µM* (100%) 
Known $ 
opioid 
receptor 
agonist 
[62] 
VU0071063 
(Kir activator) ! Kir6.2/SUR1 7 µM (100%) 
> 
Kir6.1/SUR1 
>> 
Kir6.1/SUR2
A, 
Kir6.2/SUR2
A 
[63] 
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VU573 
!
Kir2.3 
 
Kir3.x 
 
Kir7.1 
0.8 µM 
(70%) 
 
 
1.3 µM 
(80%) 
 
 
0.9 µM 
(70%) 
> Kir1.1, 
Kir2.1 [64] 
VU590 
!
Kir1.1 0.29 µM ** 
(100%) 
> Kir7.1 [20] 
VU591 ! Kir1.1 0.30 µM ** (100%) > Kir2.1, Kir2.3, Kir4.1 [21] 
VU717 ! Kir4.1 6-10** µM  (100%) Unknown [65] 
Vernakalant ! IKACh 10 µM (100%) 
Known 
blocker of 
multiple 
voltage gated 
Na and K 
channels 
[42] 
!
a At pH 8.5.!
b Obtained from 86Rb+ assay.  
 !!
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Overview of Kir channels in mosquitoes 
Vector-borne diseases, which are transmitted by infected female mosquitoes, such as 
malaria, yellow and dengue fevers or Chikungunya virus represent a major public health concern 
to more than half of the world’s population. Current vector control strategies rely mostly on 
insecticide-treated bed nets and indoor residual spraying with pyrethroids, the dominant class of 
chemicals used as insecticides worlwide [66]. However, mounting evidences suggest that these 
strategies are becoming less effective because of the emergence of insecticide resistance in 
mosquito populations [67]. Furthermore, the efforts of public health organizations in endemic 
countries to curve the transmission of vector-borne diseases is greatly hindered by the fact that 
no new insecticides has been developed in the past 30 years [68]. Therefore, there is an urgent 
need to develop new and effective insecticides for implementing new control strategies.  
In an effort to develop new chemicals for insecticidal use, and thus new vector control 
strategies, our laboratory has focused on targeting mosquito Kir channels. By engorging more 
than twice their own body weight in blood, mosquitoes are exposed to high physiological 
pressures to rapidly handle the excess fluid volume and salts (i.e. NaCl, KCl) from their 
hemolymph before succumbing as a result of their toxic effects. Therefore, mosquitoes possess 
an efficient excretory system, which include the Malpighian (renal) tubules and hindgut, 
involved in osmoregulation and urine excretion [69-71]. A barium sensitive-potassium 
conductive pathway was shown to play a critical role in fluid and salt excretion in isolated 
Malpighian tubules experiments [72,73].  These results suggested in part that Kir channels would 
be involved in osmoregulatory processes and could play other important functions in mosquito 
physiology. The aforementioned evidences have warranted for further investigations of the Kir 
channel functions in mosquitoes, and their target potential for insecticide development.  
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Molecular structure and functions of Kir channels 
The genome of the Aedes aegypti, vector of the yellow and dengue fevers, contains five 
genes encoding putative Kir channels termed, AeKir1, AeKir2A, AeKir2B, AeKir2B’ and 
AeKir3.The first A. aegypti Kir channels were recently cloned, notably Kir1, Kir2B and Kir3 
subunits, and functionally characterized in Xenopus laevis oocytes [74]. Amino acid sequence 
alignments between human and mosquito Kir channels reveal similar conserved canonical 
features including two TMs and a GYG containing SF (refer to Fig. 1). With the exception of 
Kir3, both Kir1 and Kir2B form functional channels in oocytes exhibiting barium-sensitive 
currents. AeKir1 expressing oocytes exhibit large inward rectifying currents (reminiscent of 
strong rectifiers), which are modulated by extracellular concentrations of K+ and Na+ ions. On 
the other hand, AeKir2B expressing oocytes exhibit weaker rectification and smaller inward 
rectifying currents, which are modulated by extracellular concentrations of K+ ions (Table 2). To 
date, the mRNA expression of A. aegypti Kir genes has been detected using semi-quantitative 
RT-PCR in various tissues ranging from the Malpighian (renal) tubules, midgut, hindgut and 
head (Table 2) [75]. In vivo studies reveal that A. aegypti Kir channels are involved in 
physiological processes of osmoregulation and K+ homeostasis. In Chapter VII, we discussed 
the cloning and functional characterization of the malaria vector, Anopheles gambiae Kir1 
(AaKir1) channels and its possible implication in mosquito fecundity. 
!  
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Table 2. Summary of qualitative assessment of Aedes aegypti Kir channel functions and 
tissue distributions. Functional expression was determined in Xenopus laevis oocytes as per 
current amplitude. Qualitative RT-PCR was used to determine tissues distribution. Functional 
and tissue distribution was scored as followed: +++, high; ++, moderate; +, low; #, no expression. 
ND, not determined; N/A, not applicable. Adapted from Piermarini PM et al, Insect Biochem 
Mol Biol. 2013 Jan; 43(1):75-90.!
Kir channels Functional expression Rectification property Tissue distribution of 
mRNA 
AeKir1 +++ Strong 
Malpighian tubules 
 ++ 
Midgut 
" 
Hindgut 
" 
Head 
" 
AeKir2A ND ND 
Malpighian tubules 
+ 
Midgut 
++ 
Hindgut 
++ 
Head 
+ 
AeKir2B + Weak 
Malpighian tubules 
+++ 
Midgut 
+++ 
Hindgut 
++ 
Head 
" 
AeKir2B’ ND ND 
Malpighian tubules 
+ 
Midgut 
" 
Hindgut 
" 
Head 
+++ 
AeKir3 " N/A 
Malpighian tubules 
+++ 
Midgut 
+++ 
Hindgut 
" 
Head 
" !  
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Pharmacology of Kir channels 
To date, the small-molecule pharmacology for mosquitoes specific Kir channel 
modulators remain largely undeveloped. This lack of pharmacological tools is hampering efforts 
to assess the druggability of these channels for insecticide development. However, our drug 
discovery efforts for novel human Kir channel modulators have helped in identifying non-species 
selective small-molecules such as VU573 (Chapter VI) and mosquito specific small-molecule 
modulators (Chapter VIII) to begin to probe the integrative physiology of these channels in 
mosquitoes. 
 
Objective 
As summarized above, inward rectifier potassium (Kir) channels are important K+ ion 
channels assuming essential physiological functions in humans. Moreover, we are beginning to 
uncover their physiological roles in insects, notably in mosquitoes, which we will focus in this 
dissertation. Therefore, Kir channels represent highly attractive molecular targets for developing 
not only new therapeutics for the treatment of pathologies linked to Kir channel dysfunction, but 
also new insecticides for controlling mosquito populations and reduce the transmission of vector-
borne diseases. However, assessing the druggability of these targets has been hindered for the 
most part because of the lack of pharmacological tools or probe compounds with which to 
determine their therapeutic or insecticidal potentials. The development and implementation of 
high-throughput screening assays and modern drug discovery methodologies provide us with the 
resources to begin to fill this gap, and thus generate research tools (lead compounds) that will be 
used to investigate Kir channel functions both in vitro and vivo. The development of new small-
molecule Kir channel modulators will ultimately benefit the research community to further probe 
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their integrative functions, which will guide drug discovery efforts in the setting of therapeutic 
and insecticide development. Subsequently, throughout the next chapters, we discuss our efforts 
to implement fluorescent-based high throughput screening assays for identifying and developing 
new small-molecule modulators of Kir channels with the goal to expand the pharmacology 
around this family and provide leads for therapeutic development. Furthermore, we present the 
first small-molecule discovery efforts aiming to investigate the insecticidal potentials of 
mosquito Kir channels. Lastly, using genetic tools, we begin to uncover new functions of these 
channels in mosquito physiology. 
 
Notes on figures and tables 
In the next chapters, the numbering of all figures and tables is specific for each chapter. 
For instance, “Figure 1” will be the first figure of a specific chapter, and so on. This formatting is 
designed to help the reader in quickly identifying visual materials of interest. 
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Chapter II 
HIGH-THROUGHPUT SCREENING FOR SMALL-MOLECULE MODULATORS OF 
INWARD RECTIFIER POTASSIUM CHANNELS  
This chapter was published under the same title in the Journal of Visualized Experiments in the 
January 27th, 2013 issue  
Abstract 
Specific members of the inward rectifier potassium (Kir) channel family are postulated 
drug targets for a variety of disorders, including hypertension, atrial fibrillation, and pain [76,77]. 
For the most part, however, progress toward understanding their therapeutic potential or even 
basic physiological functions has been slowed by the lack of good pharmacological tools. Indeed, 
the molecular pharmacology of the inward rectifier family has lagged far behind that of the S4 
superfamily of voltage-gated potassium (Kv) channels, for which a number of nanomolar-affinity 
and highly selective peptide toxin modulators have been discovered [78]. The bee venom toxin 
tertiapin and its derivatives are potent inhibitors of Kir1.1 and Kir3 channels [79,80], but 
peptides are of limited use therapeutically as well as experimentally due to their antigenic 
properties and poor bioavailability, metabolic stability and tissue penetrance. The development 
of potent and selective small-molecule probes with improved pharmacological properties will be 
a key to fully understanding the physiology and therapeutic potential of Kir channels. The 
Molecular Libraries Probes Production Center Network (MLPCN) supported by the National 
Institutes of Health (NIH) Common Fund has created opportunities for academic scientists to 
initiate probe discovery campaigns for molecular targets and signaling pathways in need of better 
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pharmacology [81]. The MLPCN provides researchers access to industry-scale screening centers 
and medicinal chemistry and informatics support to develop small-molecule probes to elucidate 
the function of genes and gene networks. The critical step in gaining entry to the MLPCN is the 
development of a robust target- or pathway-specific assay that is amenable for high-throughput 
screening (HTS). Here, we describe how to develop a fluorescence-based thallium (Tl+) flux 
assay of Kir channel function for high-throughput compound screening [20,21,64,82]. The assay 
is based on the permeability of the K+ channel pore to the K+ congener Tl+. A commercially 
available fluorescent Tl+ reporter dye is used to detect transmembrane flux of Tl+ through the 
pore. There are at least three commercially available dyes that are suitable for Tl+ flux assays: 
BTC, FluoZin-2, and FluxOR [20,82]. This protocol describes assay development using FluoZin-
2. Although originally developed and marketed as a zinc indicator, FluoZin-2 exhibits a robust 
and dose-dependent increase in fluorescence emission upon Tl+ binding. We began working with 
FluoZin-2 before FluxOR was available [20,82] and have continued to do so [21,64]. However, 
the steps in assay development are essentially identical for all three dyes, and users should 
determine which dye is most appropriate for their specific needs. We also discuss the assay's 
performance benchmarks that must be reached to be considered for entry to the MLPCN. Since 
Tl+ readily permeates most K+ channels, the assay should be adaptable to most K+ channel 
targets. 
 
Video link 
The video component of this chapter can be found at http://www.jove.com/video/4209/ 
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Experimental Protocol 
Generation of stable polyclonal cell lines 
  The establishment of a high quality stable cell line expressing the Kir channel of interest 
is an important first step toward developing a robust high-throughput screening assay. 
Constitutive K+ channel overexpression can lead to activation of cell death pathways, stable cell 
line degeneration and loss of assay performance. To avoid these potential problems and provide 
a convenient internal control for assay development (see below), a tetracycline-inducible 
expression system is recommended [20]. 
  Culture the parental T-REx-HEK293 cells using standard techniques in B-medium 
(DMEM growth medium containing 10% FBS, 50 U/mL Penicillin, 50 µg/ml Streptomycin and 
5 µg/mL Blasticidin S). Use early passage cells (e.g. 3-4 passages since thawing from liquid 
nitrogen storage) for transfection and stable clone selection. 
 Plate 4 million T-REx-HEK293 cells in a 75 cm2 flask so that the flask is approximately 
80% confluent the following day. Culture overnight in a 5% CO2 incubator at 37 °C. 
  Transfect the cells using 10-15 µg of pcDNA5/TO-Kir DNA and Lipofectamine 
LTX/Plus reagent according to manufacturer's protocol. After 5 hours, replace the transfection 
medium with B-medium.  
  24 hr after the transfection, replace the B-medium with B-medium containing 250 µg/mL 
Hygromycin (BH-medium) to begin stable clone selection. Feed the cells every 2-3 days with 
fresh BH-medium. 
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  Greater than 90% of the cells should die over the next 7 days, leaving behind small 
colonies of stably transfected cells. Allow the colonies to grow for an additional 10-14 days 
before splitting to a 175 cm2 flask for expansion. 
 For cryopreservation, freeze 3 x 106 cells/mL in media containing 45% conditioned BH-
medium, 45% antibiotic-free, serum-containing DMEM and 10% DMSO. Freeze the cells 
overnight at -80 °C in a cell freezing container and then move to liquid nitrogen for long-term 
storage. Thaw cells from liquid nitrogen using Invitrogen's recommended protocol. Note that the 
viability of the cells will be lower if they are frozen from a flask that is greater than 75% 
confluent at the time of processing. 
 
Generation of stable monoclonal cell lines 
  Wash a sub-confluent 75 cm2 flask of stable polyclonal cells with divalent-free HBSS. 
Add 1 mL of trypsin and incubate for 3-5 min in a 5% CO2 incubator at 37 °C. Add 5 ml of BH-
medium to the flask to inhibit trypsin activity and triturate repeatedly (e.g., 5 times) to fully 
dissociate the cells. Carefully inspect the cells under a microscope to ensure the suspension 
consists almost entirely of single cells. This will increase the likelihood of obtaining monoclonal 
cell lines. 
 Determine the cell density and dilute the suspension to a concentration of 0.7 cells per 20 
µL. Using a multi-channel pipettor, pipette 20 µL of the cell suspension into each well of BD 
PureCoat amine-coated (or equivalent poly-D-lysine coated) 384-well plates. In principle, 70% 
of wells should receive one cell with these plating conditions. Thus, a 384-well plate should 
contain more than 200 clones to analyze. Continue culturing the cells in a 5% CO2 incubator at 
37 °C. 
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  After a week, inspect the plates under a microscope for wells containing single colonies. 
Note their position on the lid with a permanent marker for future reference. Be sure to also note 
and exclude wells containing multiple colonies. These are most easily recognized by the 
appearance of colonies growing from multiple sides of the well. Be aware that evaporation tends 
to occur more quickly from wells near the edge of the plate. Add BH-medium to wells where 
significant evaporation has occurred. Otherwise, it is unnecessary to feed the cells. 
 Monitor the wells more frequently during the next 7-10 days. The cells will be ready to 
split when the wells of interest are at least 50% confluent. 
 Split the cells to duplicate 384-well plates; one plate for assaying with Tl+ flux and the 
other for continuing the monoclonal lines in culture. Aspirate the medium from the wells 
containing the cell lines of interest. Wash the cells with divalent-free HBSS, add 20 µL of trypsin 
to each well and transfer the plate to a 37 °C incubator for 15-20 min. After moving the plate 
back to the cell culture hood, add 20 µL of BH-medium to each well and triturate several times to 
dissociate the cells. Inspect the wells under a microscope to ensure the cells are fully dissociated. 
This may require multiple rounds of pipetting, as the cells will be tightly adherent. Once the cells 
are dissociated, transfer 10 µL of each cell suspension to duplicate wells of a new BD PureCoat 
amine-coated 384-well plate. Be sure to note the relationship between the source well and 
duplicate destination wells so that the clones exhibiting robust Kir channel activity (see below) 
can be traced back to the original well. Add 20 µL of BH-medium to the original source well to 
feed the remaining cells and continue them in culture in 5% CO2 incubator at 37 °C. 
 Allow the cells in the destination plate to adhere and grow for up to a week. Once most of 
the clones reach at least 50% confluence, they can be assessed for Kir channel activity using the 
Tl+ flux assay described below. 
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 The day before the assay, aspirate the culture medium and replace it with BH medium 
containing 10% dialyzed FBS. This prevents inadvertent channel expression that could arise 
from tetracycline contaminated serum. Induce Kir channel expression in only one of the 
duplicate wells for each clone by including 1 µg/mL tetracycline. The duplicate uninduced well 
will serve as a "background" control. Perform the Tl+ flux assays as described next. 
 
General Tl+ flux assay procedure 
 The day before a Tl+ flux experiment, dissociate the cells and quantitate the density of the 
cell suspension as described in sections 2.1 and 2.2. Plate 20,000 monoclonal cells stably 
transfected with a Kir channel gene of interest in each well of a BD PureCoat amine-coated 384-
well plate using a Thermo Multidrop Combi or a multi-channel pipettor. Use BH medium 
containing 10% dialyzed FBS for plating. Note that some cells will be cultured overnight with 1 
µg/mL tetracycline to induce Kir channel expression, whereas others will not. The location of 
induced and uninduced cells will differ for each type of experiment and are shown in Fig. 1. 
 The next day, inspect the plates under a microscope to ensure that the cells are adherent 
and evenly distributed across the bottom of the wells. The wells should be 80-90% confluent. 
 Use an ELx405 Microplate Washer to replace the cell culture medium with 20 µL per 
well of HBSS assay buffer containing 20 mM HEPES and buffered to pH 7.3 with NaOH. 
Alternatively, one can use a "flick and slam" method, wherein the plate is inverted and snapped 
down sharply to eject the medium into a waste container, and then patted onto stacked paper 
towels to remove the remaining media. Immediately add back HBSS assay buffer to the plate to 
prevent the cells from desiccating. 
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  Prepare the FluoZin-2, AM dye loading solution. After briefly centrifuging the tube, 
dissolve 50 µg of FluoZin-2 powder in 100 µL of anhydrous DMSO. At this point, aliquots of the 
1,000x stock solution can be stored at -20 °C for later use. When ready to use, add 50 µL of a 
20% weight per volume Pluronic F-127/DMSO solution to the dye and mix with gentle pipetting. 
Do not freeze the dye once Pluronic F-127 has been added, as low temperature may cause the 
surfactant to precipitate out of solution. Add the 150 µL volume of FluoZin-2, AM/Pluronic-
F127 to 100 mL of HBSS assay buffer and mix gently to make the dye loading buffer. Using a 
Multidrop Combi or multi-channel pipettor, add 20 µL of dye loading buffer to each well already 
containing 20 µL of HBSS assay buffer. Incubate the cells at room temperature for 
approximately 1 hr (typically incubation has been done in the dark, although there is no direct 
evidence that it is necessary). 
 While the cells are loading with dye, prepare a Tl+ stimulus plate. Freshly dissolve 0.5 g 
of sodium bicarbonate in 50 ml of 5x Tl+ stimulus buffer containing 1 mM magnesium sulfate, 
1.8 mM calcium sulfate, 5 mM glucose, 10 mM HEPES and 12 mM Tl+ sulfate. Alternatively, 
sodium bicarbonate can be replaced with sodium gluconate if, for example, the solution pH must 
be kept within a very narrow range and loss of carbon dioxide is a concern. Cap the tube tightly 
to limit the escape of carbon dioxide and invert several times until the sodium bicarbonate goes 
into solution. Using a multi-channel pipettor, add 50 µL of the solution to each well of a 
polypropylene 384-well plate (Table 1). 
 After the cells have been loaded with FluoZin-2, AM, wash the plates with an ELx405 
Microplate Washer or using the "flick and slam" method, as described above in section 3.3. 
Depending on the type of Tl+ flux experiment to be performed, add back 20 µL or 40 µL of 
HBSS assay buffer to each well. The plates are now ready for experiments. 
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  Load the cell and Tl+ plates into a Hamamatsu Functional Drug Screening System 
(FDSS) or equivalent kinetic imaging plate reader with integrated liquid dispensing capabilities. 
Use appropriate filters for fluorescein/fluorescein-based dyes such as Fluo-4. 
  Set up a single-add protocol so that 10 µl the 5x Tl+ series is added to the corresponding 
wells of the cell plate containing 40 µL of HBSS assay buffer. Record baseline fluorescence at a 
1 Hz sampling frequency for at least 10 sec. The well-to-well fluorescence should be uniform 
and stable across the plate once optimal cell plating, washing and dye loading conditions are 
established. An integrated 384-channel pipettor is used to simultaneously add the Tl+ stimulus 
buffer to each well. 
  Record for at least 2 min so that the rate and peak of the Tl+-induced increase in 
fluorescence is captured for off-line analysis. 
 
Determination of optimal Tl+ concentration 
 Tl+ readily permeates most inward rectifier K+ channels. To ensure that Tl+ 
concentrations do not exceed the dynamic range of the Tl+ reporter dye FluoZin-2, one should 
empirically determine the optimal Tl+ concentration to be used in a high-throughput screen. We 
recommend a Tl+ concentration that evokes 80% of the maximal fluorescence response (EC80) 
under conditions where the channel is maximally activated. 
 Plate, dye load and wash the cells in BD PureCoat amine-coated or equivalent poly-D-
lysine-coated 384-well plates as described above in section 3, leaving 40 µL of HBSS assay 
buffer in each well. As shown in the plate map in Fig. 1A, column 1 and rows A1-A23 should 
contain cells that have not been induced with tetracycline and therefore do not express the Kir 
channel of interest. The FluoZin-2 fluorescence signals from the uninduced wells will be used to 
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determine the level of Tl+ flux through endogenous pathways, such as the Na+- K+-ATPase pump 
and voltage gated K+ channels, which are normally expressed in HEK-293 cells. 
 Use an Agilent Bravo Automated Liquid Handling Platform or manual pipetting to 
prepare an eleven-point Tl+ concentration dilution series in HBSS assay buffer. Typically, a 3-
fold serial dilution series ranging from 100% to 0.002% Tl+ is evaluated in the assay. The series 
should be made up at a 5x concentration because the Tl+ solutions will be diluted 1:5 in the final 
assay. Prepare the dilution series by diluting the standard 5x Tl+ buffer described in section 3 
with a 5x Tl+-free buffer containing 1 mM magnesium sulfate, 1.8 mM calcium sulfate, 5 mM 
glucose and 10 mM HEPES. Again, freshly dissolve 0.5 g of sodium bicarbonate in 50 ml of the 
final Tl+ buffer immediately before plating in a polypropylene 384-well plate according to the 
plate map shown in Fig. 2A. 
 Load the cell and Tl+ stimulus plates into the FDSS. Set up a single-add protocol so that 
10 µL the 5x Tl+ series is added to the corresponding wells of the cell plate containing 40 µl of 
HBSS assay buffer. Record baseline FluoZin-2 fluorescence for 10 sec before adding Tl+ to the 
plate. Repeat the experiment on 3 separate days to establish the reproducibility of the results. 
 
Determination of assay sensitivity to DMSO 
 The small molecules interrogated in a high-throughput screen are dissolved in the organic 
solvent dimethyl sulfoxide (DMSO), which itself can affect the performance of the assay. 
Therefore, the assay's sensitivity to DMSO must first be examined to establish the highest 
DMSO concentration allowable in the screen. 
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 Plate, dye load and wash the cells in BD PureCoat amine-coated 384-well plates as 
described above in section 3, leaving 20 µL of HBSS assay buffer in each well. The entire plate 
should contain cells that have been induced with tetracycline (Fig. 3A). 
  Use a Bravo Automated Liquid Handling Platform or manual pipetting to prepare an 
eleven-point DMSO concentration dilution series in HBSS assay buffer. Typically, a 2-fold 
dilution series ranging from 10% to 0.01% v/v DMSO is evaluated for activity in the assay. The 
series should be made up at a 2x concentration because the DMSO solutions will be diluted by 
half in the final assay. The dilution series should be plated in a polypropylene 384-well plate, 
according to the plate map shown in Fig. 3A. 
 Prepare a 5x Tl+ stimulus plate based on the EC80 or optimal Tl+ concentration 
determined above in “Determination of optimal Tl+ concentration.” 
 Load the cell, DMSO and Tl+ stimulus plates into the FDSS. Set up a two-add protocol so 
that 20 µL of the 2x concentration DMSO series is added to the corresponding wells of the cell 
plate containing 20 µL of HBSS assay buffer. Leave the DMSO on the cells for the same amount 
of time the cells will be exposed to small molecule vehicle during a screen. Record baseline 
FluoZin-2 fluorescence for at least 10 sec before adding 10 µL of 5x Tl+ buffer to each well of 
the cell plate. Repeat the experiment on 3 separate days to establish the reproducibility of the 
results. 
 The assay should be tolerant to DMSO concentrations of at least 0.1% v/v for a typical 
high-throughput screen in which compounds are tested at a concentration of 10 µM. 
 
Determination of assay sensitivity to known pharmacological modulators 
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 After determining the optimal Tl+ concentration and DMSO tolerance of the assay, the 
effects of known pharmacologically active agents on Kir channel-mediated Tl+ flux should be 
examined. This series of experiments will assess the assay's sensitivity, ability to rank-order 
compounds based on their potency, ability to categorize compounds based on their mode of 
efficacy (e.g. activator, inhibitor), and identify well-behaved control compounds to be used later 
in the assay development and screen. 
 Plate, dye load and wash the cells in BD PureCoat amine-coated 384-well plates as 
described above in section 3, leaving 20 µL of HBSS assay buffer in each well. Column 1 and 
rows A1-A23 should contain cells that have not been induced with tetracycline (Fig. 4A). 
  Use a Bravo Automated Liquid Handling Platform or manual pipetting to prepare an 
eleven-point concentration dilution series of known modulators in HBSS assay buffer. Typically, 
a 3-fold dilution series ranging from 100 µM to 2 nM is evaluated for activity in the assay. The 
series should be made up at a 2x concentration because the DMSO solutions will be diluted by 
half in the final assay. The dilution series should be plated in triplicate in a polypropylene 384-
well plate, according to the plate map shown in Fig. 4A. Be sure that the dilutions are made such 
that the final DMSO concentrations are the same between drug treatments and less than or equal 
to the maximum allowable DMSO concentration defined in section 5. 
 Prepare a 5x Tl+ stimulus plate based on the optimal Tl+ concentration determined above 
in “Determination of optimal Tl+ concentration.” 
 Load the cell, compound and Tl+ stimulus plates into the FDSS. Set up a two-add 
protocol so that 20 µL the 2x concentration compound series is added to the corresponding wells 
of the cell plate containing 20 µL of HBSS assay buffer. Add the compounds to the cell plate and 
incubate for up to 20 min. Note that the optimal incubation time for the compounds to detect the 
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best signal to background ratio can be determined by running a series of experiments where 
couple different incubation times are chosen. Record baseline FluoZin-2 fluorescence for at least 
10 sec before adding 10 µL of 5x Tl+ buffer to each well of the cell plate. Repeat the experiment 
on 3 separate days to establish the reproducibility of the results. 
 
Checkerboard Analysis 
  In the next series of experiments, the uniformity and reproducibility of the assay will be 
evaluated using a "checkerboard" analysis. Typically, a control inhibitor is plated in every other 
well of each column and row of a 384-well plate, as shown in Fig. 5A. To rigorously assess the 
noise in the assay, an EC80 concentration of inhibitor should be used. DMSO is added to the 
other wells as a vehicle control. Tl+ flux in DMSO- and drug-treated cells is used to calculate a 
value for Z prime (Z$), a statistical measure of well-to-well variability between the two 
populations of wells. Z$ is calculated using the formula: 
Z$ = 1- (3SDp + 3SDn)/|meanp + meann | 
where SD is standard deviation, p is uninhibited flux and n is fully inhibited flux values. An 
assay with Z$ values greater than or equal to 0.5 on 3 separate days is considered suitable for 
high-throughput screening. 
 Plate, dye load and wash the cells in BD PureCoat amine-coated 384-well plates as 
described above in section 3, leaving 20 µL of HBSS assay buffer in each well. Note that the 
entire plate should be induced with tetracycline. 
 Make a compound/DMSO plate by pipetting into a 384-well polypropylene plate using a 
multi-channel pipettor, 80 µL/well of a known inhibitor of the target Kir channel at the 
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concentration determined in section 6.5, and 0.1% v/v DMSO vehicle as shown in Fig. 5A. Add 
the known inhibitor starting in well A1 using the multi-channel pipettor and alternate to well B2 
and so on up to well B24. Repeat this procedure with DMSO starting in well B1 and so on up to 
well A24. The final layout of the plate should match that of a checkerboard. 
 Prepare a 5x Tl+ stimulus plate based on the optimal Tl+ determined above in 
“Determination of optimal Tl+ concentration.” 
 Load the cell, compound and Tl+ stimulus plates into the FDSS. Set up a two-add 
protocol so that 20 µL the 2x concentration compound series is added to the corresponding wells 
of the cell plate containing 20 µL of HBSS assay buffer. Add the compounds to the cell plate and 
incubate for up to 20 min at room temperature. Record baseline FluoZin-2 fluorescence for at 
least 10 sec before adding 10 µL of 5x Tl+ buffer to each well of the cell plate. Repeat the 
experiment on 3 separate days to establish the reproducibility of the results. 
 
Pilot Screen 
  In the final stage of assay development, perform a pilot screen of a few thousand 
compounds to evaluate the assay's performance under conditions that will be used eventually in 
the large-scale high-throughput screen. 
 Plate, dye load and wash the cells in BD PureCoat amine-coated 384-well plates as 
described above in section 3), leaving 20 µL of HBSS assay buffer in each well. Note that the 
entire plate should be cultured overnight with tetracycline to induce Kir channel expression. 
 Select approximately 2,000 to 3,000 structurally diverse compounds to be tested. It is 
often appropriate and convenient to use compounds collections with known activities potentially 
enriched for ion channel modulators. Such collections include the Spectrum Collection 
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(MicroSource) and the LOPAC collection (Sigma). In addition, it is prudent to include known 
modulators of the Kir of interest in the pilot screen. Ideally, these compounds will be added to 
wells in a blinded fashion in order to allow an unbiased testing of the hit picking methods 
described later. Prepare the compounds in 384-well polypropylene plates (destination plates) 
using a Labcyte Echo Liquid Handler or suitable pin tool to transfer an appropriate volume of 
selected compounds in DMSO from the MLPCN collection (source plates) to the destination 
plates. Note that test compounds are only in columns 3-22; in every other well of columns 1, 2, 
23, 24 add a known inhibitor at a concentration known to fully inhibit the Kir as determined in 
section 7. In the remaining wells of columns 1, 2, 23, and 24 add the appropriate volume of 
DMSO to produce DMSO concentration-matched vehicle controls. Dilute all wells with Assay 
Buffer using the Multidrop Combi. Typically test compounds will be 20 µM, 2-fold above their 
target screening concentration. 
 Make Tl+ stimulus plates based on the optimal Tl+ concentration determined above in 
“Determination of optimal Tl+ concentration.” 
 Execute the pilot screen. Take care to stagger steps of the protocol's execution to 
maintain consistent timing between plates in the pilot screening run. 
  Once the pilot screen is completed, analyze the checkerboard wells from columns 1, 2, 23, 
and 24 using the Z$ equation. Inspect plates that show Z$ values of less than 0.5 to determine the 
source of poor separation of control populations. Hits can be selected using a number of methods. 
For pilot screens it is common to calculate the mean and standard deviation of the vehicle control 
population and pick hits based on wells producing values % 3 standard deviations from the mean 
of the vehicle controls. 
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 Following hit picking, retest selected hits in duplicate in 2 sets of plates. One set of plates 
contains the stable Kir cell in the absence of tetracycline and the other contains the stable Kir cell 
line in the presence of tetracycline. Hits that retest positive in at least one of the two retest plates 
and fail to show significant activity in the uninduced plates may be considered verified hits. 
Examine the verified hit list to determine how many of the "hidden" control samples were 
detected. Failure to detect the controls in the pilot screen indicates the need for further 
optimization of screening or hit-picking parameters. 
 
Representative Results 
The use of a tetracycline-inducible expression system provides a convenient internal 
control for distinguishing Tl+ flux through endogenous pathways and the Kir channel of interest. 
Figure 1 shows some examples of cell plating maps used in different types of experiments. The 
positions of wells containing uninduced or tetracycline-induced cells are indicated with different 
colors. Figure 2A shows the source plate map used to determine the optimal Tl+ concentration 
for assay development and compound screening. The color gradient represents the 3- fold 
dilution series ranging from 100% to 0.002% Tl+. A representative fluorescence intensity map is 
shown in Fig. 2B, with cool-to-hot colors indicating low-to-high Tl+ flux values, respectively. 
The cell plating map shown in Fig. 1C was used for this experiment. A fit of a 4-parameter 
logistic function to the Tl+ CRC (Fig. 2C) is used to determine an EC80 value of 15% Tl+. Figure 
3A shows the source plate map used to determine the DMSO tolerance of an assay. Columns 1 
and 24 contain assay buffer only, whereas the color gradient indicates the 2-fold dilution series 
ranging from 10% to 0.01% DMSO. A representative fluorescence intensity map is shown in Fig. 
3B, with low Tl+ flux values indicated with darker blue. The cell plating map shown in Fig. 1B 
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was used in this experiment. The average Tl+ flux values recorded from wells containing the 
indicated concentrations of DMSO are summarized in Fig. 3C. The data are plotted as the 
percentage of Tl+ flux recorded in the absence of DMSO. For this particular Kir channel, DMSO 
concentrations up to 2.5% had no effect on Tl+ flux and can therefore be used in experiments. 
Figure 4A shows the source plate map used to establish concentration-response curves for 
known inhibitors of a Kir channel. Each compound is indicated with a different color and is 
typically plated as a 3-fold dilution series. A representative fluorescence intensity map is shown 
in Fig. 4B. The cell plating map shown in Fig. 1C was used for this experiment. A representative 
experiment showing dose dependent inhibition of Tl+ flux by an inhibitor is shown in Fig. 4C. 
The robustness of an assay is determined in so-called "checkerboard" assays, which are 
summarized in Fig. 5. In the source plate map shown in Fig. 5A, a maximally effective 
concentration of an inhibitor or 0.1% DMSO as a vehicle control are plated in alternating wells. 
Figure 5B shows a representative fluorescence intensity map. A scatter plot of the peak Tl+ flux 
recorded from individual wells is plotted in Fig. 5C. The mean fluorescence values are indicated 
with solid line, whereas 3 standard deviations are indicated with a dotted line. The Z$ value, a 
statistical measure of how well separated the two cell populations are separated, calculated for 
this plate is 0.75, which is well above the 0.5 threshold required for high-throughput screening. 
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Figure 1. Cell plating maps used for Tl+ flux assay development. (A) Cell plating map use to 
determine the optimal assay Tl+ concentration. The wells in column 1, rows A1-23, K1-12, F13-
23, and P13-23 contain uninduced cells (-Tet). The remaining wells contain cells that were 
treated with tetracycline (+Tet) to induce Kir channel expression. (B) Cell plate map use to 
determine the assay DMSO tolerance and perform checkerboard analysis. Note that all the wells 
are treated with tetracycline (+Tet). (C) Cell plate map used to determine the assay sensitivity to 
known pharmacological modulators. The wells in column 1 and row A1-23 contain uninduced 
cells (-Tet). The remaining wells contain cells that were treated with tetracycline (+Tet).  
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Figure 2. Determination of optimal assay Tl+ concentration. (A) Source plate map used to 
determine the Tl+ concentration that evokes approximately 80% of the maximal FluoZin-2 
fluorescence increase (EC80). Row A and columns 1 and 24 (yellow) contain a 5x concentration 
of 12 mM Tl2SO4. The remaining rows contain a 3-fold dilution series ranging from 12 mM 
(100%) to 0.024 mM (0.002%) Tl2SO4. The series is repeated in columns 2-12 and 13-23. (B) 
Fluorescence intensity map depicting Tl+ flux for each well approximately 1 min after Tl+ 
addition. The pseudo-color bar on the right indicates the extent of Tl+ flux, with cooler and hotter 
colors representing low and high flux values, respectively. Note that the cooler colors in column 
1, rows A1-23, K1-12, F13-23, and P13-23 are due to low Tl+ flux in uninduced cells. The 
remaining wells, including those in column 24, contain cells that were treated with tetracycline to 
induce Kir channel expression (see cell plating map in Fig. 1A). (C) Mean ± SEM CRC for Tl+-
dependent changes in fluorescence (n = 3). Fitting a four-parameter logistic function to the data 
yielded an IC80 value of 15% Tl+.   
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Figure 3. Assay tolerance to DMSO. (A) Source plate map used to determine assay tolerance to 
DMSO. Columns 1 and 24 contain HBSS assay buffer. The rows contain a 2x concentration of a 
2-fold DMSO dilution series ranging from 10% to 0.01% v/v. (B) Representative fluorescence 
intensity map depicting Tl+ flux in each well recorded approximately 1 min after Tl+ addition. 
The pseudo-color bar on the right indicates the extent of Tl+ flux, with cooler and hotter colors 
representing low and high flux values, respectively. (C) Mean ± SEM (n = 9) Tl+ flux 
normalized to that recorded in the presence of HBSS assay buffer alone.   
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Figure 4. Assay sensitivity to known pharmacologically active compounds. (A) Source plate 
map used to assess the activity of known pharmacologically active compounds in the Tl+ flux 
assay. Row A and columns 1 and 24 contain 0.1% v/v DMSO. The plate layout allows for the 
testing of 10 compounds in triplicate in columns 2-23. The rows contain a 2x concentration of a 
3-fold serial dilution series of compounds ranging from 100 µM to 2 nM. (B) Fluorescence 
intensity map depicting Tl+ flux for each well approximately 1 min after Tl+ addition. The 
pseudo-color bar on the right indicates the extent of Tl+ flux, with cooler and hotter colors 
representing low and high flux values, respectively. Note that wells in column 1 and row A1-23 
contain uninduced cells. The remaining wells contain tetracycline-induced cells expressing the 
Kir channel of interest (See cell plate map in Fig. 1C). (C) Representative Tl+-induced changes 
in FluoZin-2 fluorescence in wells pre-treated with the indicated concentration of a Kir channel 
inhibitor. 
  
B C 
Fl
uo
re
sc
en
ce
 (F
/F
0)
 
Time (sec) 
0 20 40 60 80 100 120
0.75
1.00
1.25
1.50
1.75
2.00
2.25
2.50
2.75
  
 
100 µM 
10 µM 
3 µM 
0.3 µM 
A 
1 cmpd 
2 cmpd 
3 cmpd 
4 cmpd 
5 cmpd 
6 cmpd 
7 cmpd 
8 cmpd 
9 cmpd 
10 cmpd 
0.1% v/v DMSO 
40!!
 
 
 
 
 
 
 
 
 
 
Figure 5. Determination of assay suitability for HTS. (A) Source plate map used to evaluate 
the well-to-well variability among wells containing 0.1% DMSO (vehicle) or a maximally 
effective concentration of a known inhibitor. (B) Fluorescence intensity map depicting Tl+ flux 
in each well approximately 1 min after Tl+ addition. Note that all wells contain tetracycline-
induced cells expressing the Kir channel of interest (See cell plate map in Fig. 1B). (C) 
Representative scatter plot of steady-state fluorescence values obtained from vehicle- or 
inhibitor-treated wells. The mean fluorescence amplitude of each sample population is indicated 
with a solid line, 3 standard deviations from the mean is shown with a dashed line, and 
alternating samples for vehicle (VHL) and inhibitor (INH) are graphed as individual points. 
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Discussion 
Once the data are collected, a common step in the analysis involves normalizing each 
well's fluorescence response, F, to its initial value at the beginning of the experiment, F0. This is 
commonly referred to as the "static ratio" and symbolized "F/F0". In cases where F0 is dominated 
by the indicator dye the static ratio operation will substantially correct for many factors such as 
disuniformities in illumination, signal collection, and cell number. In cases where the dye signal 
is weak or background fluorescence or reflections in the system are high, the static ratio will not 
be effective unless the background can be appropriately dealt with prior to calculating the static 
ratio. After data normalization, it is typical to reduce the fluorescence waveform to a single value 
that will be used to quantify activity and pick hits. Most commonly, this will be done by fitting 
the data points in the 10 seconds following addition of Tl+ to obtain an initial slope of the evoked 
fluorescence increase. For hit picking, a popular approach is to assume that the vast majority of 
compounds in the test population are inactive (the null hypothesis is in force). A mean and 
standard deviation is calculated for the test population and hits are selected that are three 
standard deviations from the mean. 
For detecting Kir channel inhibitors, particularly those acting at intracellular binding sites, 
it may be valuable to incubate the cells with test compounds for an extended period of time (e.g. 
20 min) prior to the addition of Tl+. If the compounds are added "offline" before the assay is 
introduced to the plate reader, the optical properties of test compounds (e.g. fluorescence) may 
not be easily recognized and can adversely affect commonly used data normalization approaches 
such as the "static ratio" F/F0 described above resulting in false positives and/or false negatives. 
To avoid this problem while simultaneously avoiding having to keep an assay plate in a reader 
for a long incubation, one solution is to utilize a "two read" protocol. The first read is a short (e.g. 
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30 sec) experiment where the compound is added after 10 seconds to allow capture of the pre-
compound addition F0 and to assess the compounds' optical effects on the system. The plate is 
then removed from the reader and incubated for the desired period and returned to the reader for 
thallium addition. After both reads are completed, the first read F0 can be used to normalize the 
data from the second read thus avoiding many issues associated with adding compounds 
"offline" while allowing the opportunity to keep the reader busy collecting data thus improving 
screening throughput. The two read approach is most easily implemented when using an 
automated screening system. It is important to note that the two read approach will not eliminate 
problems caused by fluorescent compounds that saturate the detector and/or cause read-out 
artifacts in the CCD camera. 
Not all Kir channels are maximally activated under resting conditions, thus it may be 
possible to design an assay that can detect small-molecule activators. In these cases, selecting an 
EC80 concentration of Tl+ may not provide enough "headroom" for the assay to reliably detect 
activators. Thus, one may choose to use a lower concentration of Tl+ (e.g. EC20) in activator 
assays. In some cases, the assay may show low enough variability as to allow the use of an EC50 
concentration of Tl+ and still provide suitable resolution of both activated and inhibited channel 
populations. In this case, the assay may be conducted in dual activator/inhibitor mode. When 
available, a known activator can be used to help determine the appropriate Tl+ concentration to 
maximize the chances of discovering channel activators. 
There are some limitations that should be considered during the development and 
execution of a Tl+ flux-based high-throughput screen. For example, the assay relies on an 
indirect measure of Kir channel activity using a fluorescent probe whose optical properties could 
be directly affected by compounds in a screen. Therefore, important observations from Tl+ flux 
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experiments must be confirmed using voltage clamp electrophysiology, which is considered the 
"gold-standard" method for ion channel pharmacology. Furthermore, small-molecules may have 
direct effects on endogenous Tl+ flux pathways expressed in HEK-293 cells, leading to the 
identification of false-positive hits. The tetracycline-inducible system is particularly useful for 
distinguishing false-positive hits from Kir channel-directed modulators because the hits can be 
rapidly screened in uninduced cells for effects on endogenous pathways. Finally, the low 
solubility of Tl+ in chloride-containing buffers limit the concentration of Tl+ that can be used in 
an assay, requiring the use of a non-physiological Tl+ stimulus buffer that may augment the 
pharmacology of the target [83]. The compatibility of different buffers with the target of interest 
should be carefully evaluated during assay development. This can be done by establishing CRCs 
for known modulators using different Tl+ stimulus buffers and choosing conditions in which the 
pharmacology most closely matches that observed using physiological buffers. 
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Chapter III 
DISCOVERY, CHARATERIZATION AND STRUCTURE-ACTIVITY 
RELATIONSHIPS OF AN INHIBITOR OF INWARD RECTIFIER POTASSIUM (KIR) 
CHANNELS WITH PREFERENCE FOR KIR2.3, KIR3.X AND KIR7.1  
This chapter was published under the same title in the journal Frontiers in Pharmacology in the 
November 30th, 2011 issue  
Abstract 
The inward rectifier family of potassium (Kir) channels is comprised of at least 16 family 
members exhibiting broad and often overlapping cellular, tissue or organ distributions. The 
discovery of disease-causing mutations in humans and experiments on knockout mice has 
underscored the importance of Kir channels in physiology and in some cases raised questions 
about their potential as drug targets. However, the paucity of potent and selective small-
molecules targeting specific family members has with few exceptions mired efforts to dissect 
their individual physiological functions and assess their therapeutic potential. A growing body of 
evidence suggests that GIRK (G protein-regulated inward rectifier K) channels of the Kir3 
subfamily may represent novel targets for the treatment of atrial fibrillation and pain. We 
therefore performed a thallium (Tl+) flux-based high-throughput screen (HTS) of a Kir1.1 
inhibitor library for modulators of GIRK. One compound, termed VU573, exhibited 10-fold 
selectivity for GIRK over Kir1.1 (IC50 = 1.9 µM and 19 µM, respectively) and was therefore 
selected for further study. In electrophysiological experiments performed on Xenopus laevis 
oocytes and mammalian cells, VU573 inhibited Kir3.1/3.2 (neuronal GIRK) and Kir3.1/3.4 
(cardiac GIRK) channels with equal potency and preferentially inhibited GIRK, Kir2.3 and 
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Kir7.1 over Kir1.1 and Kir2.1. Thallium flux assays were established for Kir2.3 and the M125R 
pore mutant of Kir7.1 to support medicinal chemistry efforts to develop more potent and 
selective analogs. The structure-activity relationships of VU573 revealed few analogs with 
improved potency. However, two compounds retained most of their activity toward GIRK and 
Kir2.3 and lost activity toward Kir7.1. We anticipate that the VU573 series will be useful for 
exploring the physiology and structure-function relationships of these important potassium 
channels. 
 
Introduction 
Refer to Chapter I for a review of the inward rectifier family of potassium (Kir) 
channels. The founding Kir channel family member Kir1.1, commonly known as ROMK (for 
Renal Outer Medullary K channel), is a weak rectifier encoded by the gene KCNJ1 [84,85]. 
Kir1.1 is expressed almost exclusively in epithelial cells of the renal tubule where it critically 
regulates salt and water balance and hence blood volume and pressure [86]. Autosomal recessive 
mutations in KCNJ1 give rise to antenatal Bartter syndrome, a severe salt and water wasting 
disorder characterized by hypokalemic metabolic alkalosis and low to normal blood pressure 
[19]. In contrast, heterozygous carriers of KCNJ1 mutations have lower blood pressure but no 
overt evidence of disease [87]. These genetic data raise the intriguing possibility that Kir1.1 
represents a drug target for a novel class of diuretic. Consequently, our group recently employed 
high-throughput screening and medicinal chemistry to develop the first publicly disclosed small-
molecule inhibitors of Kir1.1 [20,21]. These, as well as inhibitors recently disclosed by 
investigators at Merck [22], should be instrumental in assessing the therapeutic potential of 
Kir1.1 for the management of hypertension. Another emerging drug target in the Kir channel 
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family is the G protein-coupled inward rectifier potassium (GIRK) channel, which is expressed 
in the heart and throughout the nervous system [1] and reviewed in Chapter I. In patients with 
chronic atrial fibrillation, GIRK channels become constitutively active in atrial cardiomyocytes 
through mechanisms that are incompletely understood [88-90]. This background current 
hyperpolarizes the membrane potential, abbreviates the action potential and increases the 
availability sodium channels for activation. A growing body of experimental and clinical data 
support the notion that electrical remodeling sets up high-frequency re-entrant current sources 
that perpetuate atrial fibrillation, suggesting that a specific blocker of GIRK could have 
antiarrhythmic actions without the ventricular side effects commonly associated with current 
therapies [16]. Similarly, the other Kir channel family member Kir2.3 is enriched in atrial 
cardiomyocytes and may also be a pharmaceutical target for atrial fibrillation [76]. As reviewed 
in Chapter I the molecular pharmacology of Kir channels remains largely undeveloped. A high-
throughput screen using a voltage-sensitive dye identified analogues of amiloride (a K+ sparing 
diuretic) and propafenone (a class 1c anti-arrhythmic) that inhibit GIRK with sub-micromolar 
potencies [91]. These and several cardiac and neurological drugs exhibiting weak off-target 
activity toward GIRK [77] may be useful lead compounds for developing more specific 
inhibitors of GIRK. The bee venom toxin tertiapin is a nanomolar affinity GIRK antagonist that 
also inhibits Kir1.1 [79,92]. [93] demonstrated that administration of tertiapin to cannulated dogs 
terminated induced atrial fibrillation, providing some of the first experimental evidence that 
GIRK is a target for anti-arrhythmic therapeutics [93]. Nissan Chemical Industries developed a 
benzopyrane derivative, termed NIP-142, which inhibits Kir3.1/3.4 GIRK channels with sub-
micromolar affinity and the cardiac Kv1.5 delayed rectifier current with equal potency [33,94]. 
NIP-142 has shown efficacy in terminating induced atrial fibrillation in dogs, but it is unknown 
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whether the improvement in sinus rhythm is due to inhibition of GIRK, Kv1.5 or both. However, 
the low nanomolar inhibitor NTC-801, which is highly selective for GIRK over other cardiac 
channels, was shown recently to be effective in several models of atrial fibrillation [95]. In an 
effort to further expand the molecular pharmacology of GIRK, we employed a Tl+ flux-based 
fluorescence assay to screen a Kir1.1 inhibitor focus library for antagonists of GIRK. One 
compound termed VU573 was found to preferentially inhibit GIRK (cardiac and neuronal forms), 
Kir2.3 and Kir7.1 over Kir1.1 and Kir2.1. We anticipate that VU573 and its analogs will be 
useful for investigating the physiology and structure-function relationships of inward rectifier 
potassium channels. 
 
Materials and Methods 
Expression vectors 
Plasmids used in this study are from the following sources: rat Kir1.1 (NM_017023; 
Chun Jiang, Georgia State University, Atlanta, GA), human Kir2.1 (NM_000891.2; Al George, 
Vanderbilt University School of Medicine, Nashville, TN), human Kir7.1 (NM_002242.2; David 
Clapham, Harvard Medical School, Cambridge, MA). Human Kir1.1 (NM_000220), Kir3.1 
(NM_002239.2), Kir3.2 (NM_002240.2), Kir3.4 (NM_000890.3) and Kir2.3 (NM_152868) were 
purchased from OriGene Technologies (Rockville, MD). The M125R mutant of Kir7.1 was 
created using the QuickChange Site-Directed Mutagenesis Kit (Agilent Technologies). The open 
reading frame of Kir7.1 was fully sequenced to ensure that no spurious mutations were 
introduced during mutation of the intended codon. 
 
 
48!!
Cell lines 
Monoclonal mGluR8/GIRK/HEK cells stably expressing Kir3.1/3.2, the M4 muscarinic 
receptor and rat mGlu8a were cultured as described previously [83]. Polyclonal stable T-REx-
HEK293 cell lines expressing Kir2.3 and Kir7.1-M125R under the control of atetracycline-
inducible promoter were established essentially as described in detail elsewhere [20,96]. 
Monoclonal Kir2.3 cell lines were isolated through limiting dilution in 384-well plates and 
testing for tetracycline inducible Tl+ flux, as described below. Polyclonal Kir7.1-M125R cells 
were used in this study. The development of monoclonal C1 T-REx- HEK293 cells expressing 
Kir1.1 (S44D) was described previously [20]. T REx-HEK293 lines were cultured in DMEM 
growth medium containing 10% FBS, 50 U/mL Penicillin, 50 g/mL Streptomycin, 5 g/mL 
Blasticidin S and 250 g/mL Hygromycin. 
 
Two-electrode voltage clamp analysis 
Stage V-VI oocytes were isolated from gravid Xenopus laevis frogs using sterile surgical 
techniques under tricaine anesthesia. All methods were in accordance with the guidelines for the 
use of laboratory animals of Vanderbilt University School of Medicine. The oocyte follicle layer 
was removed by manual dissection following enzymatic treatment with 1 mg/ml collagenase 
(Type 1A Sigma) dissolved in calcium-free OR-2 of the following composition (in mM): 82.5 
NaCl, 2 KCl, 1 MgCl2, 5 HEPES, with pH 7.5 adjusted with NaOH. Oocytes were allowed to 
recover overnight at 16 °C in modified L-15 media containing gentamicin sulfate (25 mg/ml). 
pcDNA3.1(+) vectors carrying Kir1.1, human Kir2.1, 2.3, and 7.1 cDNA were used to synthesize 
channel cRNA from a T7 RNA polymerase and nucleotides provided in the mMESSAGE 
mMACHINE kit (Ambion, Austin, TX) after linearization of the expression constructs. cRNA 
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was purified by LiCl precipitation, diluted in RNAase-free water and used for injections. The 
oocytes were injected with 0.5 to 10 ng of cRNA of Kir1.1, Kir2.1, Kir2.3, and Kir7.1 using a 
Drummond digital microdispenser. Oocytes were incubated at 16˚C in modified L-15 for 24-72 h 
prior to Kir channel recordings. Whole-cell currents were recorded from Xenopus oocytes 
injected with Kir channel cRNA using the two-electrode voltage clamp technique. Current and 
voltage commands were generated with a GeneClamp 600 amplifier, a Digidata 1200 A/D 
converter and pClamp 8.0 software (Molecular Devices, Sunnyvale, CA). The bath was actively 
clamped to 0 mV using a VG-2A bath clamp (Molecular Devices). Electrodes pulled from 
borosilicate glass (Sutter Instruments, Novato, CA) using a PP-830 vertical puller (Narishige 
International, Narishige, Japan) had resistances of 0.5-5.0 M& when filled with 3 M KCl. The 
standard bath solution contained (in mM): 85 NaCl, 5 KCl, 10 HEPES, 2 MgCl2, pH 7.4 with 
NaOH. After achieving stable current amplitude, VU573 was applied continuously. This was 
followed by application of the non-specific potassium channel blocker barium. For Kir current 
recordings, cells were voltage-clamped and stepped every 5 s from a holding potential of -70 to -
100 mV for 200 ms, then ramped at a rate of 1.6 mV/ms to 60 mV before returning to -80 mV. 
All recordings were made at room temperature (20-23ºC). 
 
Whole-cell patch clamp electrophysiology 
T-REx-HEK293-Kir2.3 cells were patch clamped after overnight induction with 
tetracycline (1 g/ml). GIRK (Kir3.1/3.2) and wild type Kir7.1 were studied in HEK-293 cells 
transiently co-transfected with the respective channel expression vectors and pcDNA3.1-EGFP 
(transfection marker) using Lipofectamine LTX/Plus reagent according to manufacturer’s 
protocol (Invitrogen, Carlsbad, CA). The standard intracellular solution contained 135 mM KCl, 
50!!
2 mM MgCl2, 1 mM EGTA, 10 mM HEPES-free acid, and 2 mM Na2ATP (Roche), pH 7.3, 
adjusted to 275 mOsmol/kg with sucrose. For Kir2.3 recordings, MgCl2 was reduced to 1 mM to 
prevent channel rundown [97]. The standard bath solution contained 135 mM NaCl, 5 mM KCl, 
2 mM CaCl2, 1 mM MgCl2, 5 mM glucose, and 10 mM HEPES-free acid, pH 7.4, 290 
mOsmol/kg. In some experiments, a high-K+ bath was used that contained 90 mM NaCl, 50 mM 
KCl, 2 mM CaCl2, 1 mM MgCl2, 5 mM glucose, and 10 mM HEPES-free acid, pH 7.4, 290 mM 
mOsmol/kg. Kir current recordings were collected as previously described [21]. After achieving 
stable whole-cell currents, VU573 was applied intermittently or continuously for 2 to 10 min, 
followed by application of 2 mM BaCl2. Data acquisition and analysis were performed using 
pClamp 9.2 software (Molecular Devices). All recordings were made at room temperature (20-
23ºC). 
 
Test compound and stimulus plate preparation 
Compound master antagonist plates were created by serial diluting compounds 1:3 from 
10mM stock in 100% DMSO using the BRAVO liquid handler (Agilent Technologies, Santa 
Clara, CA). Assay daughter plates were created using the ECHO 555 liquid hander (Labcyte, 
Sunnyvale, CA), transferring 240 nL from the master plate to the daughter plate for each well 
followed by addition of 40 µL of assay buffer resulting in antagonist compound concentration 
response curves starting at 60 µM (2X final concentration). Glutamate was diluted in Tl+ buffer 
(125 mM sodium bicarbonate (added fresh the morning of the experiment), 1 mM magnesium 
sulfate, 1.8 mM calcium sulfate, 5 mM glucose, 12 mM Tl+ sulfate, and 10 mM HEPES, pH 7.3) 
at 5X the final concentration to be assayed. 
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Kinetic imaging, data analysis, and statistics 
Cells were loaded with the Tl+ sensitive fluorescent dye FluoZin-2 and plated in clear-
bottom 384-well plates essentially as described previously [20,21] Cell plates and daughter 
compound plates were loaded onto a kinetic imaging plate reader (FDSS 6000; Hamamatsu 
Corporation, Bridgewater, NJ). All recordings were made at room temperature (20-23ºC). 
Appropriate baseline readings were taken (10 images at 1 Hz; excitation, 470 ± 20 nm; emission, 
540 ± 30 nm) and 20 µL test compounds were added followed by 50 images at 1Hz additional 
baseline. Following a 20-min incubation period, baseline readings were taken for 30 seconds 
followed by addition of 10 µL Glutamate at an EC80 concentration. An additional 170 images 
were taken at 1Hz. Glutamate EC80 concentration was determined the day of the assay. 
Data were analyzed using Excel (Microsoft Corp, Redmond, WA). Raw data were 
opened in Excel and each data point in a given trace was divided by the first data point from that 
trace (static ratio). For experiments in which antagonists were added, data were again normalized 
by dividing each point by the fluorescence value immediately before the glutamate addition to 
correct for any subtle differences in the baseline traces after the compound incubation period. 
The slope of the fluorescence increase beginning 5 s after Tl+/glutamate addition and ending 15 s 
after Tl+/glutamate addition was calculated. The data were then plotted in Prism software 
(GraphPad Software, San Diego, CA) to generate concentration-response curves after correcting 
for the slope values determined for baseline waveforms generated in the presence of vehicle 
controls. Potencies were calculated from fits using a four parameter logistic equation. 
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Chemical synthesis 
 
Synthetic Scheme I: 
 
General:  All NMR spectra were recorded on a 400 MHz AMX Bruker NMR spectrometer.  1H 
chemical shifts are reported in ' values in ppm downfield with the deuterated solvent as the 
internal standard.  Data are reported as follows: chemical shift, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, br = broad, m = multiplet), integration, coupling constant (Hz). 
Low resolution mass spectra were obtained on an Agilent 1200 series 6130 mass spectrometer 
with electrospray ionization.  High-resolution mass spectra were recorded on a Waters Q-TOF 
API-US plus Acquity system with electrospray ionization.  Analytical thin layer chromatography 
was performed on EM Reagent 0.25 mm silica gel 60-F plates.  Samples were analyzed for 
%95% purity using LC-UV/Vis-MS.  Analytical HPLC was performed on an Agilent 1200 series 
with UV detection at 214 nm and 254 nm along with ELSD detection.  LC/MS: Method 1 =  (J-
Sphere80-C18, 3.0 x 50 mm, 4.1 min gradient, 5%[0.05%TFA/CH3CN]:95%[0.05%TFA/H2O] 
to 100%[0.05%TFA/CH3CN]; Method 2 = (Phenomenex-C18, 2.1 X 30 mm, 2 min gradient, 
7%[0.1%TFA/CH3CN]:93%[0.1%TFA/H2O] to 100%[0.1%TFA/CH3CN]; Method 3 = 
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(Phenomenex-C18, 2.1 X 30 mm, 1 min gradient, 7%[0.1%TFA/CH3CN]:93%[0.1%TFA/H2O] 
to 95%[0.1%TFA/CH3CN].   Preparative purification was performed on a custom HP1100 
purification system (reference 16) with collection triggered by mass detection.  Solvents for 
extraction, washing and chromatography were HPLC grade.   All reagents were purchased from 
Aldrich Chemical Co. and were used without purification. 
 
Reagents: Substituted phenols where purchased from various commercial sources, 2-Amino-1-
benzylbenzimidazole and 2-Amino-1-methylbenzimidazole where purchased from Acros 
Organics. 1-(4-Chlorophenylmethyl)-2-aminobenzimidazole was made using published 
procedures [98].  
 
General synthetic procedure: The desired phenol (2 mmol) was dissolved in 0.4 mL NaOH (5 
M) and then treated with epichlorohydrin (0.32 mL, 3.7 mmol). The mixture was heated in a 
Biotage Initiator microwave reactor at 100 °C for a 15 min period. The reaction was cooled to 
ambient temperature and diluted with dichloromethane. The aqueous layer was removed and the 
organic layer extracted with water. The mixture was dried and solvent removed under reduced 
pressure.  The crude mixture was then treated with the desired 2-aminobenzimidazole (3 mL, 0.2 
mmol, 0.7 M MeOH) dissolved in methanol. The mixture was allowed to stir for 4 days at 
ambient temperature. The solvent was removed under reduced pressure and the residue was 
diluted with dichloromethane. The mixture was extracted with water, dried, and concentrated 
under reduced pressure. The crude was purified using reverse phase chromatography (C18, 
Acetonitrile/H2O 0.1% TFA). 
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Results 
VU573: A weak Kir1.1 inhibitor with preference for GIRK  
We recently performed a high-throughput screen (HTS) for small-molecule modulators of 
Kir1.1 [20], the founding member of the inward rectifier potassium (Kir) channel family [84,99] 
and putative diuretic target [19,87,100]. A focus library of reproducibly active inhibitors was 
assembled from the primary screen, with the goal of mining the library for antagonists of other 
inward rectifiers. As noted in the Introduction, a growing body of evidence suggests that GIRK 
channels expressed in atrial cardiomyocytes may represent a viable drug target for the treatment 
of atrial fibrillation. Given the paucity of potent and selective small-molecule inhibitors of GIRK 
and therapeutic interest in the channel, we screened the focus library for GIRK modulators using 
a Tl+ flux-based fluorescence assay developed recently at Vanderbilt [83]. The assay reports Tl+ 
flux through heteromeric Kir3.1/3.2 channels co-expressed in HEK-293 cells with the group III 
metabotropic glutamate receptor mGluR8. Intracellular Tl+ concentration is reported using the 
commercially available Tl+-sensitive fluorescent dye FluoZin-2. As shown in Fig. 1A, glutamate 
addition dose-dependently increased Tl+ flux as GIRK channels are activated by mGluR8 
stimulation. The focus library was screened at a single concentration of 10 µM using an 80% 
maximally effective concentration (EC80) of glutamate. Several compounds were identified that 
preferentially inhibited GIRK over Kir1.1 (data not shown). One of these compounds, termed 
VU573, was selected for further study. 
The chemical structure of VU573 is shown in the inset of Fig. 1C. The potency of 
VU573 was evaluated in 11-point concentration-response curves (CRC) using an EC80 of 
glutamate to activate GIRK. As shown in Fig. 1B, VU573 inhibited GIRK-dependent Tl+ flux in 
a dose-dependent manner with a 50% inhibition concentration (IC50) of approximately 1.9 µM 
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(Fig. 1C). 
To verify that VU573 is a more potent inhibitor of GIRK than Kir1.1, a full VU573 CRC 
was generated using an established Tl+ flux assay for Kir1.1 [20,21]. The assay employs an 
inducible system in which Kir1.1 is expressed from a tetracycline-regulatable promoter. As 
shown in Fig. 2A, extracellular Tl+ addition produced a dramatic increase in FluoZin-2 
fluorescence in cells cultured with tetracycline, but not in uninduced cells. Thus, most of the Tl+ 
flux in tetracycline-induced cells occurs through Kir1.1. VU573 exhibited weak yet dose-
dependent inhibition of Kir1.1 (Fig. 1F), with an IC50 of approximately 19 µM. Whole-cell patch 
clamp experiments confirmed that 20 (M VU573 inhibited Kir1.1 by 49.5 ± 0.03% (n = 5). Thus, 
VU573 is a preferential inhibitor of GIRK over Kir1.1. 
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Figure 1. VU573 inhibits mGluR8-activated Kir3.1/3.2 channel activity in thallium flux 
assays. (A) Representative FluoZin-2 fluorescence traces recorded from HEK-293 cells stably 
expressing mGluR8 and Kir3.1/3.2 before and after co-application of thallium and different 
doses of glutamate (shaded box). From an 11-point glutamate concentration-response curve (not 
shown), the glutamate concentration evoking approximately 80% (EC80) of the maximal 
response (ECmax) was determined and used for subsequent experiments. (B) Representative 
traces for changes of Tl+-induced FluoZin-2 fluorescence following 20 min pre-treatment of cells 
with the indicated concentrations of VU573 and subsequent thallium and glutamate-EC80 
addition (shaded box). (C) Mean ± SEM concentration-response curve for VU573-dependent 
inhibition of Kir3.1/3.2 (n = 3). The chemical structure of VU573 is shown in the inset. (D) 
Representative FluoZin-2 fluorescence traces recorded from monoclonal Kir1.1-S44D 
expressing cells cultured overnight in absence (-Tet) or presence (+Tet) of Tetracycline. (E) 
Representative traces for changes of Tl+-induced FluoZin-2 fluorescence following pre-treatment 
of cells with the indicated concentrations of VU573 and then exposed to thallium (shaded box). 
(F) Mean ± SEM concentration-response curve for VU573-dependent inhibition of Kir1.1-S44D 
(n = 3). 
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VU573 shows preference for Kir2.3, GIRK and Kir7.1 over Kir1.1 and Kir2.1 
To further assess the selectivity of VU573, several members of the Kir channel family 
were expressed in Xenopus oocytes and screened for VU573 sensitivity using the two-electrode 
voltage clamp technique (TEVC). We first tested whether VU573 discriminates between 
Kir3.1/3.2 and Kir3.1/3.4 channels, the predominate heterotetrameric forms of GIRK found in 
the nervous system and heart, respectively [1]. Figure 3A illustrates a typical experiment 
performed on an oocyte co-injected with cRNA encoding Kir3.1 and Kir3.2. Current recorded at 
-80 mV is shown as a function of time. The oocyte was initially bathed in a potassium-free (0K) 
solution and then switched to one containing 90 mM K+ (90K) to activate GIRK. The dramatic 
increase in inward current in the presence of 90K buffer was not observed in water-injected 
oocytes (data not shown) and therefore largely reflects current through Kir3.1/3.2 channels. Bath 
application of 10 (M VU573 inhibited GIRK current by approximately 50%, which was 
significantly lower than expected from Tl+ flux experiments (Fig. 1C). The residual current was 
blocked by Ba2+. Figure 3B shows mean ± SEM % block of Kir3.1/3.2 and Kir3.1/3.4 channels 
by 1, 10 and 25 µM VU573 or Ba2+. The mean ± SEM time constant ()) for inhibition of 
Kir3.1/3.2 and Kir3.1/3.4 currents by 25 µM VU573 were 28 ± 4 (n = 6) and 27 ± 5 (n = 6) sec, 
respectively. There were no significant (P >0.05) differences in the degree of VU573-dependent 
block of Kir3.1/3.2 and Kir3.1/3.4 channels at any of the concentrations.  
GIRK channels are co-expressed with other members of the Kir channel family in a 
tissue- and cell type-specific manner. As noted in the Introduction, there is growing evidence that 
inhibitors of cardiac GIRK channels may be therapeutically beneficial in patients with atrial 
fibrillation. However, Kir2.1 and Kir2.3 are also expressed in the heart [1] and therefore 
represent potential off-targets for VU573 actions. GIRK, Kir2.1 and Kir2.3 are also co-expressed 
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in various brain regions, as is one of the newest Kir channel family members, Kir7.1 [101]. We 
therefore determined whether VU573 inhibits any of these channels expressed in Xenopus 
oocytes. Kir1.1 was also expressed to confirm the results from Tl+ flux experiments.  
Representative TEVC recordings from oocytes expressing Kir1.1, Kir2.1, Kir2.3, or 
Kir7.1 are shown in Fig. 3. The oocytes were voltage clamped at -75 mV and stepped for 200 
msec every 5 sec to -120 mV to evoke inward current. The current amplitude at -120 mV is 
shown as a function of time. Barium was again used at the end of each experiment as a control 
blocker. Consistent with the Tl+ flux data showing greater potency toward GIRK than Kir1.1, 50 
µM VU573 inhibited Kir1.1 by only 4.3 ± 1.7% with a time constant of 95 ± 15 sec (n = 8). 
Kir2.1 was also relatively insensitive to VU573, and the time constant was very slow () = 735 ± 
85 sec; n = 4)(Fig. 2C). After 25 minutes of constant bath perfusion, 50 µM VU573 inhibited 
Kir2.1 by only 30.2 ± 9.4%. In contrast, Kir2.3 was inhibited comparatively quickly () = 154 ± 
32 sec) by 80.9 ± 5.0% (n = 7). Similarly, Kir7.1 was inhibited by 66.0 ± 6% (n = 9) with a rapid 
constant of 38 ± 6 sec (n = 8).  
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Figure 2. Effect of VU573 on Kir channels expressed in oocytes. (A) Representative 
Kir3.1/3.2 current traces recorded from an oocyte using the two-electrode voltage clamp 
technique. Oocytes were initially bathed in a potassium-free (0K) solution and then switched to 
one containing 90 mM potassium (90K) to activate Kir3.1/3.2. After reaching a steady state, the 
oocyte was exposed to 10 µM VU573 (in 90K) bath to inhibit Kir3.1/3.2. Residual Kir3.1/3.2 
currents were inhibited with 2 mM barium (Ba2+). A final switch back to 0K was used to 
measure leak current at the end of each experiment. Representative whole-cell current traces 
recorded from oocytes expressing respectively (B) Kir1.1, (C) Kir2.1, (D) Kir2.3 and (E) Kir7.1 
before and after application of 50 µM VU573. Residual Kir currents were inhibited with 2 mM 
barium (Ba2+). (F) Mean ± SEM percent inhibition of current evoked by Kir3.1/3.2, Kir3.1/3.4, 
Kir1.1, Kir2.1, Kir2.3 and Kir7.1 with the indicated concentrations of VU573 (%&'(! )*&+) or 
Ba2+ (),*-.!)*&+) (n = 4-6).  
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Patch clamp analysis of VU573 potency in mammalian cells 
GIRK is inhibited by VU573 with an IC50 of approximately 2 µM in Tl+ flux assays in 
HEK-293 (Fig. 1) cells and 10 µM in TEVC experiments in oocytes (Fig. 2). To determine if the 
discrepancy is due to the expression system or assay type, whole-cell patch clamp techniques 
were used to assess the potency of VU573 toward Kir3.1/3.2 GIRK channels expressed in HEK-
293 cells. The cells were voltage clamped at a holding potential of -75 mV and then stepped to -
120 mV for 200 msec, after which the membrane potential was ramped between -120 mV and 
120 mV at a rate of 2.4 mv/msec. As shown in Fig. 3A, GIRK activity was low in the presence of 
5 mM extracellular K+ (5K), but increased upon elevation of bath K+ to 50 mM (50K), 
paralleling the behavior of GIRK observed in oocytes. Consistent with Tl+ flux data (Fig. 1C), 
bath application of 30 µM VU573 led to a near complete inhibition of GIRK. The residual 
current was inhibited by barium (Ba2+; Fig. 3B). The mean ± SEM time constant of inhibition 
was 16 ± 1 sec (n = 5). A fit of the CRC data (Fig. 3C) from patch clamp experiments yielded an 
IC50 of 1.3 µM, which is very near that derived from Tl+ flux assays (Fig. 1C).   
We extended our patch clamp experiments to include Kir2.3 and Kir7.1 due to their 
strong inhibition by VU573 in oocytes (Fig. 2F). A monoclonal stable T-REx-HEK293 cell line 
expressing Kir2.3 under the control of a tetracycline-inducible promoter was patch clamped 
following overnight induction with tetracycline. Kir7.1 was studied in transiently transfected 
HEK-293 cells (see Methods). The cells were subjected to the same voltage ramp protocol 
described above for GIRK. Steady state Kir2.3 and Kir7.1 currents recorded before (black line) 
and after (gray line) bath application of 30 µM VU573 are shown in Figs. 3D and 3G, 
respectively. Both channels were inhibited with a rapid time course and IC50 values of 
approximately 1 µM (Figs. 3F and 3I).  
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Figure 3. VU573-dependent inhibition of Kir3.1/3.2, Kir2.3 and Kir7.1 channel activity 
expressed in HEK-293 cells. (A, D, G) Representative whole-cell Kir3.1/3.2, Kir2.3 and Kir7.1 
current traces recorded from transfected HEK-293 cells. The cell was voltage ramped every 5 sec 
between -120 mV and 120 mV for 200 ms from a holding potential of -75 mV. Normalized 
Kir3.1/3.2, Kir2.3 and Kir7.1 currents recorded before (black line) and after reaching steady-
state inhibition by 30 (M VU573 (gray line) are shown. (B, E, H) Representative time course 
traces of VU573-dependent inhibition of Kir3.1/3.2, Kir2.3 and Kir7.1 by 30 µM VU573 using 
the protocol described above. After achieving whole-cell access, the current was allowed to 
stabilize before adding 30 µM VU573 and then 2 mM barium (Ba2+) to inhibit channel activity. 
(C, F, I) Mean ± SEM concentration-response curves for Kir3.1/3.2 (n = 4-7), Kir2.3 (n = 4-6) 
and Kir7.1 (n = 4-7), respectively.  
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Development of Tl+ flux assays for Kir2.3 and Kir7.1-M125R  
We next set out to employ medicinal chemistry in an effort to improve the potency and 
selectivity of VU573 toward GIRK, Kir2.3 and Kir7.1. Conventional electrophysiological 
methods are too slow and labor intensive to support a robust medicinal chemistry campaign, 
leading us to establish high-throughput Tl+ flux assays for Kir2.3 and Kir7.1. As shown in Fig. 
4A, robust tetracycline-inducible Tl+ flux was observed in monoclonal stable T-REx-HEK-293 
expressing Kir2.3. VU573 dose-dependently inhibited Tl+ flux through Kir2.3 with an IC50 of 4.7 
µM, a value that is reasonably close to that derived from patch clamp experiments (Fig. 3F).  
In contrast, despite numerous attempts on multiple polyclonal and monoclonal cell lines, 
we were unable to detect Tl+ flux through Kir7.1. Western blot analysis revealed that this was 
not due to lack of channel protein expression (data not shown), suggesting that other channel 
properties were responsible. Kir7.1 is unique among Kir channels in that it has a very small 
unitary conductance, which has been estimated from noise analysis to be on the order of 50 
femptoSiemens (fS) [101]. We reasoned that this could keep Tl+ flux through Kir7.1 below the 
limit of detection of FluoZin-2. The small conductance of the channel is due at least in part to a 
non-conserved Methionine (M) residue at position 125 located in the pore. Mutation of the 
residue to Arginine (R), which occupies the homologous position in all other Kir channels (not 
shown), has no effect on protein expression or targeting to the plasma membrane, but increases 
the single channel conductance by approximately 20-fold [101]. We therefore determined if the 
M125R mutation would enable measurement of Tl+ flux using FluoZin-2. As shown in Fig. 4D, 
tetracycline-induced robust Tl+ flux in polyclonal stable T-REx-HEK-293 cells expressing 
Kir7.1-M125R. VU573 induced concentration-dependent inhibition of Tl+ flux with an IC50 of 
4.9 µM (Figs. 4E and 4F). The good correlation between IC50 values from patch clamp and Tl+ 
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flux experiments and the fact that the M125R mutation had no effect on the sensitivity to VU573 
in patch clamp experiments (Fig. 5A) indicated that the Kir7.1-M125R assays could be used as a 
screening tool to support a medicinal chemistry efforts for VU573. 
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Figure 4. Development of a thallium flux assay for Kir2.3. (A) Thallium flux-dependent 
FluoZin-2 fluorescence recorded from monoclonal Kir2.3 T-REx-HEK-293 cells cultured 
overnight in absence (-Tet) or presence (+Tet) of Tetracycline. The fluorescence emission was 
recorded before and after the addition of extracellular thallium (shaded box). (B) Representative 
traces for changes of Tl+-induced FluoZin-2 fluorescence following 20 min pre-treatment of cells 
with the indicated concentrations of VU573. (C) CRC for VU573-dependent inhibition of Kir2.3 
activity. Values are mean ± SEM (n = 3). A fit of the CRC with a single-site four-parameter 
logistic function yielded IC50 of 4.7 (M.  
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Figure 5. Development of a thallium flux assay for Kir7.1 (M125R). (A) Mean ± SEM % 
inhibition of wild type (closed bars; n = 6-7) or M125R mutant (open bars; n = 4-6). Kir7.1 by 
the indicated concentration of VU573. Note that the wild type data are reproduced from Fig. 3. 
(B) Thallium flux-dependent FluoZin-2 fluorescence recorded from polyclonal Kir7.1 (M125R) 
T-REx-HEK-293 cells cultured overnight in absence (-Tet) or presence (+Tet) of Tetracycline. 
The fluorescence emission was recorded before and after the addition of extracellular thallium 
(shaded box). (C) Representative traces for changes of Tl+-induced FluoZin-2 fluorescence 
following 20 min pre-treatment of cells with the indicated concentrations of VU573. (D) CRC 
for VU573-dependent inhibition of Kir2.3 activity. Values are mean ± SEM (n = 3). A fit of the 
CRC with a single-site four-parameter logistic function yielded IC50 of 4.9 (M.  
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Table 1. Structure-activity relationships and lead optimization summary.!
!
Cmpd R VU#/Barcode 
IC50 (µM) 
Kir2.3 Kir7.1 GIRK Kir1.1 
1 
 
VU0160573-1/ 
IC4X 4.15 ± 0.35 4.77 ± 2.89 2.17 ± 0.40 10.8 ± 3.8 
2 
 
VU0403134-1/ 
IC3Y 5.33 ± 2.08 4.73 ± 2.57 3.20 ± 0.71 7.07 ± 2.30 
3 
 
VU0403131-1/ 
IC58 4.20 ± 1.25 5.17 ± 1.89 2.90 ± 1.10 6.57 ± 3.80 
4 
 
VU0340260-1/ 
IC38 7.53 ± 2.34 8.00 ± 3.86 4.95 ± 1.80 11.2 ± 2.8 
5 
 
VU0026784-1/ 
IC3L 3.43 ± 0.67 4.47 ± 2.40 1.95 ± 0.49 11.7 ± 4.1 
6 
 
VU0288495-1 
IC39 5.33 ± 1.70 4.10 ± 1.93 1.95 ± 0.07 11.9 ± 2.2 
7 
 
VU0451348-1/ 
R6P 3.53 ± 1.33 4.20 ± 0.95 1.40 ± 0.35 7.57 ± 2.20 
8 
 
VU0451344-1/ 
R80 5.03 ± 1.96 6.03 ± 1.60 3.37 ± 0.70 6.77 ± 1.70 
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9 
 
VU0451342-1/ 
R70 24.0 ± 10.4 >100 15.3 ± 0.6 >100 
10 
 
VU0451341-1/ 
R7M 2.80 ± 0.99 6.07 ± 2.71 3.83 ± 1.10 6.13 ± 0.23 
11 
 
VU0451340-1/ 
R5C 2.33 ± 0.68 >100 3.17 ± 0.86 5.23 ± 0.59 
12 
 
VU0451339-1/ 
R56 11.3 ± 1.2 19.7 ± 7.4 5.27 ± 0.40 15.7 ± 2.1 
13 
 
VU0066224-6/ 
R7N 3.87 ± 1.40 6.70 ± 1.39 1.50 ± 0.44 12.7 ± 1.2 
14 
 
VU0451336-1/ 
R5B 3.13 ± 1.45 3.47 ± 0.67 1.43 ± 0.25 10.1 ± 2.9 
15 
 
VU0451333-1/ 
R5X 4.95 ± 1.34 5.33 ± 2.91 2.77 ± 0.60 8.60 ± 1.20 
16 
 
VU0451337-1/ 
R5K 5.10 ± 1.27 6.10 ± 3.12 3.43 ± 0.21 8.53 ± 1.70 
17 
 
VU0451332-1/ 
R7B 5.30 ± 1.56 4.33 ± 1.33 1.40 ± 0.30 8.27 ± 0.29 
18 
 
VU0451338-1/ 
R71 4.45 ± 0.92 5.63 ± 2.24 2.83 ± 0.42 11.7 ± 2.1 
19 
 
VU0451330-1/ 
R6J 7.15 ± 0.71 8.27 ± 2.37 1.93 ± 0.21 14.3 ± 1.5 
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20 
 
VU0451331-1/ 
RKN 3.65 ± 0.21 3.03 ± 0.68 4.33 ± 0.68 16.0 ± 2.0 
21 
 
VU0451846-2/ 
R87 3.60 ± 0.28 8.50 ± 2.18 5.13 ± 1.60 19.3 ± 1.5 
!
!
Cmpd R R’ VU#/Barcode 
IC50 (µM) 
Kir2.3 Kir7.1 GIRK Kir1.1 
22 
  
VU0401333-1/ 
IC4L 7.20 ± 1.73 8.93 ± 3.53 4.80 ± 1.10 14.7 ± 2.1 
23 
 
 
VU0403132-1/ 
IC48 5.70 ± 3.18 19.5 ± 28.2 3.35 ± 0.92 6.53 ± 3.90 
24 
  
VU0451343-1/ 
RJ4 2.80 ± 0.89  3.00 ± 0.87 4.20 ± 0.69 13.7 ± 4.4 
25  
 
VU0451335-1/ 
R5P 16.5 ± 0.7 25.3 ± 8.5 12.3 ± 2.5 13.0 ± 2.6 
26  
 
VU0451334-1/ 
R7L 4.90 ± 0.14 5.20 ± 1.82 2.87 ± 0.31 6.97 ± 2.00 
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Synthesis and structure-activity relationships of VU573 analogs  
Lead optimization efforts directed at VU573 (1) to improve its potency and selectivity 
toward Kir2.3, GIRK and Kir7.1 were initiated by conserving the benzyl moiety and substituting 
the R group (Table 1). Structure-activity relationships revealed few analogs with channel 
selectivity. Replacement of the phenoxy moiety with a morpholino group to the VU573 scaffold 
resulted in compound (9), which lost activity (IC50 values >100 µM) for Kir7.1 and Kir1.1. The 
IC50 values for Kir2.3 and GIRK were 24 and 15.3 µM, respectively. Substitution of the R group 
of the VU573 scaffold with a phenoxy benzyloxy functional group led to an analog (11), which 
was equipotent for Kir2.3 and GIRK, but loss activity toward Kir7.1 (IC50 values >100 µM). An 
alternate functional group for the VU573 scaffold, a 4-cyanophenyl (12), led to an analog 
compound with moderate selectivity for GIRK (IC50 = 5.27 µM) and weak inhibition of Kir2.3 
and Kir7.1, with IC50 values of 11.3 and 19.7 µM, respectively. All other analogs in which 
substitutions were made at both R and R’ groups led to similar potency among the Kir2.3, Kir7.1 
and GIRK channels as compared to VU573, but with weak inhibition for Kir1.1. The 
development of two VU573 analogs, R70 and R5C (Table 1), that retain activity toward GIRK 
and Kir2.3 but have lost activity toward Kir7.1 suggest that chemically optimized analogs based 
on the VU573 scaffold can be developed to increase their selectivity.  
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To determine if the apparent loss of activity is an artifact of the Tl+ flux assay or the use 
of the M125R mutant, we examined the effects of the VU573 analog R70 on wild type Kir7.1 
currents in whole-cell patch clamp experiments. The cells were voltage clamped between -120 
mV and 120 mV in 20 mV increments from a -75 mV holding potential (Fig. 6E). As illustrated 
in the average current traces recorded before (Fig. 6A) or during bath application of 10 µM R70 
(Fig. 6B), the analog had no effect on wild type Kir7.1 activity. In contrast, subsequent addition 
of 10 µM VU573 led to a near complete inhibition of the channel. The mean ± SEM current-
voltage relationships recorded in the three conditions are shown in Fig. 6D. 
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Figure 6. Lack of effect of R70 on wild type Kir7.1 activity. Average Kir7.1 current traces (n 
= 4 each) recorded in the absence (A) or presence of (B) 10 (M R70 or (C) 10 (M VU573. (D) 
Mean ± SEM (n = 4) current-voltage Kir7.1 relationships recorded in the indicated conditions 
using the voltage-clamp protocol shown in (E).  
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Discussion 
The Tl+ flux assay developed by [82] and subsequently commercialized by Invitrogen 
under the FluxOR© label has had a major impact on high-throughput screening for potassium 
channels. The assay takes advantage of the fact that Tl+ readily permeates most K+ channel pores. 
With the exception of wild type Kir7.1, the assay seems to be particularly well suited for inward 
rectifier K+ channels due to their high open probability near the resting membrane potential of a 
cell. This obviates the need, for example, of depolarizing the cell with a high-potassium step to 
open voltage-gated K+ channels. To date, Tl+ flux assays have been reported for the inward 
rectifiers Kir1.1 [20], Kir2.1 [102], Kir2.3 (this study), Kir3.1/3.2 [83], and Kir7.1-M125R (this 
study). Thallium flux assays have also been developed for some ligand- and voltage- gated 
potassium channels, including SK3 and KCNQ2 [82], KCNQ4 [103] and hERG [104-107]. A Tl+ 
flux assay was used to screen for modulators of the potassium-chloride co-transporter KCC2 
[108]. This is notable because KCC2 is electroneutral and therefore cannot be screened using 
voltage-sensitive dyes. Thus, the Tl+ flux assay appears to be broadly adaptable to both 
electrogenic and electroneutral K+ transport proteins.    
In the present study, Tl+ flux- and electrophysiological-based counterscreens revealed a 
preferential inhibitor of GIRK, Kir2.3 and Kir7.1. It is unclear why IC50 values are lower in 
oocytes compared to mammalian cells, but likely reflects differences in membrane properties or 
intracellular factors between the two cell types. VU573 inhibits GIRK independent of GPCR 
stimulation and does not discriminate between cardiac (Kir3.1/3.4) and neuronal (Kir3.1/3.2) 
forms of the channel. The latter observation suggests that the VU573 binding site is located 
within the Kir3.1 subunit, which is common to both heteromeric forms, or is shared between all 
three subunits. Pharmacology experiments on homotetrameric Kir3.1, Kir3.2 and Kir3.4 
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channels should help resolve the issue. Given the broad tissue distribution and important 
physiological functions of GIRK channels in the periphery and central nervous system, the 
development of sub-type selective modulators may be important for developing, for example, 
cardiac-specific drugs to treat atrial fibrillation without toxic side effects on the nervous system. 
The availability of high-resolution crystal structures of the GIRK cytoplasmic domain [109], 
GIRK-bacterial Kir channel chimeras [110] and now full-length mammalian Kir2.2 [7] should be 
helpful in guiding and interpreting experiments to define the molecular binding site for VU573 
and other GIRK antagonists. The relatively flat SAR of VU573 against GIRK, Kir2.3 and Kir7.1 
suggests that the VU573 scaffold may be amenable to the addition of diazirine or other reactive 
moieties for photoaffinity labeling of the channels for identification of the binding site using 
mass spectrometry. A detailed understanding of both unique and overlapping binding sites will 
provide novel insights into the molecular architecture of GIRK and should facilitate the 
development of subtype-specific inhibitors.          
Members of the Kir2.X sub-family, including Kir2.1, Kir2.2, Kir2.3, Kir2.4 and Kir2.6, 
are broadly expressed in neurons, cardiac, skeletal and smooth muscle cells, endothelial cells, 
macrophages and epithelial cells [111]. Much of our understanding of the physiology of Kir2.X 
channels comes from studies of disease-causing mutations in humans [112,113] and knockout 
mice [114]. While it is clear from this work that Kir2.X channels are essential in many organ 
systems, pinpointing their individual roles has been difficult due to their overlapping expression 
profiles, propensity to form Kir2.X heterotetramers and poorly developed pharmacology. The 
development of sub-type selective Kir2.X inhibitors would undoubtedly bolster efforts to 
understand the physiology and druggability of Kir2.X homo- and heteromeric channels. To date, 
however, the inhibitor pharmacology of Kir2.X channels is limited to barium, cesium and a 
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handful of non-specific drugs such as chloroquine [39], mefloquine [115], quinacrine [116], 
carvedilol [117], tamoxifen [58] and pentamidine [56]. Pregnenolone sulfate [43] and flecainide 
[44] are activators of Kir2.3 and Kir2.1, respectively. Like VU573 (this study), mefloquine, 
quinacrine, tamoxifen and carvedilol preferentially inhibit Kir2.3 over Kir2.1. 
Electrophysiological analysis of mutagenized channels suggests that chloroquine and 
pentamidine are cytoplasmic pore blockers, whereas mefloquine and carvedilol appear to disrupt 
channel interactions with the activating membrane phospholipid phosphatidylinositol 4,5-
bisphosphate (PIP2). There is evidence that quinacrine has a complex mechanism of action 
involving both pore block and disruption of channel-PIP2 interactions. In this regard, studies are 
underway to determine the blocking mechanism of VU573. Because VU573 is also a preferential 
inhibitor of Kir2.3, we are currently testing if it shares a common mechanism of action and 
binding site(s) with these drugs. Looking ahead, it will be important to determine whether 
VU573 or any of the aforementioned drugs show preference for homomeric versus heteromeric 
Kir2.X channels. These studies may help inform medicinal chemistry efforts to develop subtype-
specific inhibitors of Kir2.X channels.  
To our knowledge, VU573 is only the second and most potent Kir7.1 inhibitor available. 
We recently reported that the ~300 nM Kir1.1 inhibitor 7,13-Bis[(4-nitrophenyl)methyl]-1,4,10-
trioxa-7,13-diazacyclopentadecane dihydrochloride, or VU590, inhibits Kir7.1 with an IC50 of 
approximately 8 µM, making VU590 the first publically disclosed small-molecule inhibitor of 
both Kir1.1 and Kir7.1 [20]. In the present study, we found that VU573 preferentially inhibits 
Kir7.1 (IC50 ~1 µM) over Kir1.1 (IC50 ~19 µM).  
Kir7.1 is widely expressed in the brain, retinal pigment epithelial cells of the eye, the 
choroid plexus, and epithelial cells of the intestine, nephron and inner ear [101,118-121]. Very 
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little is known about the physiology of Kir7.1 due in part to the unusually small (i.e. ~50 fS) 
single-channel conductance of the channel. This precludes the use of single channel recording 
techniques to study its activity in native cell types, where other inward rectifiers with larger 
unitary conductances are often co-expressed. Whole-cell patch clamp recordings could 
conceivably be used to dissect out the relative contributions of Kir7.1 and other Kir channels to 
the macroscopic current provided that specific blockers were available. This scenario highlights 
the need for better pharmacological modulators of Kir7.1 and other members of the Kir channel 
family. The development of a Kir7.1 cell line that is sensitive to thallium is a significant 
headway for the identification of such modulators. The discovery of VU573 and its inactive 
analogs represent important steps toward filling this gap. Furthermore, and importantly, the 
development of a robust Tl+ flux assay using the Kir7.1-M125R mutant will enable HTS for 
chemically diverse modulators of the channel.  
Interestingly, heritable mutations in the Kir7.1-encoding gene KCNJ13 were recently 
found in patients with two forms of retinal disease [122,123]. These findings confirm the 
importance of Kir7.1 in retinal pigmented epithelia of the eye and raise important questions 
regarding the physiological roles of this channel in other organ systems. The development of 
potent and selective Kir7.1 antagonists will greatly facilitate those efforts.  
  
76!!
Chapter IV 
DEVELOPMENT AND VALIDATION OF FLUORESCENCE- AND AUTOMATED 
PATCH CLAMP-BASED FUNCTIONAL ASSAYS FOR THE INWARD RECTIFIER 
POTASSIUM CHANNELS KIR4.1  
This chapter was published under the same title in the journal ASSAY and Drug Development 
Technologies in the November/December 2013 issue  
Abstract 
The inward rectifier potassium (Kir) channel Kir4.1 plays essential roles in modulation of 
neurotransmission and renal sodium transport and may represent a novel drug target for temporal 
lobe epilepsy and hypertension. The molecular pharmacology of Kir4.1 is limited to neurological 
drugs, such as fluoxetine (Prozac©), exhibiting weak and nonspecific activity toward the channel. 
The development of potent and selective small-molecule probes would provide critically needed 
tools for exploring the integrative physiology and therapeutic potential of Kir4.1. A 
fluorescence-based thallium (Tl+) flux assay that utilizes a tetracycline-inducible T-Rex-
HEK293-Kir4.1 cell line to enable high-throughput screening (HTS) of small-molecule libraries 
was developed. The assay is dimethyl sulfoxide tolerant and exhibits robust screening statistics 
(Z' = 0.75 ± 0.06). A pilot screen of 3,655 small molecules and lipids revealed 16 Kir4.1 
inhibitors (0.4% hit rate). 3,3-Diphenyl-N-(1-phenylethyl)propan-1-amine, termed VU717, 
inhibits Kir4.1-mediated thallium flux with an IC50 of ~6 µM. An automated patch clamp assay 
using the IonFlux HT workbench was developed to facilitate compound characterization. Leak-
subtracted ensemble "loose patch" recordings revealed robust tetracycline-inducible and Kir4.1 
currents that were inhibited by fluoxetine (IC50 = 10 µM), VU717 (IC50 = 6 µM), and structurally 
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related calcium channel blocker prenylamine (IC50 = 6 µM). Finally, we demonstrate that VU717 
inhibits Kir4.1 channel activity in cultured rat astrocytes, providing proof-of-concept that the Tl+ 
flux and IonFlux HT assays can enable the discovery of antagonists that are active against native 
Kir4.1 channels. 
Introduction 
Refer to Chapter I for a review of the inward rectifier family of potassium (Kir) 
channels. Kir4.1 (KCNJ10) plays important roles in humans as underscored by loss-of-function 
mutations leading to SeSAME/EAST syndrome (reviewed in Chapter I), and thus may represent 
a druggable target for epilepsy and hypertension.   
Kir4.1 constitutes the major K+ conductance in brain and spinal cord astrocytes and 
contributes to a large negative membrane potential in these cells. It is generally believed that K+ 
released into the extracellular space during trains of action potentials moves down its 
electrochemical gradient and into astrocytes via Kir4.1. The large negative membrane potential 
generated by Kir4.1 also contributes to glutamate uptake by astrocytes. Accordingly, knockout of 
KCNJ10 depolarizes the astrocyte membrane potential and slows the rate of K+ and glutamate 
uptake [26,27]. The loss of spatial buffering likely accounts, at least in part, for the reduced 
seizure threshold in SeSAME/EAST syndrome [28,29]. However, the severity of the 
SeSAME/EAST syndrome may be due in part to gliosis, aberrant myelination, and neuronal 
death during embryological development [24,27]. The development of selective small-molecule 
antagonists that are active in vivo would provide important tools for exploring the “druggability” 
of Kir4.1 and dissecting the relative contributions of acute versus chronic Kir4.1 loss-of-function 
in SeSAME/EAST syndrome.  Furthermore, small-molecule activators of Kir4.1 may facilitate 
spatial buffering and lower the seizure threshold in epilepsy patients.  
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The renal consequences of SeSAME/EAST syndrome include polyuria, hypokalemia, 
and metabolic alkalosis, and are consistent with impaired NaCl reabsorption in the distal 
convoluted tubule (DCT). In the DCT, NaCl absorption is mediated by the thiazide diuretic-
sensitive NaCl cotransporter (NCC), which is located in the apical membrane of this nephron 
segment. Heteromeric Kir4.1/5.1 channels expressed in the basolateral membrane of the DCT 1) 
recycle K+ across the basolateral membrane to help maintain the activity of the Na+-K+-ATPase, 
and 2) hyperpolarize the basolateral membrane potential to facilitate the electrogenic exit of Cl- 
ions. Knockout of KCNJ10 in mice recapitulates the salt-wasting phenotype of subjects with 
SeSAME/EAST syndrome [28]. However, deletion of the Kir5.1-encoding gene KCNJ16 
paradoxically increases renal NaCl reabsorption [124]. As alluded to earlier, unlike homomeric 
Kir4.1 channels, Kir4.1/5.1 is critically regulated by intracellular pH (pHi) and is partially 
inhibited at physiological pHi. A loss of this negative regulation in KCNJ16-knockout mouse 
leads to an increase in Kir4.1 activity and NaCl reabsorption in the DCT [29]. Kir4.1/5.1 
antagonists would be expected to mimic thiazide diuretics by indirectly inhibiting NCC-mediated 
NaCl reabsorption. However, they could offer some important advantages over conventional 
diuretics due to the localization of the channel on the basolateral membrane [125-127]. Loop and 
thiazide diuretics must first be secreted by renal proximal tubule cells before reaching their sites 
of action on the apical membrane [128-131]. Interactions between diuretics and other secreted 
drugs, including antibiotics, NSAIDs, antivirals, as well as organic acid in the setting of renal 
failure, can limit their secretion and natriuretic effects. Kir4.1/5.1 inhibitors acting directly on the 
basolateral membrane should circumvent this limitation. Furthermore, Zaika et al. (2013) 
reported recently that dopamine inhibits Na+ reabsorption in the cortical collecting duct (CCD) 
through inhibition of Kir4.1 homomeric and Kir4.1/5.1 heteromeric channels [132]. Conceivably, 
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Kir4.1/5.1 antagonists would exhibit greater clinical efficacy that thiazide diuretics due to 
inhibition of sodium reabsorption in multiple nephron segments, unlike conventional diuretics 
that tend to work on single segments. Identifying subtype-selective modulators active against 
Kir4.1 or Kir4.1/5.1 channels will be essential for investigating the druggability of Kir4.1 as an 
anti-hypertensive target.   
Loss-of-function mutations in the methyl CpG binding protein 2 (MECP2) gene give rise 
to Rett syndrome, a neurological disorder characterized by difficulties with communication, 
learning, and motor coordination. Of relevance to the present discussion, the MECP2-null mouse 
exhibits increased expression of Kir4.1 in the locus coeruleus, a brainstem region involved in 
regulation of respiratory activity by carbon dioxide (CO2) [133]. Zang et al. (2011) proposed that 
an increase in CO2/pH-insensitive Kir4.1 homotetrameric channels and loss of CO2/pH-sensitive 
Kir4.1/5.1 heteromeric channels leads to a blunted respiratory response to CO2 and dysregulation 
of respiratory rhythmogenesis in Rett syndrome patients. If this is correct, and barring untoward 
general effects on neurotransmission, then small-molecule antagonists of homotetrameric Kir4.1 
channels may help correct breathing abnormalities in Rett syndrome patients [134,135].  
Evaluating the therapeutic potential of Kir4.1 awaits the development of potent, specific, 
and bioavailable small-molecule modulators, as the molecular pharmacology of Kir4.1 is limited 
to a small number of neurological drugs (e.g. selective serotonin reuptake inhibitors and tricyclic 
antidepressants) exhibiting weak off-target activity toward the channel. Here we report the 
development and validation of a fluorescence-based thallium (Tl+) flux assay to enable high-
throughput library screening and an automated patch clamp electrophysiology assay that utilize 
an IonFlux HT workstation to facilitate hit validation and characterization. 
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Materials and Methods 
Molecular biology and stable cell line generation 
The human Kir4.1 channel open reading frame was purchased from OriGene 
Technologies (NM_002241.4; Origene) and sub-cloned into pcDNA5/TO (Life Technologies) 
using standard molecular biology techniques. Polyclonal T-REx-HEK293 cell lines stably 
transfected with pcDNA5/TO-Kir4.1 were established essentially as described previously 
[20,136]. Monoclonal cell lines were isolated through limiting dilution in 384-well plates and 
tested for tetracycline inducible Tl+ flux, as outlined below. The cell lines were maintained in 
DMEM growth medium containing 10% FBS, 50 U/ml Penicillin, 50 (g/mL Streptomycin, 5 
(g/mL Blasticidin S and 250 (g/mL Hygromycin in a 5% CO2 incubator at 37 ºC.  
  
Manual patch clamp electrophysiology 
T-REx-HEK293-Kir4.1 cells were used for patch clamp analysis following overnight 
induction with tetracycline (1 µg/mL). The standard pipette solution contained (in mM): 135 KCl, 
2 MgCl2, 1 EGTA, 10 HEPES-free acid, and 2 Na2ATP (Roche), pH 7.2, 275 mOsmol/kg. The 
standard bath solution contained (in mM): 135 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 5 glucose, and 10 
HEPES-free acid, pH 7.4, 290 mOsmol/kg. Electrodes pulled from capillary glass had resistances 
of 3.0-3.5 M& when filled with pipette solution. Voltage and current signals were generated and 
acquired using an Axopatch 200B amplifier and Digidata 1322A analog-to-digital converter 
(Molecular Devices). Data acquisition and analysis were performed using pClamp 9.2 software 
(Molecular Devices). All recordings were made at room temperature (20-23ºC). 
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Western blot analysis 
Monoclonal T-REx-HEK293-Kir4.1 cells were plated at a density of 1x105 cells/cm2 and 
cultured overnight in the absence or presence of tetracycline (0.01-1.0 (g/mL), washed three 
times with ice-cold phosphate-buffered saline (PBS) and solubilized in ice-cold RIPA buffer 
containing (in mM): 150 NaCl, 100 NaF, 50 Tris-HCl (pH 8.0), 35 sodium deoxycholate, 5 
EDTA, 1% Triton X-100, 0.1% SDS and 1X Protease Inhibitor Cocktail. Cell lysates were 
scraped into Eppendorf tubes, sonicated, rotated end-over-end for 30 min at 4°C, and then 
centrifuged for 10 min to pellet insoluble material.  The protein concentration of cleared lysates 
was quantitated using BCA reagent (Thermo Scientific). Cell lysates were either used 
immediately or frozen as single-use aliquots at -80°C for subsequent immunoblot analysis.     
Proteins were separated electrophoretically using 10% Bis-Tris NuPAGE gels (Life 
Technologies) and transferred to 0.45 (m pore nitrocellulose membranes (BioRad, Hercules, 
CA) for immunoblot analysis. Membranes were blocked overnight at 4ºC in Tris-buffered saline 
(25 mM Tris, 1.3 mM KCl and 137 mM NaCl) containing 0.1% TWEEN-20 (TBST) and 5% 
nonfat milk. Membranes were incubated for 1 h at room temperature in polyclonal Kir4.1 
antiserum (Alomone Labs) diluted 1:500 in milk-TBST and subsequently for 1 h at room 
temperature in milk-TBST containing HRP-conjugated secondary antiserum diluted 1:40,000.  
Protein bands were visualized on film using enhanced chemiluminescence detection methods 
(Thermo Scientific). Membranes were stripped in buffer containing 100 mM 2-mercaptoethanol, 
62.5 mM Tris-HCl (pH 6.7) and 2% SDS (50°C for 30 min) and reprobed with !-actin antiserum.    
 
 
82!!
Tl+ flux assay development and library screening 
A Tl+ flux assay of Kir4.1 function was developed essentially as described previously 
[137]. Briefly, T-REx-HEK293-hKir4.1 cells (20,000 cells/20 (L per well) were plated in clear-
bottomed, amine-coated, black-walled 384-well plates (BD Biosciences) and cultured overnight 
in DMEM containing 10% dialyzed FBS, 50 U/mL Penicillin, 50 (g/mL Streptomycin, 5 (g/mL 
Blasticidin S and 250 (g/mL Hygromycin and 1 (g/mL tetracycline (assay media) at 37 °C in 
the presence of 5% CO2. The following day, a dye stock was prepared fresh by dissolving 50 µg 
Fluozin-2 (Life Technologies) in 100 µL of anhydrous DMSO. To prepare the dye loading 
solution, 50 (L of 20% pluronic acid is added to the above dye stock and the dye stock was 
diluted to 2 (M with Assay Buffer (AB) (Hanks Balanced Salt Solution + 20 mM HEPES, pH 
7.3). Twenty microliters was added to each well containing cells. The cells were incubated for 60 
min at room temperature (RT), followed by automated washing using the ELx405 plate washer 
(BioTek) primed with AB. A final aspiration step resulted in 20 (L residual volume. The plate 
was loaded into the Functional Drug Screening System 6000 (FDSS6000; Hamamatsu) to obtain 
an initial baseline image (F0)–10 images at 1 Hz (excitation, 470 ± 20 nm; emission, 540 ± 30 
nm). The FDSS’s integrated 384-channel pipettor simultaneously added 20 (L of DMSO vehicle 
control, fluoxetine or test compounds to each plate for final concentrations of 0.1 %, 100 and 10 
(M, respectively. Test compounds in 40 (L of AB were prepared by transferring 80 nL into a 
384 well polypropylene plate using the ECHO 550 acoustic formatter (Labcyte) from a 10 mM 
stock (BioFocus DPI). Four columns in each plate were filled with DMSO vehicle control or 
fluoxetine-containing buffer for determination of Z$ (e.g. Fig. 3B), while the remaining 20 
columns were used for compound screening. The compounds were allowed to incubate on the 
cells for 20 min at RT; then, the plate was reloaded into the FDSS and a second baseline 
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acquired. The FDSS's integrated pipettor added 10 (L of thallium stimulus (125 mM sodium 
gluconate, 12 mM thallium sulfate, 1 mM magnesium sulfate, 1.8 mM calcium gluconate, 5 mM 
glucose, 10 mM HEPES, pH 7.3) while imaging of the flux continued at 1 Hz for 4 min total 
sampling time.  
 
Concentration-response curves  
Compound master plates were created by serial diluting compounds 1:3 from 10 mM 
stock in 100% DMSO using the BRAVO liquid handler (Agilent Technologies). Assay daughter 
plates were created using the ECHO 555 liquid hander (Labcyte), transferring 240 nL from the 
master plate to the daughter plate for each well followed by addition of 40 (L of AB resulting in 
antagonist compound concentration-response curves (CRCs) starting at 60 (M (2X final 
concentration). Concentration-response series were done in triplicate in the daughter plate. Cell 
plates and daughter compound plates were loaded onto an FDSS 6000. Baseline readings were 
taken (10 images at 1 Hz; excitation, 470 ± 20 nm; emission, 540 ± 30 nm) and 20 (l of test 
compounds was added followed by 50 images at 1 Hz additional baseline. Following a 20-min 
incubation period, baseline readings were taken for 30 seconds followed by addition of Tl+ 
stimulus buffer, followed by a 4-min read.  
Data were analyzed using Excel (Microsoft Corp.). Raw data were opened in Excel and 
each data point in a given trace was divided by the first data point from that trace (static ratio). 
For experiments in which antagonists were added, data were again normalized by dividing each 
point by the fluorescence value immediately before the thallium addition to correct for any subtle 
differences in the baseline traces after the compound incubation period. The slope of the 
fluorescence increase beginning 5 s after Tl+ addition and ending 15 s after Tl+ addition was 
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calculated. The data were then plotted in Origin software (OriginLab Software, Inc.) to generate 
concentration-response curves after correcting for the slope values determined for baseline 
waveforms generated in the presence of vehicle controls. Potencies were calculated from fits 
using a four-parameter logistic equation. 
 
Automated patch clamp electrophysiology  
T-REx-HEK293-Kir4.1 cultured cells were induced overnight with 0.1 (g/ml tetracycline 
prior to IonFLux automated electrophysiology. For cell isolation, cultured cells were washed 
with Ca- and Mg-free HBSS buffer, followed by Detachin™ solution (Genlantis) to detach them. 
The cells were resuspended in extracellular solution at 3x106 cells/ml. The extracellular solution 
contained (mM): 135 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 5 glucose, and 10 HEPES-free acid, pH 
7.4, 290 mOsmol/kg. The intracellular solution for the whole cell voltage clamp contained (mM): 
5.4 CaCl2, 1.8 MgCl2, 120 KCl, 4 Na2ATP, 10 HEPES, and 10 EGTA, pH 7.2 with KOH. The 
cell suspension in extracellular solution was dispensed into an IonFlux plate for recording. The 
IonFlux plate has been described previously [138,139]. In brief, the IonFlux HT plate consists of 
32 unique experimental patterns with each experimental pattern being comprised of 12 wells in 
the form of an SBS standard 384-well plate with a unique microfluidic bottom.  Within a 12-well 
experimental pattern, two wells, referred to as “traps” are filled with intracellular solution, eight 
wells are designated for compounds which can be applied at any time during the experiment, one 
well is filled with cell suspension in extracellular solution and the remaining, “waste” well 
contains the solution outflow during the experimental run.  For each experimental pattern, there 
are two recordings.  Each recording is from and ensemble of 20 cells patched in parallel on a 
single “trap”, such that the current measured is the sum of all 20 cells of the ensemble.  Given 
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the variability in the quality of the seal for each given cell, the ensemble recording ends up being 
similar to “loose seal” recording conditions. 
For recording Kir4.1 current, cells were voltage-clamped at -80 mV (which is near EK for 
the solution pair used) and stepped to -120 mV then ramped at 0.5 mV/s to +120 mV, and finally 
stepped back to -80 mV. Given that the cells are being held near EK, the current flow at the 
holding potential is primarily non-specific leak current, due in large part to the “loose seal” 
recording conditions. Kir4.1-specific current was estimated using the following formula:                                      
IKir4.1 = I-120 mV – (I-80 mV*1.5) 
This equation is based on the assumption that the current measured at -80 mV is 
exclusively, nonspecific leak.  Data analysis and graphical presentation were performed using a 
combination of IonFlux, Excel and Origin software. 
 
Animals 
Experiments were performed on Sprague-Dawley rats and were approved by the 
University of Alabama Institutional Animal Care and Use Committee.   
 
Astrocyte cultures 
Spinal cord astrocytes were cultured in phenol red-free medium as described previously 
[26].  Briefly, postnatal day 0 (P0) pups were decapitated and spinal cords were dissected into 
ice-cold serum-free EMEM (Gibco) containing 20 mM glucose. Once the meninges were 
stripped and cords were minced and placed into an O2 saturated papain solution (Worthington) 
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for 20 min.  The tissue was washed twice with spinal cord astrocyte media (EMEM 
supplemented with 10% fetal calf serum, 20 mM glucose, and penicillin/streptomycin) and then 
triturated. Cells were plated at a density of 1.0 x 106 cells/mL on polyornithine- and laminin-
coated coverslips. The medium was changed every day for the first 3 days and then every fourth 
day thereafter. Electrophysiology was performed on astrocytes that had been in culture for 7-10 
days.  
  
Astrocyte electrophysiology  
Whole-cell voltage-clamp recordings were made as described previously [26].  
Coverslips were transferred to a Zeiss Observer D1 microscope (Zeiss) equipped with DIC optics.  
Signals were acquired using an Axopatch 200B amplifier, controlled by Clampex 10.2 software 
via a Digidata 1320 interface (Axon Instruments). Signals were filtered at 2 kHz and digitized at 
5 kHz.  Data acquisition and storage were conducted with the use of pClamp 10.2 (Axon 
Instruments).  Whole-cell capacitance and series resistances were measured directly from the 
amplifier, with the upper limit for series resistance being 12 M% and series resistance 
compensation adjusted to 80% to reduce voltage errors. Coverslips were continuously perfused 
with artificial cerebral spinal fluid (ACSF) containing (in mM): 120 NaCl, 3 KCl, 1 MgCl2, 2 
CaCl2, 26.2 NaHCO3, 11 glucose and 5 HEPES, bubbled with 95% O2 and 5% CO2. The pipette 
solution contained (in mM) 125 K-gluconate, 10 KCl, 10 HEPES, 10 creatine phosphate, 2 
MgATP, 0.2 NaGTP and 0.5 EGTA.  Drugs were diluted in DMSO to a stock concentration and 
added directly to the bathing solution at a concentration of 1 (L per milliliter (1:1,000). 
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Results 
Cell line characterization 
A monoclonal T-REx-HEK293 cell line expressing Kir4.1 from a tetracycline-inducible 
promoter was developed and characterized. Tetracycline-inducible cell lines are useful because 
1) they can limit potential cell line degeneration and loss of assay performance due to K+ channel 
overexpression, and 2) they provide a convenient internal control for distinguishing effects of 
pharmacologically active compounds on endogenous Tl+ flux pathways versus the overexpressed 
Kir channel of interest. Manual whole-cell patch clamp electrophysiology was used to 
characterize the functional and pharmacological properties of Kir4.1 channels expressed in T-
REx-HEK293 cells. Under current clamp conditions, the resting membrane potential of cells 
cultured overnight in the absence or presence of tetracycline (1 (g/mL) was -23.8 ± 3.9 mV (n = 
8) and -72.5 ± 0.6 mV (n = 5), respectively. The cells were voltage clamped at -75 mV, and then 
stepped between -120 mV and +120 mV in 10-mV increments for 250 ms to evoke whole-cell 
currents. Uninduced cells exhibited relatively small-amplitude outward currents at positive test 
potentials (Fig. 1A) carried by voltage-gated K+ and Cl- channels endogenously expressed in 
HEK293 cells [140],[141]. In sharp contrast, tetracycline induced the expression of large-
amplitude inward and outward currents exhibiting weak rectification at positive test potentials 
(Fig. 1B). The current was inhibited by barium (not shown) as well as the selective serotonin 
reuptake inhibitor (SSRI) fluoxetine (Fig. 1C), as reported by Kurachi and colleagues [46,142]. 
The mean ± SEM current-voltage (I-V) relationships recorded from uninduced cells (open 
circles; n = 5) or induced cells in the absence (closed circles; n = 8) or presence (open triangles; 
n = 4) of 100 (M fluoxetine are shown in Fig. 1D. Fluoxetine also inhibited the endogenous 
outward current in HEK cells (Fig. 1C-D), consistent with reports the drug inhibits other ion 
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channels [143-145]. Thus, overnight induction with tetracycline gives rise to robust, fluoxetine-
inhibitable Kir4.1 channel activity in this stable cell line. As shown in Fig. 1E, western blot 
analysis revealed that overnight incubation with tetracycline led to the dose-dependent induction 
of Kir4.1 channel expression that reached a maximum level with 0.1 (g/mL tetracycline. No 
Kir4.1-immunoreactive bands were observed in lysates prepared from nontransfected “parental” 
T-REx cells, indicating that the antiserum is specific for Kir4.1.   
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Figure 1. Tetracycline-inducible Kir4.1 expression in stably transfected T-REx-HEK293 
cells. (A, B, C) Representative whole-cell currents recorded from monoclonal T-REx-HEK293-
Kir4.1 cells cultured without tetracycline (A), or with tetracycline before (B) and after (C) bath 
addition of the Kir4.1 channel blocker fluoxetine. Cells were voltage clamped between -120 mV 
and +120 mV for 500 ms in 10mV increments from a holding potential of -75 mV. (D) Mean ± 
SEM current–voltage (I-V) relationships from uninduced (U) or induced cells bathed in control 
buffer (I) or buffer containing 100 (M fluoxetine (I + F). Current amplitude was normalized to 
cell capacitance and is expressed as pA/pF (n = 5–6). (E) Western blot analysis of Kir4.1 
expression in lysates prepared from parental T-REx or T-REx-Kir4.1 cells cultured overnight 
with the indicated concentrations of tetracycline. Tet (0.1 and 1 (g/mL) induced in T-REx-
Kir4.1 cells, but not in the parental cells (T-REx), the expression of a prominent ~42 kDa band 
and higher-molecular-weight bands corresponding to differentially glycosylated forms of the 
channel. The membrane was stripped and reprobed for !-actin to ensure equal protein loading.  
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Tl+ flux assay 
A quantitative Tl+ flux assay was developed to enable high-throughput screening (HTS) 
for small-molecule Kir4.1 modulators. The assay employs the fluorescent dye FluoZin-2 to 
report the inwardly directed movement of the K+ congener Tl+ through the channel pore, as 
reported by us for other Kir channels previously [20,21,64,137]. Monoclonal T-REx-HEK293-
hKir4.1 cells were plated in clear-bottomed 384-well plates, cultured overnight in the absence or 
presence of tetracycline, and used in Tl+-flux assays the following day (see Materials and 
Methods for details). Figures 2A and 2B show FluoZin-2 fluorescence emission traces recorded 
from wells containing uninduced or induced cells, respectively, before and after addition of 
various Tl+ concentrations (arrow; see below). The Tl+-induced fluorescence increase in 
uninduced cells (Fig. 2A) was relatively small, reflecting the movement of the cation through 
endogenous pathways. However, induction of Kir4.1 expression led to a dramatic increase in the 
rate and extent of Tl+ flux (Fig. 2B). Indeed, we were concerned that Tl+ flux was so high that 
the indicator dye may become saturated and limit the assay’s ability to detect weak inhibitors or 
agonists, and therefore established a Tl+ concentration-response curve (CRC) to identify a 
submaximal concentration that still provided a robust signal window. The inset of Fig. 2B shows 
that mean ± SEM change in FluoZin-2 fluorescence exhibited a sigmoidal, dose-dependent 
relationship that saturated around 2 mM Tl+. The concentration required to evoke ~80% of the 
maximal response was determined from the fit of a four-parameter logistic function to be 0.84 
mM. This concentration was used for assay development and the pilot screen to provide 
“headroom” for identifying small-molecule activators of Kir4.1.        
The sensitivity of the assay to the small-molecule solvent DMSO was determined by 
assessing Tl+ flux across a 2-fold dilution series of DMSO ranging from 0.1% to 5% v/v. As 
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shown in Fig. 2C, Tl+ flux was unaffected at concentrations up to 0.3% v/v, but it dropped off 
dose-dependently at higher concentrations. DMSO had no effect on Kir4.1-mediated Tl+ flux at 
the screening concentrations of 0.1% and 0.3% v/v (see below).  
“Checkerboard” assays were performed on 3 separate days to determine the well-to-well 
uniformity within a plate and day-to-day reproducibility. Every other well of a 384-well plate 
containing tetracycline-induced T-REx-HEK-293-Kir4.1 cells was treated for 20 min with 
DMSO (vehicle) or 100 (M Fluoxetine (nonspecific blocker) before initiating Tl+ flux. In Figure 
2D, Tl+-induced FluoZin-2 fluorescence from each well of one plate is plotted, with the mean 
fluorescence and 3 standard deviations from the mean indicated with a µ and 3*, respectively. 
The assay conditions afforded clear separation of the two cell populations, yielding a mean ± 
SEM Z’ value for 9 plates on 3 separate days of 0.75 ± 0.06. Thus, the assay is robust, 
reproducible, and suitable for HTS.               
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Figure 2. Thallium flux reporter assay of Kir4.1 channel function. (A, B) Representative Tl+ 
-induced changes in FluoZin-2 fluorescence recorded from T-REx-HEK293-Kir4.1 cells cultured 
overnight without (A) or with (B) tetracycline. Baseline fluorescence was recorded for 4 min 
before Tl+ addition (arrow). Mean ± SEM (n = 3) concentration–response curve (CRC) and 4-
parameter logistic fit for Tl+ flux recorded from tetracycline-induced cells is shown in the inset 
of panel (B). (C) Dimethyl sulfoxide (DMSO) tolerance of Kir4.1-mediated Tl+ flux. Data are 
means ± SEM Tl+ flux normalized to that recorded in the presence of DMSO (n = 9). (D) 
Representative checkerboard assay using DMSO (vehicle) or 100 (M fluoxetine. The mean peak 
fluorescence amplitude of each sample population is indicated with a solid line. Three standard 
deviations from the mean are shown with a dashed line. The mean ± SD Z’ calculated over nine 
plates on 3 separate days was 0.75 ± 0.06.  
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Discovery of a novel Kir4.1 inhibitor  
The assay was validated with a screen of 3,655 small molecules and bioactive lipids at 
the Vanderbilt HTS center. Small molecules and lipids were tested at a nominal concentration of 
10 (M (0.1% DMSO) and 3 (M (0.3% DMSO), respectively. The mean Z’ for the entire 19-
plate run, calculated from the peak fluorescence amplitude in vehicle or fluoxetine-treated wells, 
was 0.82 ± 0.04. The hit rate was 0.4% (16/3,655 compounds). All of the hits were inhibitors, 
none of which were lipids. The most potent inhibitor identified was 3,3-diphenyl-N-(1-
phenylethyl) propan-1-amine, which we termed VU717. The chemical structure is shown in Fig. 
3A. In Tl+ flux assays, VU717 dose-dependently inhibited Kir4.1 activity with an IC50 of 6.3 (M 
and Hill coefficient of 4.5 (Figs. 3B-C).   
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Figure 3. Discovery of a novel Kir4.1 channel inhibitor in a Tl + flux-based pilot screen. (A) 
Chemical structure of 3,3-diphenyl-N-(1-phenylethyl) propan-1-amine (VU717). (B) 
Representative FluoZin-2 fluorescence traces recorded from induced T-REx-HEK293-Kir4.1 
cells treated with the indicated doses of VU717. (C) Mean ± SEM CRC for VU717-dependent 
inhibition of Kir4.1-mediated Tl+ flux. Data are from three independent experiments performed 
in triplicate.  
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Development of an automated patch clamp assay for Kir4.1 using the IonFlux HT 
Patch clamp electrophysiology is the gold standard technique for interrogating the 
pharmacology of ion channels. However, manual patch clamping is low-throughput and thus 
imposes a considerable bottleneck. We therefore set out to develop an automated patch clamp 
assay to minimize this bottleneck and facilitate the development of Kir4.1 channel modulators.   
We first established the time required to induce Kir4.1 channel expression and function in 
T-REx-HEK293-Kir4.1 cells following induction with tetracycline. Figure 4A shows a 
representative Western blot of Kir4.1 (top panel) or actin (bottom panel, loading control) 
expression in lysates prepared from cells cultured with tetracycline (1 (g/ml) for 0, 2, 4, 6, or 18 
h. Kir4.1 expression was time dependent and reached a maximum following 18 h of induction.  
We then assessed Kir4.1 channel activity in cells induced for the same time period using 
an IonFlux HT automated patch clamp workstation. The IonFlux HT utilizes a network of 
microfluidic channels that enables fully automated cell introduction, trapping, sealing, whole-cell 
formation, and voltage clamp using 64 independent voltage clamp amplifiers. Recordings are 
made in the “loose patch” configuration from an ensemble of 20 cells per channel. This approach 
has the advantage of increasing the robustness and throughput of recordings, but may suffer from 
significant “leak” current introduced by sub-Giga-Ohm-resistance seals. We therefore employed 
Ba2+ to discriminate Kir4.1-mediated current from leak current. Cells were voltage clamped at a 
holding potential of -80 mV, which is near the calculated Nernst equilibrium potential for K+, 
and then stepped to a test potential of -120 mV. Currents were leak-subtracted as described in 
Material and Methods. The mean ± SEM of Ba2+-sensitive current at -120 mV is shown in Fig. 
4B. In contrast to the Western blot results showing abundant Kir4.1 protein expression after only 
6 h of tetracycline induction, no Ba2+-sensitive currents were detectable at this time point. 
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Following 18 h of induction, however, robust Ba2+-inhibitable were clearly observed. Cells were 
therefore induced overnight with tetracycline in all subsequent experiments.  
Figure 4C shows representative, leak-subtracted current traces recorded in the absence or 
presence of 300 (M Ba2+ from cells subjected to a voltage ramp between -120 mV and +120 mV. 
In control solution, the current exhibited a steep voltage-dependent relationship between -120 
mV and +50 mV, a plateau around +60 mV, and rectification at potentials more positive than 
+70 mV. This current waveform is similar to that recorded from T-REx-HEK293-Kir4.1 cells 
using the manual patch clamp technique (Fig. 1D). The inward current was abolished by 300 (M 
Ba2+.  
Figure 5A summarizes the current amplitudes recorded in the absence or presence of 
Ba2+ from an entire 384-well format plate on two separate days. Each plate consists of 32 
“experimental patterns”, each containing 2 cell “traps”. Each data point represents the average 
current amplitude from two daughter traps. The mean ± SD current amplitudes in control and 
Ba2+-treated cells were, respectively, -5857 ± 1438 pA and 886 ± 478 pA. Out of 64 patterns 
tested, 59 of these led to successful cell trapping, whole-cell formation, and recordings of Ba2+-
inhibitable Kir4.1 channel activity (92% success rate).  
The mean ± SEM Ba2+ CRC recorded on two separate days are shown in Fig. 5B. The 
IC50 values derived from 4-parameter logistic functions for days 1 and 2 were 3.59 ± 0.12 (M 
and 2.37 ± 0.12 (M, respectively. Taken together, these data indicate that robust Kir4.1-
dependent channel activity can be readily measured using the IonFlux HT workstation. 
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Figure 4. Automated patch clamp electrophysiology assay for Kir4.1. (A) Time-course of 
Kir4.1 protein expression in lysates prepared from cells cultured for the indicated times with 
tetracycline (0.1(g/mL). !-actin was used as a loading control. (B) Corresponding time-course 
analysis of Ba2+-inhibitable Kir4.1 current amplitude at -120 mV recorded using an IonFlux HT 
automated patch clamp workstation. Following overnight induction with tetracycline, the cells 
were voltage clamped at a holding potential of -80mV and then ramped between -120 mV and 
+120 mV in the absence (control) and presence of 300 (M barium (Ba2+). Data are mean ± SEM 
current amplitude at -120 mV. (C) Representative leak-subtracted (see the ‘‘Materials and 
Methods’’ section), whole-cell currents recorded in the absence or presence of Ba2+.  
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Figure. 5. The IonFlux HT assay is reproducible. (A) Leak-subtracted whole-cell current 
amplitude recorded at -120 mV from individual microfluidic patterns in the absence or presence 
of 300 (M Ba2+. Data recorded on two separate days are shown. (B) Mean ± SEM Ba2+ CRC 
recorded on two separate days (n = 10–30).  
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Characterization of small-molecule Kir4.1 antagonists with the IonFlux HT 
VU717 and fluoxetine share some chemical features that likely contribute to their activity 
toward Kir4.1, including two hydrophobic benzene rings and an ionizable secondary amine 
group (Fig. 6A). In an effort to identify other inhibitors of Kir4.1, a search of the National Center 
for Biotechnology Information PubChem database for structurally related substances revealed 
that the calcium channel blocker prenylamine (3,3-diphenyl-N-(1-phenylpropan-2-yl)propan-1-
amine), shares these chemical features (Fig. 6A). Prenylamine was formerly used clinically as a 
vasodilator in the treatment of angina pectoris, but was discontinued because of its propensity to 
induce torsades de pointes by blocking hERG channels [146]. The potencies of VU717, 
prenylamine, and fluoxetine were compared across a 3-fold dilution series ranging from 300 nM 
to 100 (M. The mean ± SEM CRCs for the three compounds are shown in Fig. 6B. The IC50 
values for VU717 (n = 6-43), prenylamine (n = 4-20), and fluoxetine (n = 2-17) were 6.0 ± 1.3 
µM, 6.2 ± 1.0 µM, and 10.4 ± 3.2 µM, respectively, and the Hill coefficients were 1.9, 2.0, and 
2.3, respectively. For comparison, CRCs were established in Kir4.1 Tl+ flux assays for VU717, 
prenylamine, and fluoxetine, which yielded IC50 values of 9.72 ± 2.0 µM, 14.8 ± 1.9 µM, and 
22.8 ± 0.9 µM, respectively. Thus, although the potencies derived from electrophysiology and 
Tl+ flux assays differ by ~ 2.5-fold, the Tl+ flux assay assigned the correct rank-order potency 
across this series.  
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Figure 6. Characterization of small-molecule Kir4.1 inhibitors using the IonFlux HT. (A) 
Chemical structures of VU717, prenylamine, and fluoxetine. (B) Mean ± SEM CRCs for VU717 
(triangle, n = 6–43), prenylamine (circle, n = 4–20), and fluoxetine (square, n = 2–17). A fit of 
the CRC with a single-site four-parameter logistic function yielded IC50 values of 6.0 ± 1.3, 6.2 ± 
1.0, and 10.4 ± 3.2 (M, respectively, for VU717, prenylamine, and fluoxetine.  
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VU717 inhibits native Kir4.1 channels in astrocytes     
Given that VU717 was discovered in a screen against a heterologously expressed channel, 
we assessed the effects of the compound on astrocyte currents to determine if VU717 is active 
against native Kir4.1 channels. Astrocytes exhibiting significant arborization were selected under 
DIC microscopy for voltage clamp recording (Fig. 7A, inset). In response to a linear voltage 
ramp (-160 mV to +160 mV over 300 ms) these cells responded with a large amplitude current 
that reversed at -80 mV (Fig. 7B). This current was nearly completely inhibited in the presence 
of 250 µM Ba2+ containing ACSF, identifying this current as Kir4.1 mediated current as 
previously described [26,147]. Barium was then washed off and the currents quickly returned to 
baseline. ACSF containing 10 (M or 30 (M VU717 was then applied to the voltage clamped cell 
until maximum inhibition was achieved.  Figure 7B shows that 10-30 (M VU717 inhibited 
approximately 90% of the whole-cell current at -120 mV, which is nearly identical to that 
blocked by 250 (M barium. This is comparable to that observed in conventional patch clamp 
recordings from Kir4.1-expressing HEK293 cells in which VU717 inhibited 94 ± 1.8% (n = 5) of 
current at -120 mV. This data clearly indicates that the Tl+ flux assay is capable of identifying 
inhibitors of native Kir4.1 channels.  
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Figure 7. VU717 inhibition of native Kir4.1 activity channels in astrocytes. (A, B) 
Representative I-V relationships recorded by voltage ramping a cell from -160 mV to +160 mV 
in control artificial cerebral spinal fluid (ACSF) or ACSF containing 30 (M VU717 or 250 (M 
Ba2+. A DIC image of a cultured astrocyte is shown in the inset. (B) Mean ± SEM % inhibition 
of astrocyte whole-cell current at -120 mV by VU717 (10 and 30 (M; n = 5, n = 6, respectively) 
or Ba2+ (250 (M; n = 16).  
0
20
40
60
80
100
 10 µM 
VU717 
30 µM 
VU717 
250 µM 
barium 
Figure 7 
%
 B
lo
ck
 a
t -
12
0 
m
V 
A B 
103!!
Discussion 
The assays developed herein should support a robust small-molecule probe discovery 
effort for Kir4.1. The Tl+ flux assay developed originally by Weaver et al. (2003) and later 
commercialized by Invitrogen and TEFlabs under the FluxOR© and Thallos labels, respectively, 
has now been used to establish fluorescence-based functional assays for a variety potassium 
channels, including Kir1.1, Kir2.1, Kir2.3, Kir3.1/3.2, Kir7.1, hERG, KCNQ4 
[20,21,50,64,82,83,85,148-150], as well as the potassium-chloride co-transporter KCC2 [108]. 
Most Kir channels are well suited for the Tl+ flux assay, because they typically exhibit a large 
open probability near the resting membrane potential of the cell and therefore do not require 
activation by depolarization or an agonist. This is not true of G protein-coupled Kir3 channels, 
which require activation with a Gi/o-coupled receptor before Tl+ addition [64,83].  
Like most of the Tl+ flux assays developed by our group [20,21,64,137], the Kir4.1 assay 
employs a tetracycline-inducible HEK293 cell expression system. This offers a number of 
experimental advantages over constitutive expression systems for assay development and HTS. 
For example, the ability to quantitate “background” Tl+ flux through endogenous pathways and a 
K+ channel target of interest is useful for selecting stably transfected clones affording the most 
robust signal window for screening. Dozens of clones cultured in the absence or presence of 
tetracycline can be assayed simultaneously, and those exhibiting the strongest tetracycline-
inducible signal can be selected for assay development. In the absence of suitable reference 
compounds (e.g. fluoxetine used in this study), uninduced cells could be included in assay plates 
as a “blocked” control for calculating Z’ scores. Finally, false-positive hits acting on endogenous 
Tl+ flux pathways, as opposed to the K+ channel target, can be rapidly identified and triaged in 
screens against uninduced cells. As shown in Figs. 2A and 2B, Kir4.1-mediated Tl+ flux 
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dominates the signal window, which increases the ability of the assay to identify specific Kir4.1 
modulators. 
 In pilot experiments, we noted that the fluorescence emission of FluoZin-2 approached 
its asymptotic value within ~60 sec of adding Tl+ to the cell plate. Such robust Tl+ flux was not 
surprising given that 1) the cell line was selected for high Kir4.1 expression and function, and 2) 
Kir4.1 is a “weak rectifier” exhibiting a high open-state probability across a broad range of 
membrane potentials, unlike some voltage-gated K+ channels that require depolarization for 
channel opening and Tl+ flux [82]. However, the robustness of Tl+ flux raised concerns that the 
dye would become saturated and fail to report subtle changes in Kir4.1 activity caused by 
pharmacologically weak modulators in a screen. We reasoned that using a lower Tl+ 
concentration would prevent saturation, increase the sensitivity of the assay, and provide 
“headroom” for identifying activators. From dose-response experiments, an EC80 concentration 
of 0.84 mM was determined, which represents only 15% of that used previously by our group 
[20,21,64,137]. Despite the use of lower Tl+ concentrations, which tended to slightly increase the 
well-to-well variability in fluorescence and reduce the mean Z’ score (data not shown), the assay 
generated robust screening statistics indicating that it is suitable for HTS of chemical libraries. 
Our studies of VU717 show that the assay is clearly capable of identifying a ~6 µM IC50 
inhibitor of Kir4.1 in a primary screen, which is a reasonable starting point to developing a 
submicromolar inhibitor suitable for in vitro and ideally in vivo pharmacology.     
With an anticipated hit rate of 0.4%, it would take several weeks to characterize a hit 
collection from a large compound screen using “gold standard” manual patch clamp 
electrophysiology techniques. We therefore evaluated the IonFlux HT as an automated patch 
clamp workstation for characterizing Kir4.1 modulators in a shorter time frame while 
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maintaining fidelity.  The IonFlux platform technology is based on the Fluxion’s proprietary 
microfluidic system, which enables ensemble cell recording in a continuous manner. While 
already validated for the study of ligand-gated, voltage-gated, sodium and hERG channels 
pharmacology [138,139], this is the first study to show that the IonFlux platform can be adapted 
for the study of Kir channel pharmacology. Kir4.1 is considered a “weak rectifier” since a 
decrease in channel conductance (i.e. rectification) is only observed at relatively large positive 
potentials (e.g. Fig. 4A). This presented a challenge for discriminating Kir4.1-derived current in 
“loose patch” recordings contaminated by “leak” current, because both channel-mediated and 
leak currents exhibit Ohmic (linear) current-voltage relationships across most of the voltage 
range tested. To circumvent this problem, we reasoned that all of the Kir4.1-mediated current 
would reverse directions at the Nernst equilibrium potassium for potassium (EK), which was 
approximately -80 mV under the recording conditions used as opposed to 0 mV for leak-
mediated currents. Leak current, defined as the offset current at -80 mV multiplied by 1.5 (i.e. -
80 mV x 1.5 = -120 mV), was subtracted from the whole-cell current amplitude at -120 mV to 
yield values for leak-subtracted Kir4.1 current amplitude. The results suggest that this platform is 
sufficiently robust (> 90% success rate) to provide an initial electrophysiological characterization 
of small molecule inhibitors of Kir4.1. With a runtime of ~30 min per plate and the ability to 
characterize up to 30 compounds along with controls on a given plate the system will be capable 
of producing CRCs for hundreds of compounds per day.   
In conclusion, we have developed and validated a robust Tl+ flux assay to support a 
primary screen for small-molecule modulators of Kir4.1. A pilot screen of 3,655 small-molecules 
and lipids and a subsequent structural homology search led to the discovery of the novel Kir4.1 
antagonists VU717 and prenylamine. In addition, we demonstrated for the first time that Kir4.1 
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channel pharmacology can be characterized in automated loose patch clamp electrophysiology 
assays using the IonFlux HT workstation. The development of small-molecule Kir4.1 modulators 
using these assay platforms will provide critically needed tools for investigating the integrative 
physiology and therapeutic potential of Kir4.1 in temporal lobe epilepsy and hypertension.  
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Chapter V 
DIRECT ACTIVATION OF !-CELL KATP CHANNELS WITH A NOVEL XANTHINE 
DERIVATIVE  
This chapter was reprinted with permission of the American Society for Pharmacology and 
Experimental Therapeutics. All rights reserved. 
Abstract 
ATP-regulated potassium (KATP) channel complexes of Kir6.2 and SUR1 critically 
regulate pancreatic islet beta-cell membrane potential, calcium influx, and insulin secretion, and 
consequently, represent important drug targets for metabolic disorders of glucose homeostasis. 
The KATP channel opener diazoxide is used clinically to treat intractable hypoglycemia caused by 
excessive insulin secretion, but its use is limited by off-target effects due to lack of potency and 
selectivity. Some progress has been made in developing improved Kir6.2/SUR1 agonists from 
existing chemical scaffolds and compound screening, but there are surprisingly few distinct 
chemotypes that are specific for SUR1-containing KATP channels. Here we report the 
serendipitous discovery in a high-throughput screen of a novel activator of Kir6.2/SUR1, termed 
VU0071063. The xanthine derivative rapidly and dose-dependently activates Kir6.2/SUR1 with 
a half-effective concentration (EC50) of approximately 7 µM, is more efficacious than diazoxide 
at low micromolar concentrations, directly activates the channel in excised membrane patches, 
and is selective for SUR1- over SUR2A-containing Kir6.1 or Kir6.2 channels, as well as Kir2.1, 
Kir2.2, Kir2.3, Kir3.1/3.2, and Kv2.1. Finally, we show that VU0071063 activates native 
Kir6.2/SUR1 channels, thereby inhibiting glucose-stimulated calcium entry in isolated mouse 
pancreatic beta-cells. VU0071063 represents a novel tool/compound for investigating beta-cell 
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physiology, KATP channel gating, and a new chemical scaffold for developing improved 
activators with medicinal chemistry.   
 
Introduction 
By integrating cellular metabolism, membrane potential (Vm), and excitability, ATP-
sensitive K+ (KATP) channels carry out fundamental roles in nerve, muscle, epithelial, and 
endocrine tissue physiology [30]. The molecular structure of KATP channels is reviewed in 
Chapter I.  
Pancreatic islet !-cell KATP channels are validated drug targets for type 2 diabetes and 
severe hypoglycemia resulting from excessive insulin secretion [2].  Increases in blood glucose 
induce MgATP-dependent Kir6.2/SUR1 channel inhibition, Vm depolarization, Ca2+ influx 
through L-type voltage-dependent Ca2+ channels (VDCC), and secretion of insulin, which, in 
turn, acts on a myriad of target tissues to promote glucose uptake and utilization [151]. 
Sulfonylurea drugs (e.g. glibenclamide, tolbutamide) that directly inhibit Kir6.2/SUR1 and 
stimulate insulin secretion are used clinically to help manage glycemic levels in type 2 diabetic 
patients. In contrast, KATP channel activators (e.g. diazoxide) are used to treat disorders of severe 
hypoglycemia, such as congenital hyperinsulinism and insulin-producing pancreatic tumors 
[151,152]. The major KATP channel subtype in cardiomyocytes consists of Kir6.2 and SUR2A 
[32], and potassium channel opener (KCO) activation of sarcolemmal KATP channels and Vm 
hyperpolarization affords cardioprotection from subsequent ischemia-reperfusion injury [153]. 
Activation of vascular smooth muscle Kir6.1/SUR2B with pinacidil or diazoxide leads to 
vasodilation and a reduction in blood pressure [31], but can also result in pathological edema and 
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other cardiovascular pathologies reminiscent of those found in Cantu syndrome, which results 
from gain-of-function mutations in SUR2 [32].  
Given the broad tissue distribution of KATP channels, their important physiological roles, 
and therapeutic as well as pathological potential in various conditions, there is considerable 
interest in the continued development of pharmacological modulators for targeting specific 
subtypes of KATP channels [154]. Here, we report the serendipitous discovery of a novel xanthine 
derivative that directly activates heterologously expressed Kir6.2/SUR1 channels and native 
pancreatic !-cell KATP channels. The activator, termed VU0071063, is more potent and 
efficacious than diazoxide and is selective for SUR1-containing KATP channels. VU0071063 
represents a new tool compound for interrogating Kir6.2/SUR1 channel physiology and 
structure-function relationships of KATP channel gating.   
 
Materials and Methods 
Expression vectors 
The following vectors were used in this study:  pcDNA5/TO-Kir6.2 (NM_010602), 
pcDNA5/TO-Kir6.1 (NM_004982), pcDNA3.1-SUR1 (L40623.1), pCMV6c-SUR2A 
(D83598.1), pcDNA5/TO-Kir2.1 (NM_000891.2), pcDNA5/TO-Kir2.2 (NM_021012), 
pcDNA5/TO-Kir2.3 (NM_152868).  
 
Cell lines and transfections 
T-REx-HEK293 cells were transfected with pcDNA5/TO-Kir6.2 using Lipofectamine 
2000 (Life Technologies) and cultured with Blasticidin and Hygromycin to select stably 
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transfected cells as previously described [20,64]. After confirming they exhibited tetracycline-
inducible Kir6.2 expression by Western blot analysis (Fig. 1A), the cells were co-transfected 
with pcDNA3.1-SUR1 and grown in G418-containing medium to select cells carrying stably 
integrated plasmids for both KATP channel subunits. Monoclonal lines were isolated by limiting 
dilution, expanded, and tested for tetracycline-inducible thallium (Tl+) flux, as described below. 
One cell line exhibiting robust Tl+ flux was selected for assay development and small-molecule 
screening. Monoclonal T-REx-HEK293 cell lines expressing other mammalian Kir channels 
were generated as described previously [20,64]. Monoclonal mGluR8/GIRK/HEK293 cells 
stably expressing Kir3.1/3.2, the M4 muscarinic receptor and rat mGluR8a were cultured as 
described previously [83]. For transient transfections, HEK293T cells were transfected with 1 µg 
of Kir6.x, 2 µg SURx, and 0.5 µg of pcDNA3.1-EGFP (transfection marker) using 
Lipofectamine LTX Plus according to the manufacturer’s instructions. 
    
Western blot analysis       
Western blot analysis of Kir6.2 expression was performed following 24-h induction with 
tetracycline essentially as described previously [20]. Goat polyclonal Kir6.2 antiserum (SC-
11226) and donkey anti-goat HRP-conjugated antiserum (SC-2020) were purchased from Santa 
Cruz.     
 
Tl+ flux assays 
Tl+ flux assays were performed essentially as described previously [137]. Briefly, stably 
transfected T-Rex-HEK-293 cells expressing Kir6.2/SUR1 channels were cultured overnight in 
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384-well plates (20,000 cells/20 µL/well black-walled, clear-bottomed PureCoat amine-coated 
plates; BD, Bedford, MA) with a platting media containing DMEM, 10% dialyzed FBS and 
1µg/mL tetracycline. On the day of the experiment, the cell culture medium was replaced with 
dye-loading solution containing assay buffer (Hanks Balanced Salt Solution with 20 mM HEPES, 
pH 7.3), 0.01% (w/v) Pluronic F-127 (Life Technologies, Carlsbad, CA), and 1.2 µM of the 
thallium-sensitive dye Thallos-AM (TEFlabs, Austin, TX). Following 1 hr incubation at room 
temperature, the dye loading solution was washed from the plates and replaced with 20 µL/well 
of assay buffer. The plates were transferred to a Hamamatsu Functional Drug Screening System 
6000 (FDSS6000; Hamamatsu, Tokyo, Japan) and 20 µL/well of test compounds in assay buffer 
(as prepared below) was added. After a 20 minute incubation period, a baseline recording was 
collected at 1 Hz for 10 s (excitation 470 ± 20 nm, emission 540 ± 30 nm) followed by addition 
of Tl+ stimulus buffer (10 µL/well) and data collection for an additional 4 min. The Tl+ stimulus 
buffer contains in (mM) 125 NaHCO3, 1.8 CaSO4, 1 MgSO4, 5 glucose, 1.8 Tl2SO4, 10 HEPES, 
pH 7.4. For Tl+ flux assay on Kir3.1/3.2 expressing cells, the thallium stimulus buffer contains 
12 mM Tl2SO4 and either an EC20 or EC80 of glutamate (Sigma-Aldrich, St. Louis, MO). 
Test compounds from the Vanderbilt Institute of Chemical Biology (VICB) library were 
dispensed into in polypropylene 384-well plates (Greiner Bio-One, Monroe, NC) using an 
Echo555 liquid handler (Labcyte, Sunnyvale, CA) diluted in assay buffer to 2X final 
concentrations to generate 4- or 11-point 3-fold serial dilution series. The KATP channel 
inhibitors glibenclamide and tolbutamide were resuspended in assay buffer containing 
VU0071063 or diazoxide. Tl+ flux assays on Kir2.1, Kir2.2, Kir2.3, and Kir3.1/3.2 were 
performed as described previously [64].    
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Tl+ flux data were analyzed as previously [137] described using a combination of Excel 
(Microsoft Corp, Redmond, WA) with XLfit add-in (IDBS, Guildford, Surrey, UK) and 
OriginPro (OriginLab, Northampton, MA) software.  Each data point in a given trace was 
divided by the first data point from that trace (static ratio) followed by subtraction of data points 
from control traces generated in presence of vehicle controls.  The slope of the fluorescence 
increase beginning 5 s after Tl+ addition and ending 15 s after Tl+ addition was calculated. The 
data were then plotted in Prism software (GraphPad Software, San Diego, CA) to generate 
concentration-response curves (CRCs).  Potencies were calculated from fits to CRC data using a 
four parameter logistic equation. 
 
Patch clamp electrophysiology 
Transfected cells were dissociated with trypsin, plated on poly-L-lysine-coated glass 
coverslips, and allowed to recover for at least 1 h before experiments. Coverslips were 
transferred to a small-volume perfusion chamber and mounted on the stage of an inverted 
microscope. Patch electrodes were pulled from 1.5-mm outer diameter glass capillaries and had 
resistances ranging from 3-5 M& when filled with the following intracellular solution (in mM): 
135 KCl, 2 MgCl2, 1 EGTA, 10 HEPES, and 3 Na2ATP, pH 7.3. The standard bath solution 
contained (in mM): 135 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 5 glucose, and 10 HEPES, pH 7.4. 
Whole-cell currents were recorded under voltage-clamp conditions using an Axopatch 200B 
amplifier (Molecular Devices). The cells were voltage-clamped and stepped every 5 s from a 
holding potential of -75 to 120 mV for 200 ms, then ramped at a rate of 2.4 mV/ms from -75 to 
120 mV before returning to -75 mV. Electrophysiological data were collected at 5 kHz and 
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filtered at 2 kHz. Data acquisition and analysis were performed using pClamp 9.2 software 
(Molecular Devices). 
For excised-patch clamp measurements, COSm6 cells were transiently transfected with 
Kir6.2, SUR1, and EGFP for 24 hours before patch-clamp analysis.  Transfected cells were 
identified by GFP fluorescence and membrane patches were voltage-clamped. The pipette 
(resistance 1-2.5 M&) and bath solutions were (in mM): 140 KCl, 10 HEPES and 1 EGTA and 
0.5 free Mg2+, pH 7.35). After sealing, the membrane patch was excised to the inside-out 
configuration. Currents were recorded at a membrane potential of -50 mV using pClamp 8.2 
software.  
 
Calcium imaging 
Islet-cell intracellular calcium ([Ca2+]i) was measured using Ca2+ sensitive dye fura-2 
(Life Technologies) as previously described [155]. Briefly, mouse islets were dissociated in 
0.005% trypsin, plated on glass coverslips, and cultured for 16 h in RPMI-1640 medium 
supplemented with 10% fetal calf serum (FCS), concentrations of glucose specified, 100 IU 
mL#1 penicillin, and 100 mg mL#1 streptomycin. Cells were dye-loaded for 20 min at 37°C 
with 2 (M fura-2-AM in solution containing (in mM): NaCl, 119; CaCl2+[(H2O)6], 2.5; KCl, 4.7; 
Hepes, 10; MgS04, 1.2; KH2PO4, 1.2; glucose, 2; pH 7.35. Fluorescence imaging was performed 
using a Nikon Eclipse TE2000-U microscope equipped with an epifluorescent illuminator (Sutter 
instruments, Novato, CA), a CoolSNAP HQ2 camera (Photometrics, Tucson, AZ) and Nikon 
Elements software (Nikon, Japan). The [Ca2+]i ratios of emitted fluorescence intensities at 
excitation wavelengths of 340 and 380 nm (F340/F380) were determined every 5 s with 
background subtraction. Cells were perifused at 37°C at a flow of 2 mL/min; the solutions 
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utilized during the experiments are the loading solution with various glucose concentrations and 
VU0071063, as indicated.  
 
Measurement of complex II activity 
Mitochondria were isolated from four mouse hearts using differential centrifugation in 
sucrose-based buffer as previously described [156,157]. Complex II enzymatic activity was 
measured spectrophotometrically at 600 nm as previously described [156,158]. 
 
Chemicals 
VU0071063 was purchased from AldrichCPR (Sigma-Aldrich, LLC, Milwaukee, WI). 
Diazoxide, glibenclamide, and tolbutamide were purchased from Sigma-Aldrich. All compounds 
were dissolved in anhydrous dimethyl sulfoxide (DMSO, Fisher Scientific, Pittsburgh, PA, USA) 
and diluted in bath solution before use. The final concentration of DMSO used was less than or 
equal to 0.3% (v/v). 
 
Results 
Serendipitous discovery of the Kir6.2/SUR1 activator VU0071063 
A Tl+ flux assay of Kir6.2/SUR1 KATP channels was developed to assess the specificity of 
inhibitors of a mosquito Kir channel identified in a high-throughput screen (Raphemot, Denton, 
unpublished). The assays employ stably transfected T-REx-HEK293 cells expressing Kir6.2 
from a tetracycline-inducible promoter and SUR1 constitutively (Fig. 1B). Kir6.2/SUR1 is 
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inhibited in T-REx-HEK293 cells under control conditions and must be activated by metabolic 
poisoning (data not shown) or the SUR1-prefering KATP channel opener diazoxide to mediate Tl+ 
flux. While testing approximately 300 mosquito Kir1 antagonists for selectivity, diazoxide was 
inadvertently excluded from one plate, revealing a dose-dependent increase in Tl+ flux in wells 
I3, I4, I5, and I6 containing 30, 10, 3, and 1 µM of a mosquito Kir1 antagonist, respectively (Fig. 
2B-C). The small-molecule added to these wells, which we termed VU0071063, was re-ordered 
as a powder, freshly dissolved in DMSO, and characterized in Tl+ flux and electrophysiological 
assays.   
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Figure 1. T-REx-HEK293-Kir6.2/SUR1 cell line characterization. (A) Cells were cultured 
overnight with the indicated concentration of tetracycline and subjected to Western blot analysis 
of Kir6.2 expression in whole-cell lysates. Membranes were stripped and re-probed for b-actin as 
a loading control. (B) Representative Tl+ flux experiment in cells cultured overnight with (red) or 
without (black) tetracycline and then pre-treated with 250 µM diazoxide for 20 min before Tl+ 
(12 mM Tl2SO4) addition. 
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Figure 2. Discovery of VU0071063 in a Tl+ flux assay of Kir6.2/SUR1. (A) Plate map used in 
CRC analyses. DMSO (solvent) and broad-spectrum Kir channel inhibitor VU0573 (Raphemot 
et al., 2011) were used as controls. 4-point test compound CRCs were distributed horizontally, 
whereas 11-point VU0573 CRCs were distributed vertically. (B) Fluorescence heat map recorded 
from the assay plate containing 4 doses of VU0071063 (red box). Fluorescence intensity is 
indicated by the pseudocolored scale (right), with cooler (blue) to hotter (red) colors 
corresponding to low high Tl+ flux, respectively. (C) Representative time versus normalized 
(F/F0) fluorescence intensity in wells containing the indicated concentrations of VU0071063.  
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Effects of VU0071063 on pancreatic Kir6.2/SUR1 KATP channels 
The activity of VU0071063 on Kir6.2/SUR1 was compared to diazoxide and the SUR2-
preferring opener pinacidil in 11-point CRCs in Tl+ flux assays. The chemical structures of the 
three agonists are illustrated in Fig. 3A. Tetracycline-induced T-REx-HEK293-Kir6.2/SUR1 
cells were treated with the agonists for 20-min prior to Tl+ addition to allow full activation of the 
channel. As shown in the representative fluorescence traces in Fig. 3B, 30 µM VU0071063 led 
to a slightly greater steady-state activation of Kir6.2/SUR1-dependent Tl+ flux than did 250 (M 
diazoxide. VU0071063 and diazoxide led to a dose-dependent activation of Tl+ flux, whereas 
pinacidil was predictably inactive against Kir6.2/SUR1 (Fig. 3C). Half-maximal effective 
concentrations (EC50) derived from logistical fits to CRC data for VU0071063 and diazoxide 
were 10.3 µM (95% CI: 9.5-11 µM) and greater than 100 (M (EC50 ~120 µM), respectively (n = 
4-6 independent experiments). To confirm that Tl+ flux is dependent on Kir6.2/SUR1 channels, 
and not endogenous Tl+ flux pathways, the dose-dependent effects of KATP channel inhibitors 
glibenclamide and tolbutamide were evaluated. The cells were pre-treated with EC80 doses of 
VU0071063 (20 µM) or diazoxide (250 µM) and 3-fold dilutions of glibenclamide or 
tolbutamide ranging from 2 nM to 90 µM. Similar to published half-maximal inhibitory 
concentration (IC50) values, the IC50 for glibenclamide and tolbutamide in VU0071063-treated 
cells were 5.60 nM (95% CI: 5-6 nM) and 3.07 µM (95% CI: 2-5 µM), respectively. These 
values are similar to those of diazoxide-treated cells (glibenclamide IC50 = 16.6 nM [95% CI:  
15-18 nM]; tolbutamide IC50 = 1.60 µM [95% CI:  1.4-2 µM]).  
 Whole-cell patch clamp electrophysiology was used to further characterize the effects of 
VU0071063 and diazoxide on Kir6.2/SUR1. Bath application of VU0071063 rapidly (Fig. 4A) 
and dose-dependently (Fig. 4C) activated Kir6.2/SUR1 currents, with a maximal activation of 
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1077 ± 87% at a dose of 50 µM.  In contrast, diazoxide activated Kir6.2/SUR1 more slowly (Fig. 
4B) and with significantly (T-test P = 0.01) lower efficacy (maximal activation 580 ± 105% at 50 
µM) than VU0071063. As shown in Fig. 4B, following steady-state activation with 50 (M 
diazoxide, bath addition of 50 (M VU0071063 led to further Kir6.2/SUR1 activation. These data 
show that at low micromolar concentrations, VU0071063 is a more potent activator of 
Kir6.2/SUR1 than diazoxide.   
To exclude the possibility that VU0071063 might be activating channels in intact cells by 
altering cell metabolism, currents were recorded from COSm6 cells expressing Kir6.2 and SUR1, 
in inside-out membrane patches. In the presence of 0.1 mM MgATP, which inhibits WT 
channels ~90%, both 10 µM and 20 µM of VU0071063 markedly increased the patch current 
(Fig. 5). 
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Figure 3. Characterization of VU0071063 activity against Kir6.2/SUR1 in Tl+ flux assays. 
(A) Chemical structures of VU0071063 (VU063), diazoxide, and pinacidil. (B) Representative 
Tl+ flux experiment demonstrating activation of Kir6.2/SUR1 by 30 µM VU0071063 or 250 µM 
diazoxide, but not the vehicle control DMSO (0.3%). Fluorescence data have been normalized 
(F/F0) to baseline values recorded before Tl+ addition. (C) Dose-dependent activation of 
Kir6.2/SUR1 by VU0071063 and diazoxide, but not pinacidil (n = 4-6 independent experiments, 
each performed in triplicate). (D) Dose-dependent inhibition of VU0071063- and diazoxide-
dependent Tl+ flux by glibenclamide and tolbutamide (n = 3 independent experiments, each 
performed in triplicate).  
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Figure 4. Characterization of VU0071063 activity against Kir6.2/SUR1 with patch clamp 
electrophysiology. (A) Transfected cells expressing Kir6.2/SUR1 were voltage clamped at -75 
mV and stepped every 5 sec to -120 mV to elicit inward current. Minor current run-up was 
observed following establishment of the whole-cell configuration and dialysis with the pipette 
solution. Addition of 1 µM or 30 µM VU0071063 led to rapid activation of inward current. (B) 
In contrast, addition of 50 mM diazoxide activated Kir6.2/SUR1 slowly. After achieving steady-
state activation, addition of 50 µM VU0071063 led to further activation of Kir6.2/SUR1. Inward 
currents were blocked with 2 mM Ba2+. (C) Mean ± SEM dose-response data fitted with 4-
parameter logistic functions to derive EC50 values of 7 µM and 11 µM for VU0071063 (closed 
square) and diazoxide (open square), respectively (n = 5 – 10 per concentration). Data are 
normalized and expressed as percent (%) activation from baseline current in the absence of 
agonist.  
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Figure 5. VU0071063 activates Kir6.2/SUR1 in excised inside-out patches. (A) 
Representative inside-out membrane patch of COS cells transiently expressing Kir6.2 and SUR1. 
Membrane potential held at -50mV. Patches were excised in ATP-free K-internal (150 mM-KCl, 
10 mM-HEPES, 1 mM-EGTA) solution and then exposed to 0.1 mM-MgATP followed by 0.1 
mM-Mg-ATP + VU0071063 (10 µM or 20 µM) solutions as indicated by solid lines above the 
representative trace. (B) The relative current in 0.1 mM Mg-ATP + VU0071063 (10 µM or 20 
µM) with respect to current in ATP-free solution averaged from all recordings (n = 4).!  
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VU0071063 is selective SUR1-containing KATP channels  
The pharmacological selectivity of known KATP channel agonists is achieved through 
interactions with the SUR subunit. To determine if VU0071063 activity is also dependent on the 
SUR, we tested its effects on Kir6.2 or Kir6.1 channels containing SUR1 or SUR2A using patch 
clamp electrophysiology. Diazoxide and pinacidil were used as positive controls for SUR1- and 
SUR2A-containting channels, respectively. As shown in the representative timecourse 
experiment in Fig. 6A, and summary data (mean ± SEM; n = 7) in Fig. 6C, bath application of 
50 (M VU0071063 rapidly and reversibly activated Kir6.2/SUR1 to a greater extent than an 
equal concentration of diazoxide. Qualitatively similar results were observed in cells transfected 
with Kir6.1/SUR1 (Fig. 6D). In striking contrast, VU0071063 had no effect on Kir6.2/SUR2A 
(Figs. 6B, 6E) or Kir6.1/SUR2A (Fig. 6F), whereas pinacidil activated both channel subtypes. 
Dose-response experiments revealed that VU0071063 had no appreciable effects on 
Kir6.2/SUR2A at concentrations up to 150 (M (Fig. 7), which is 15-fold higher than the IC50 for 
Kir6.2/SUR1.  
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Figure 6. VU0071063 is selective for SUR1-containing KATP channels. (A) Representative 
whole-cell patch clamp experiment showing the effects of 50 µM VU0071063, 50 µM diazoxide, 
and 2 mM Ba2+ on Kir6.2/SUR1 current at -120 mV. Note the differences in the kinetics of 
activation of VU0071063 and diazoxide. (B) Representative recording showing effects of 50 µM 
VU0071063, 50 µM pinacidil, and 2 mM Ba2+ on Kir6.2/SUR2A currents. (C, E, D, F) Mean ± 
SEM current at -120 mV recorded from cells transfected with Kir6.2/SUR1, Kir6.1/SUR1, 
Kir6.2/SUR2A, or Kir6.1, SUR2A, respectively (n = 4-7).  
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Figure 7. Lack of effect of VU0071063 on Kir6.2/SUR2A channels. (A) Whole-cell 
Kir6.2/SUR2A currents were measured every 5 sec at -120 mV before and after addition of 5, 15, 
or 50 µM VU007106 or 50 µM pinacidil (positive control), followed by application of 2 mM 
Ba2+. (B) Single-dose exposure to 150 µM VU0071063 has only a modest effect on 
Kir6.2/SUR2A channel activity. (C) VU0071063 CRC data normalized to 50 µM pinacidil 
response. Data are means ± SEM (n = 4 at each dose).!  
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VU0071063 inhibits glucose-stimulated !-cell Ca2+ influx 
Glucose-stimulated closure of !-cell KATP channels results in membrane potential 
depolarization, activation of voltage-dependent Ca2+ channels (VDCC), Ca2+ influx, and Ca2+-
induced insulin secretion. We therefore tested whether VU0071063 activates native Kir6.2/SUR1 
channels by measuring the effect of the activator on !-cell Ca2+ influx during glucose-stimulation.  
Treatment of !-cells with high (14 mM) glucose induced a significant rise in Ca2+ as determined 
by the fluorescent Ca2+ indicator fura-2, which shows an increase in the fluorescent ratio of Ca2+ 
bound to Ca2+ unbound dye in response to glucose (red cells, Fig. 8). Activation of !-cell KATP 
channels with VU0071063 in the presence of high (14 mM) glucose resulted in inhibition of !-
cell Ca2+ influx and reduction in Ca2+ levels back to those observed in low (2 mM) glucose 
conditions (green cells, Fig. 8).  The reduction in Ca2+ influx mediated via KATP activation is 
reversible following removal of VU0071063, which results in a return of !-cell Ca2+ levels to 
high (14 mM) glucose levels (red cells, Fig. 8). This data indicates that VU0071063 activates 
native !-cell KATP channels and thereby reduces VDCC activation and Ca2+ influx. 
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Figure 8. VU0071063 inhibits glucose-stimulated !-cell calcium entry. (A) Two 
representative !-cells loaded with FURA-2; displayed as a fluorescent ratio (340/380 nm) in 
response to 2mM glucose (1), 14 mM glucose (2), 14 mM glucose + 10 µM VU0071063 (3), and 
14 mM glucose (4). (B) Relative calcium responses of mouse islet-cells following treatment with 
2mM glucose and as indicated by the conditions labeled above (black lines, n = 239 islet-cells 
over 3 days and 13 plates of cells).   
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Kir6.2/SUR1 activation by VU0071063 is not mediated by a PDE inhibitory pathway  
Vascular smooth muscle KATP channels are activated by cAMP/PKA- and cGMP/PKG-
dependent pathways following phosphodiesterase (PDE) inhibition with theophylline (see 
discussion). Because VU0071063 contains a theophylline moiety (Fig. 9A), we tested whether 
theophylline could activate Kir6.2/SUR1 in Tl+ flux assays under conditions identical to those 
used to discover VU0071063. However, as shown in Fig. 9B, theophylline at a concentration of 
250 µM had no effect on Kir6.2/SUR1-dependent Tl+ flux. 
 !  
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Figure 9. Lack of effect of theophylline on Kir6.2/SUR1-dependent Tl+ flux. (A) Chemical 
structure of theophylline. (B) Mean ± SEM slope fluorescence recorded from wells treated with 
30 µM VU0071063, 250 µM diazoxide, or 250 µM theophylline for 20 min before Tl+ addition. 
Data are from 2 independent experiments performed in triplicate. Significance *P = 0.03, ** P = 
0.003, unpaired Students t-test.!  
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Ancillary Pharmacology 
The selectivity of VU007106 was evaluated in 11-point CRCs in Tl+ flux assays against 
Kir2.1, Kir2.2, Kir2.3, and Kir3.1/3.2. VU0071063 was inactive against Kir2.1 and Kir2.2 (IC50 
> 100 µM) and showed weak inhibitor activity against Kir3.1/3.2 (IC50 = 65 µM) and Kir2.3 
(IC50 = 91 µM)(Fig. 10). Patch clamp electrophysiology was used to determine whether 
VU0071063 acts on the voltage-gated K+ channel Kv2.1, which contributes to action 
repolarization in pancreatic !-cells [159,160]. Cells were voltage clamped at a holding potential 
of -75 mV and stepped to +50 mV every 5 seconds. Bath application of 10 µM VU0071063 led 
to a 7.8 ± 0.9 % (n = 4) reduction in outward Kv2.1 current at 40 mV that was fully reversible 
(Fig. 11). 
 !  
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Figure 10. Selectivity of VU0071063 among members of the Kir channel family. 11-point 
CRC of VU0071063 were established for Kir2.1, Kir2.2, Kir2.3, and Kir3.1/3.2 expressing cell 
lines (n = 2 independent experiments performed in triplicate per cell line).!  
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Figure 11. Effects of VU0071063 on heterologously expressed Kv2.1. (A) Time versus current 
amplitude plot illustrating the rapid and reversible inhibition of Kv2.1 current at 40 mV by 10 
µM VU0071063. (B) Representative current traces recorded at 40 mV before and during bath 
perfusion with 10 µM VU0071063. (C) Mean ± SEM current amplitude at 40 mV in the absence 
(control) or presence of 10 µM VU0071063. *P = 0.01, paired Students t-test.!  
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Discussion 
Pancreatic KATP channels are validated drug targets for intractable hypoglycemia due to 
insulinoma and congenital hyperinsulinism, and therefore considerable efforts have been made to 
develop specific activators of Kir6.2/SUR1 channels [154,161,162]. Diazoxide is the best known 
SUR1-preferring opener and has been used clinically for more than 50 years. However, its use 
has been limited by a lack of potency and selectivity, leading to undesirable side effects such as 
low blood pressure, blurred vision, reduced urination, fluid retention, and hirsutism, mimicking 
the effects of Cantu Syndrome, which results from gain-of-function in the cardiovascular SUR2 
isoform [32], and reflecting enhanced opening of vascular smooth muscle KATP channels and 
potentially effects on mitochondrial respiration [163]. In an effort to develop openers with fewer 
side effects, several groups have synthesized analogs from existing lead compounds that show 
improved potency and selectivity toward Kir6.2/SUR1. Structural modifications to the diazoxide 
scaffold have led to several new series with sub-micromolar potency and selectivity for 
pancreatic over smooth muscle KATP channels (de Tullio et al., 2011; Pirotte et al., 2010). One 
analog, termed NN414 [40], shows favorable activity in obese rats [164,165], as well as healthy 
and type 2 diabetes patients [166,167]. Clinical trials were initiated but later suspended due to 
drug-induced elevations of key liver enzymes [154]. Analogs of the SUR2-preferring openers 
cromakalim and pinacidil that exhibit selectivity for pancreatic KATP channels [168-173] have 
also been developed, showing that is possible to switch SUR preference with chemical 
modifications to the scaffold. To our knowledge, the only unique pancreatic KATP channel 
activator chemotypes reported in the last 2 decades were identified in screens of small-molecule 
libraries. These include the 4-sulfamoylphenylbenzamide and nitropyrazole series of KATP 
activators. A 4-sulfamoylphenylbenzamide derivative was shown to activate heterologously 
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expressed Kir6.2/SUR1 channels and inhibit glucose-stimulated insulin secretion from primary 
rat islets with sub-micromolar efficacy; the activity toward SUR2-containing channels was not 
reported [174]. One nitropyrazole analog exhibits nanomolar-affinity toward Kir6.2/SUR1 and at 
least 15-fold selectivity over SUR2A and SUR2B-containing channels [175]. No in vivo efficacy 
of either series has been published. 
To our knowledge, VU0071063 is only the third publically disclosed SUR1-preferring 
chemotype identified with compound screening and therefore provides an important starting 
point for the development of new channel openers. The discovery of VU0071063 underscores 
the value of mining focused libraries from primary screens for modulators of diverse inward 
rectifier K+ channels. VU0071063 is slightly more potent than diazoxide, and activates the 
channel with a faster timecourse. The reason for the discrepancy in IC50 values derived from Tl+ 
flux and patch clamp experiments is unclear, but likely reflects 1) differences in the behavior of 
Tl+ and K+ in the KATP channel pore, and 2) the slower kinetics of diazoxide action compared to 
that of VU0071063 (e.g. Fig. 6). In an effort to avoid the latter issue, T-REx-HEK293-
Kir6.2/SUR1 cells were incubated with compounds for 20 min before adding Tl+ stimulus buffer, 
however we still observed a rightward shift in the EC50 value for diazoxide.  
VU0071063 is selective for Kir6.2/SUR1 over Kir6.2/SUR2A and Kir6.1/SUR2A, as 
well as Kir3.1/3.2, Kir2.1, Kir2.2, Kir2.3, and Kv2.1. Kv2.1 was tested for VU0071063 
sensitivity because it plays important roles in the electrophysiology of pancreatic !-cells by 
modulating action potential repolarization, Ca2+ influx through VDCC, and insulin secretion. At 
the same dose shown to reduce high glucose-induced Ca2+ influx in pancreatic !-cells, 10 µM 
VU0071063 significantly inhibited Kv2.1 currents by approximately 10%. Inhibition of Kv2.1 
would be expected to prolong the action potential depolarization and increase, not decrease, Ca2+ 
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influx through VDCC, excluding a potential role of Kv2.1 in the VU0071063 mechanism of 
action. Specific effects of VU0071063 on the electrical excitability and underlying ion channels 
in !-cells will be examined in future studies. Furthermore, the selectivity of VU0071063 
suggests the binding site is located within SUR1, which belongs to the ABC superfamily of 
transporters. Considering that the ABC transporter family member CFTR is inhibited at high 
concentrations (IC50 = 250 µM;[176]) of diazoxide, future studies should address whether 
VU0071063 inhibits CFTR or other members of this superfamily. Finally, although VU0071063 
does not activate SUR2A-containing channels, potential effects on SUR2B-containing channels 
and hence vascular smooth muscle tone should be considered before using VU0071063 as an in 
vivo probe of SUR1-containing KATP channels. Despite several attempts and different 
experimental conditions, we were unable to measure the activity of SUR2B-containing KATP 
channels in our expression system and could not determine the effect of VU0071063 on these 
channels (unpublished observations). 
VU0071063 is structurally related to the xanthine derivative KMUP-1, which induces 
smooth muscle relaxation and vasodilation through activation of the cGMP and cAMP pathways. 
KMUP-1 induces the accumulation of cGMP and cAMP in part by inhibiting their degradation 
by phosphodiesterase (PDE) enzymes. Pharmacological agents that prevent cGMP accumulation 
predictably suppress KMUP-1-induced dilation. Inhibitors of several different families of K+ 
channels, including tetraethylammonium, 4-aminopyridine, iberiotoxin, charybdotoxin, and 
glibenclamide, blunt the vasodilatory effects of KMUP-1, indicating an important role of the 
membrane potential in its mechanism of action [177-179]. However, this does not appear to 
involve direct K+ channel activation. For example, [180] found that KMUP-1 activates large-
conductance Ca2+-activated K+ (BK) currents in cerebral smooth muscle cells, but this was 
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dependent on cGMP generation. Although the effects of KMUP-1 on KATP currents have not 
been reported, cGMP is known to activate vascular KATP channels [181]. The PDE-inhibitory 
activity of KMUP-1 is likely mediated through the theophylline moiety, since the addition of 
theophylline, a non-specific PDE inhibitor, recapitulates the effects of KMUP-1 on cGMP levels 
and vascular tone [180]. As noted earlier, VU0071063 also contains a theophylline group, raising 
the possibility that PDE inhibition and cGMP or cAMP accumulation contributes to 
Kir6.2/SUR1 activation. However, theophylline at a concentration of 250 µM had no effect on 
Kir6.2/SUR1-mediated Tl+ flux following 20-min incubation. This, together with the observation 
that VU0071063 directly activates Kir6.2/SUR1 in excised membrane patches (Fig. 5), suggests 
that PDE inhibition and cyclic nucleotides are not essential components of its mechanism of 
action.      
 There are several important questions regarding VU0071063 and its mechanism of action 
remaining to be answered. KMUP-1 and VU0071063 differ only in the structure of their side-
chains that project off a common theophylline moiety, yet only VU0071063 appears to be a 
direct SUR1/Kir6.2 channel activator. Determination of VU0071063 structure-activity 
relationships with medicinal chemistry will inform a deeper understanding of pharmacophore 
requirements for activation of SUR1- and SUR2-containing KATP channels and may lead to the 
development of improved xanthine-based activators. Do VU0071063 and diazoxide activate 
Kir6.2/SUR1 through common molecular mechanisms? For instance, do they share the same 
receptor binding site in SUR1, and does VU0071063 require ATP hydrolysis for channel 
activation like diazoxide [182]? It is well established that diazoxide has direct effects on 
mitochondrial respiration, although the underlying mechanisms are a matter of ongoing debate 
[163]. At least some of the effects of diazoxide in cardiac and smooth muscle cells are mediated 
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through inhibition of mitochondrial complex II [183,184], which has made it difficult to ascribe 
beneficial and undesirable effects of the drug to KATP channel-mediated effects or other 
mechanisms. Importantly, VU0071063 (< 100 (M) had no effect on complex II activity (Table 
1). It will be important to determine whether VU0071063 action is limited to plasma membrane 
SUR1-containing channels or also has off-target effects on mitochondrial respiration and 
potentially other signaling pathways. The activation of KATP channels are linked to signaling 
pathways that can protect a cellular against stress [185]. While the location of the channel that 
mediates protection (e.g. canonical surface KATP vs. mitochondrial KATP channels) remains 
elusive [185-187], VU0071063 may prove to be a valuable tool to investigate the role of KATP 
channels in stress responses.   
 
Table 1. Percent inhibition of Complex II activity in response to VU0071063 and diazoxide. 
Mitochondria isolated from mouse hearts underwent three cycles of freeze-thaw and subject to 
the complex II enzymatic activity assay. Complex II activity was measured and expressed as 
percent inhibition. Control complex II activity was 88.0 ± 3.1 nmol/min/mg protein. Data are 
mean ± S.E.M. percent inhibition. N = 4 independent mitochondria preparations. 
 
 
 
 
 
 
 
 
 
  Complex II activity (% inhibition)  
[Compound] 
#M 
VU0071063 Diazoxide 
1 1.5 ± 3.5 - 
3 -2.2 ± 4.5 - 
10 2.4. ± 2.7 7.6 ± 2.5 
30 0.0 ± 4.3 14.9 ± 6.0 
100 4.9 ± 2.9 24.2 ± 4.3 
300 - 36.0 ± 3.5 
600 - 41.6 ± 0.7 
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In conclusion, VU0071063 is a novel xanthine derivative that directly and selectively 
activates KATP channels containing SUR1. Despite KATP channels being validated drug targets for 
numerous diseases, VU0071063 is only the third SUR1-preferring chemotype discovered using 
small-molecule library screening. We anticipate that the Tl+ flux assay described here will enable 
the discovery of additional small-molecule modulators of Kir6.2/SUR1 and other KATP channel 
subtypes.   
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Chapter VI 
ELICITING RENAL FAILURE IN MOSQUITOES WITH A SMALL-MOLECULE 
INHIBITOR OF INWARD-RECTIFYING POTASSIUM CHANNELS 
This chapter was published under the same title in the journal PLoS One in the May 29th, 2013 
issue  
Abstract 
Mosquito-borne diseases such as malaria and dengue fever take a large toll on global 
health.  The primary chemical agents used for controlling mosquitoes are insecticides that target 
the nervous system.  However, the emergence of resistance in mosquito populations is reducing 
the efficacy of available insecticides.  The development of new insecticides is therefore urgent.  
Here we show that VU573, a small-molecule inhibitor of several mammalian inward-rectifying 
potassium (Kir) channels, inhibits a Kir channel cloned from the renal (Malpighian) tubules of 
Aedes aegypti (AeKir1).  Injections of VU573 into the hemolymph of adult female mosquitoes 
(Ae. aegypti) render them incapacitated (flightless or dead) within 24 hours by disrupting their 
production and excretion of urine in a manner consistent with channel block of AeKir1.  
Moreover, the toxicity of VU573 in mosquitoes (Ae. aegypti) is exacerbated when hemolymph 
potassium levels are elevated.  Our study demonstrates that renal failure is a promising 
mechanism of action for killing mosquitoes, and motivates the discovery of selective small-
molecule inhibitors of mosquito Kir channels for use as insecticides. 
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Introduction 
Mosquitoes are vectors of debilitating diseases that take an immense toll on global health.  
Anopheline mosquitoes transmit pathogenic protozoans (Plasmodium sp.) that cause malaria.  
On an annual basis, there are an estimated hundreds of millions of episodes of malaria, which 
claim nearly one million lives; ~85% of the victims are children under 5 years of age [188]. 
Culicine mosquitoes transmit viral pathogens that cause chikungunya, dengue, West Nile, and 
yellow fevers.  Of the estimated 50-100 million individuals infected with dengue each year, 
hundreds of thousands require hospitalization and tens of thousands die [189] .  These protozoan 
and viral pathogens are transmitted to humans solely by adult female mosquitoes, which feed on 
vertebrate blood to obtain nutrients for developing eggs.   
The primary chemical agents currently in use for controlling mosquitoes are insecticides 
that target the nervous system.  Although the development of insecticides such as DDT and 
pyrethroids, which modulate the activity of ion channels in the central nervous system of insects, 
offered promise for the eradication of mosquitoes in the 20th century, the emergence of 
resistance in mosquito populations has reduced their efficacy [190,191].  Currently, there are not 
many alternatives, because no new insecticides for public-health use have been developed in 
over 30 years [68].  Thus, the discovery of chemicals that target novel physiological processes 
and molecular targets in mosquitoes are urgently needed [68,192]. 
A physiological process in the mosquito that has not yet been targeted by insecticides is 
the excretion of urine.  The renal (Malpighian) tubules generate urine via the transepithelial 
secretion of NaCl, KCl, other solutes, and water from the extracellular fluid (hemolymph) to the 
tubule lumens [193,194].  The tubules empty their secretions into the hindgut where solute 
and/or water is removed or added to the final urine before it is ejected via muscular contractions 
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of the hindgut.  Thus, inhibiting the function of Malpighian tubules—i.e., causing renal failure—
is expected to disrupt extracellular fluid homeostasis with detrimental consequences to normal 
functions in the mosquito.  Female mosquitoes would be particularly vulnerable to renal failure, 
because they would not be able to excrete the unwanted salt and water ingested during a blood 
meal [195-197]. 
The aim of the present study is to elicit renal failure in adult female mosquitoes (Aedes 
aegypti) using a small-molecule inhibitor of inward-rectifying potassium (Kir) channels.  The 
molecular structure of Kir channels in mosquitoes is review in Chapter I. In mosquito 
Malpighian tubules, Kir channels of the basolateral membrane are considered one of the two 
major routes for the uptake of K+ into the epithelium [74,198].  The Malpighian tubules of Ae. 
aegypti express three cDNAs encoding Kir channel subunits (AeKir1, AeKir2B, AeKir3), which 
we have cloned and functionally characterized [74].  AeKir1 mediates robust K+ currents when 
expressed in Xenopus oocytes, whereas AeKir2B and AeKir3 produce relatively small and 
nominal K+ currents, respectively [74].  Thus, we focused on inhibiting AeKir1 in the present 
study. 
 
Materials and Methods 
Expression vectors and sub-cloning   
The open-reading frame of the AeKir1 cDNA cloned from Malpighian tubules of adult 
female Ae. aegypti [74] was subcloned into a pcDNA5/TO expression vector (Invitrogen, 
Carlsbad, CA) using BamHI and XbaI restriction sites.  The accuracy of the resulting AeKir1-
pcDNA/TO vector was confirmed by sequencing it in both the 5’ and 3’ directions.   
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Stable cell line generation   
Stably transfected polyclonal T-REx-HEK293 cell lines expressing AeKir1 under the 
control of a tetracycline-inducible promoter were established as described previously [20,136].  
Monoclonal cell lines were isolated through limiting dilution in 384-well plates and tested for 
tetracycline inducible Tl+ flux, as described below. T-REx-HEK293 lines were cultured in 
DMEM growth medium containing 10% FBS, 50 U/mL Penicillin, 50 (g/mL Streptomycin, 5 
(g/mL Blasticidin S and 250 (g/mL Hygromycin.  
 
Whole-cell patch clamp electrophysiology   
T-REx-HEK293-AeKir1 cells were voltage clamped in the whole-cell configuration of 
the patch clamp technique after overnight induction with tetracycline (1 µg/mL).  Patch 
electrodes were pulled from silanized 1.5 mm outer diameter borosilicate microhematocrit tubes 
using a Narishige PP-830 two-stage puller.  Electrode resistance ranged from 2.5 to 3.5 M& 
when filled with the following intracellular solution (in mM):  135 KCl, 2 MgCl2, 1 EGTA, 10 
HEPES free acid, 2 Na2ATP (Roche, Indianapolis, IN), pH 7.3, 275 mOsm.  The standard bath 
solution contained (in mM): 135 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 5 glucose, 10 HEPES free acid, 
pH 7.4, 290 mOsm.  The high-K+ bath contained (in mM): 90 NaCl, 50 KCl, 2 CaCl2, 1 MgCl2, 5 
glucose, and 10 HEPES-free acid, pH 7.4, 290 mOsmol.  Whole-cell currents were recorded 
under voltage-clamp conditions using an Axopatch 200B amplifier (Molecular Devices, 
Sunnyvale, CA).  Electrical connections to the amplifier were made using Ag/AgCl wires and 3 
M KCl/agar bridges.  Electrophysiological data were collected at 5 kHz and filtered at 1 kHz.  
Data acquisition and analysis were performed using pClamp 9.2 software (Axon Instruments).  
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After achieving stable whole-cell currents, VU573 or VU342 was applied intermittently or 
continuously for 2 to 10 min, followed by application of 2 mM BaCl2.  All recordings were made 
at room temperature (20-23ºC).  
 
Test compound and stimulus plate preparation   
Compound master antagonist plates were created by serial diluting compounds 1:3 from 
30mM stocks in 100% DMSO using the BRAVO liquid handler (Agilent Technologies, Santa 
Clara, CA).  Assay daughter plates were created using the ECHO 555 liquid hander (Labcyte, 
Sunnyvale, CA), transferring 240 nl from the master plate to the daughter plate for each well 
followed by addition of 40 (l of assay buffer resulting in antagonist compound concentration 
response curves starting at 200 (M (2X final concentration).  Tl+ stimulus buffer contained (in 
mM): 125 sodium bicarbonate (added fresh the morning of the experiment), 1 magnesium sulfate, 
1.8 calcium sulfate, 5 glucose, 12 Tl+ sulfate, and 10 HEPES, pH 7.3 at 5X the final 
concentration to be assayed. 
 
Thallium flux assays   
Cells were loaded with the Tl+ sensitive fluorescent dye FluoZin-2( acetoxymethyl ester 
form) and plated in clear-bottom 384-well plates essentially as described previously [20,21].  
Cell plates and daughter compound plates were loaded onto a kinetic imaging plate reader (FDSS 
6000; Hamamatsu Corporation, Bridgewater, NJ).  All recordings were made at room 
temperature (20-23ºC).  Appropriate baseline readings were taken (10 images at 1 Hz; excitation, 
470 ± 20 nm; emission, 540 ± 30 nm) and 20 (l test compounds were added followed by 50 
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images at 1Hz additional baseline.  Following a 20 minute incubation period, baseline readings 
were taken for 10 seconds followed by addition of 10 (L of Tl+ stimulus buffer.  An additional 
240 images were taken at 1 Hz.  
 
Chemical synthesis   
The methods for synthesizing VU573, VU342, and other analogs are described in detail 
elsewhere [64].  
 
Mosquito colonies 
The following reagents were obtained through the MR4 as part of the BEI Resources 
Repository, NIAID, NIH: Aedes aegypti LVP-IB12, MRA-735, deposited by M.Q. Benedict, and 
Aedes albopictus ALBOPICTUS, MRA-804, deposited by Sandra Allan.  Eggs from both Aedes 
species were raised to adults as described previously [199].  Adult female mosquitoes of 
Anopheles gambiae (Mbita strain) and Culex pipiens (Buckeye strain) were provided by the 
laboratories of Drs. Woody A. Foster and David L. Denlinger, respectively (the Ohio State 
University).  For all experiments described below, only adult females of 3-10 days post-
emergence were used. 
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Mosquito toxicology experiments  
Mosquitoes were first anesthetized on ice and then injected with 69 nL of fluid (see 
below) using a pulled-glass capillary attached to a nanoliter injector (Nanoject II, Drummond 
Scientific Company, Broomall, PA).  The injected fluid was a sodium-based phosphate-buffered 
saline (Na+-PBS) containing 15% DMSO and various concentrations of VU573 or VU342 to 
deliver the doses indicated in Figs. 2A, 2C, and S3.  The Na+-PBS consisted of the following in 
mM: 137 NaCl, 2.7 KCl, 10 Na2HPO4, and 2 KH2PO4 (pH 7.5).  After injection, the mosquitoes 
were placed in a small cage (10 females per cage) within a rearing chamber (28°C, 80% relative 
humidity, 12:12 light:dark) and allowed free access to a solution of 10% sucrose.  The 
mosquitoes were observed 24 h after injection.   
A similar approach was used to determine the toxicity of VU573 after a stress to 
hemolymph Na+ or K+ homeostasis (Fig. 2F).  However, in these experiments, each mosquito 
was injected with 900 nL of fluid (100 nl/s) and the mosquitoes were not given access to sucrose.  
The injected fluid was a Na+-PBS or K+-PBS containing 1.1% DMSO and 0.77 mM of VU573.  
Vehicle controls received the respective PBS with DMSO alone.  The K+-PBS consisted of the 
following in mM: 2.7 NaCl, 137 KCl, 2 Na2HPO4, and 10 KH2PO4 (pH 7.5).   
 
Isolated Malpighian tubule experiments  
Fluid secretion assays.  Fluid secretion rates from isolated Malpighian tubules (Ae. 
aegypti) were measured in vitro using the method described in [200], which is modified from 
that of Ramsay [201].  In brief, isolated tubules were bathed in a 50 (L drop of a mosquito 
Ringer solution with elevated K+ (see composition below), which was then covered with light 
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mineral oil.  A glass hook was used to pull the open proximal end of the tubule into the mineral 
oil where fluid was secreted.  The diameter of the droplet was measured to calculate the secreted 
volumes.   
In one set of tubules, the initial spontaneous rate of fluid secretion was calculated during 
the first 30 min (control).  In another set of tubules, the rates of fluid secretion were determined 2 
h after adding one of the following to the peritubular bath:  the vehicle (0.05% DMSO), VU573 
(10 (M), or VU342 (10 (M).  The Ringer solution consisted of the following in mM:  119.4 
NaCl, 34 KCl, 25 HEPES, 1.8 NaHCO3, 1.7 CaCl2, and 1.0 MgSO4, pH 7.1. 
Electrophysiology.  The basolateral membrane voltage (Vbl) and input resistance (Rpc) of 
principal cells were measured in isolated Malpighian tubules using two-electrode voltage 
clamping, as described previously [202].  In each experiment, a single principal cell near the 
distal (blind) end of the tubule was impaled with two glass microelectrodes:  one measured Vbl 
and the other injected current (Im).  The Rpc of the impaled cell was calculated from current-
voltage plots that were generated via voltage clamping (see ref. [200] for details).  After 
recording a steady-state Vbl and Rpc (control) from the impaled cell, either VU573 (10 µM) or 
BaCl2 (5 mM) was added to the peritubular bath.  The resulting Vbl and Rpc (treatment) were 
measured again upon reaching a new steady-state (usually 1-2 min later).   
 
Mosquito excretion experiments   
Urine excretion rates from intact mosquitoes (Ae. aegypti) were measured using a method 
modified from the laboratory of Hansen [203].  After anesthetizing mosquitoes on ice they were 
injected as described above with 900 nL of fluid (100 nL/s).  The injected fluid was one of two 
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HEPES-buffered saline (HBS) solutions containing 1.8% DMSO with 0.77 mM VU573 or 0.77 
mM VU342.  Vehicle controls received the respective HBS with DMSO alone.  The Na+-HBS 
consisted of the following in mM: 146 NaCl, 4.2 N-methyl-D-glucammonium (NMDG)-Cl, and 
25 HEPES (pH 7.5).  The K+-HBS consisted of the following in mM:  10 NaCl, 75 KCl, 65.2 
NMDG-Cl, and 25 HEPES (pH 7.5).  After injection, mosquitoes were placed immediately in a 
graduated, packed-cell volume tube (MidSci, St. Louis, MO; 3 mosquitoes per tube) at room 
temperature.  The mosquitoes were removed from the tubes with forceps after 2 h and the 
excreted urine was centrifuged into the graduated column of the tube for measurement.  
Uninjected control mosquitoes were handled exactly as above sans the injection step.  
 
Statistical analyses  
Tl+-flux assays.  Data were analyzed using Excel (Microsoft Corp, Redmond, WA).  Raw 
data were opened in Excel and each data point in a given trace was divided by the first data point 
from that trace (static ratio).  The slope of the fluorescence increase beginning 5 s after Tl+ 
addition and ending 15 s after Tl+ addition was calculated. The data were then plotted in Prism 
software (GraphPad Software, San Diego, CA) to generate concentration-response curves after 
correcting for the slope values determined for baseline waveforms generated in the presence of 
vehicle controls.  Potencies were calculated from fits using a four parameter logistic equation. 
Mosquito toxicology and urine excretion.  Data were analyzed using Prism 5 for 
Windows (Graphpad Software).  To generate a dose-response curve for VU573, the doses (x-
axis) were log transformed and then a non-linear curve was fitted to the data using the 
‘log(agonist) vs. response’ algorithm.  An ED50 was calculated from this curve.  To compare 1) 
the incapacitating effects among the vehicle, VU573, and VU342 treatments, and 2) the rates of 
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urine excretion among the control, vehicle, VU573, and VU342 treatments, one-way ANOVAs 
were performed with Newman-Keuls posttests.  To compare the incapacitating effects between 
the vehicle and VU573 within each mosquito species, a paired t-test was used.   
Malpighian tubule experiments.  Data were analyzed using Prism 5 for Windows 
(Graphpad Software) and Excel (Microsoft Corp). To compare the rates of fluid secretion among 
control, vehicle, VU573, and VU342 treatments, a one-way ANOVA was performed with a 
Newman-Keuls posttest.  To compare the Vbl and Rpc values of principal cells between control 
and treatment periods a paired t-test was performed. 
 
Results and Discussion 
With few exceptions, the small-molecule pharmacology of the Kir channel family is 
undeveloped [204].  In an effort to reveal new modulators of human Kir1.1, we previously 
performed a high-throughput screen of approximately 225,000 small molecules from the 
National Institutes of Health Molecular Libraries Small-Molecule Repository [20].  The screen 
discovered compound VU573 (Fig. 1A), which inhibits several human Kir channels [64].  Thus, 
we tested whether VU573 also inhibits the mosquito Kir channel, AeKir1.   
The tetracycline-induced expression of AeKir1 in a human cell line (T-REx-HEK-293 
cells) produces robust, barium-sensitive, inward-rectifying K+ currents in whole-cell patch clamp 
recordings (Fig. 2).  Bath application of VU573 inhibits the AeKir1-mediated currents in a dose-
dependent manner (Fig. 1B, C) with an IC50 of 5.14 (M (Fig. 1C); this IC50 is similar to that 
observed for human Kir2.3, Kir3.x, and Kir7.1 [64].   
To facilitate our search for derivatives of VU573 with an improved potency for AeKir1 
over human Kir channels, we developed a high-throughput, fluorescence-based assay to measure 
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AeKir1 activity in T-REx-HEK-293 cells.  The assay uses thallium (Tl+) as a surrogate of K+ 
[20,21,64,204]. The flux is inhibited in a dose-dependent manner by VU573 with an IC50 of 15 
(M (Fig. 1D, E).  The slightly higher IC50 of VU573 calculated via the Tl+-flux assay vs. patch 
clamp recordings is consistent with results of our previous study on the inhibition of human 
Kir2.3 and Kir7.1 channels by VU573 [64], and likely reflects different channel permeabilities to 
Tl+ and K+ [85].   
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Figure 1. Small-molecule probes of AeKir1 expressed in T-REx-HEK-293 cells. (A) 
Chemical structures 3 of the AeKir1 antagonist VU573 and inactive analog VU342. The 
‘northern’ and ‘southern’ groups are indicated by yellow and blue shading, respectively. (B) 
Normalized AeKir1 current-voltage (I-V) 5 relationships illustrating VU573-dependent 
inhibition at 0, 10, and 30 (M. Cells were voltage clamped at -75 mV and ramped between -120 
mV and +60 mV. (C) Concentration-response curves of VU573 (filled circles) and VU342 (open 
circles) derived from patch clamp experiments (n = 4-9). The IC50 of VU573 and VU342 are 
5.14 ± 1.2 µM and 112 ±1.1 µM, respectively. (D) Dose-dependent inhibition of the AeKir1-
mediated Tl+ flux by VU573 ranging in concentrations from , 0.3 to 100 (M. The arrow 
indicates when Tl+ was added to the extracellular bath. (E) Concentration-response curves of 
VU573 (filled circles) and VU342 (open circles) derived from Tl+ flux assays. n = 2-3 
independent experiments, each performed in triplicate. (F) Representative I-V relationships 
showing minimal effects of VU342 on the AeKir1-mediated currents at concentrations of 0, 10, 
and 30 (M. Values in panels C and E are means ± SEM.  
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Figure 2. Functional expression of AeKir1 in T-REx-HEK293 cells and its inhibition by 
barium (Ba2+). (A) Representative current traces recorded from stably transfected cells cultured 
overnight in the presence of tetracycline to induce channel expression of AeKir1. Recordings 
were made from a cell superfused with 5 mM K+ (top panel), 50 mM K+ (middle panel), or the 
control blocker 2 mM Ba2+ in 50 mM K+ (bottom panel). (B) Current-voltage (I-V) relationships 
for AeKir1 bathed in 5 mM K+ (dark circle), 50 mM K+ (grey circle), or 50 mM K+ plus 2 mM 
Ba2+ (white circle). n = 3–7. (C) Concentration-response curve of Ba2+-dependent inhibition of 
AeKir1 with a 50% inhibition concentration (IC50) of 10 (M. Data are means ± SEM (n = 4–6).  
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We used the Tl+-flux assay to assess the structure-activity relationships of 47 analogs of 
VU573 (Table 1), focusing on the ‘northern’ benzyl and ‘southern’ aryl-ether of VU573 (Fig. 
1A, Table 1) (see [64] for synthesis).  Modification of the northern or the southern group of 
VU573 did not produce analogs with improved potency for AeKir1 (Table 1).  However, the 
replacement of the southern aryl ether with a morpholine moiety produced compound VU342 
(Fig. 1A; Compound 9 in Table 1), which nominally inhibits the AeKir1-mediated Tl+ flux (IC50 
> 100 (M; Fig. 1E).  When assessed in whole-cell patch-clamp experiments of T-REx-HEK-293 
cells, VU342 is 22-times less potent than VU573 at inhibiting AeKir1 (IC50 = 112 (M; Fig. 1C, 
F); the maximal inhibition of AeKir1 is only ~65% and requires a concentration of 300 µM (Fig. 
1C).  Accordingly, in subsequent experiments, we used VU342 as a negative control. 
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Table 1. Structure-activity relationships for VU573 and its analogs.  Values are means ± 
SEM (n = 1-3 independent Tl+ flux experiments in triplicate). 
 
Compound R R’ VU#/Barcode IC50 (#M) 
1 (VU573) 
 
N/A VU0160573-1/ 
IC4X 15 ± 1.2 
2 
 
N/A VU0403134-1/ 
IC3Y 13 ± 3.7 
3 
 
N/A VU0403131-1/ 
IC58 10 ± 0.0 
4 
 
N/A VU0340260-1/ 
IC38 20 ± 2.00 
5 
 
N/A VU0026784-1/ 
IC3L 11 ± 2.1 
6 
 
N/A VU0288495-1 
IC39 12 ± 0.5 
7 
 
N/A VU0451348-1/ 
R6P 9.4 ± 0.3 
8 
 
N/A VU0451344-1/ 
R80 14 ± 0.5 
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9 (VU342) 
 
N/A VU0451342-1/ 
R70 >100 
10 
 
N/A VU0451341-1/ 
R7M 11 ± 1.2 
11 
 
N/A VU0451340-1/ 
R5C 13 ± 3.7 
12 
 
N/A VU0451339-1/ 
R56 10 ± 0.0 
13 
 
N/A VU0066224-6/ 
R7N 20 ± 2.00 
14 
 
N/A VU0451336-1/ 
R5B 11 ± 2.1 
15 
 
N/A VU0451333-1/ 
R5X 12 ± 0.5 
16 
 
N/A VU0451337-1/ 
R5K 9.4 ± 0.3 
17 
 
N/A VU0451332-1/ 
R7B 14 ± 0.5 
18 
 
N/A VU0451338-1/ 
R71 >100 
19 
 
N/A VU0451330-1/ 
R6J 12 ± 2.1 
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20 
 
N/A VU0451331-1/ 
RKN 18 ± 4.0 
21 
 
N/A VU0451846-2/ 
R87 
19 ± 3.0 
 
 
Compound R R’ VU#/Barcode IC50 (#M) 
22 
  
VU0401333-1/ 
IC4L 16 ± 1.5 
23 
 
 
VU0403132-1/ 
IC48 >100 
24 
  
VU0451343-1/ 
RJ4 18 ± 2.0 
25  
 
VU0451335-1/ 
R5P 24 ± 0.5 
26  
 
VU0451334-1/ 
R7L 8.0 ± 0.5 
 
Compound R R’ VU#/Barcode IC50 (#M) 
27 
 
N/A VU0467122-1/ 
1CQH 7.9 ± 1.1 
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28 
 
N/A VU0467123-1/ 
15L2 33 ± 2.9 
29 
 
N/A VU0467128-1/ 
15ND 8.4 ± 1.1 
30 
 
N/A VU0467127-1/ 
15NC 30 ± 1.1 
31 
 
N/A VU0467126-1/ 
15LR 7.6 ± 1.2 
32 
 
N/A VU0467125-1/ 
15KQ 12 ± 1.1 
33 
 
N/A VU0467124-1/ 
15LD 17 ± 1.2 
34 
 
N/A VU0026649-2/ 
1LTK 26 
35 
 
N/A VU0027181-2/ 
1LR8 17 
 
Compound R R’ VU#/Barcode IC50 (#M) 
36  
 
VU0469204-1/ 
1LTW >100 
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37  
 
VU0469203-1/ 
1LTH >100 
38  
 
VU0035129-2/ 
1LRM 30 
39  
 
VU0469202-1/ 
1MCF >100 
40  
 
VU0469201-1/ 
1MDX 22 
41  
 
VU0094518-2/ 
1MCC >100 
42  
 
VU0469200-1/ 
1LTU >100 
43  
 
VU0469194-1/ 
1LTG >100 
44  
 
VU0469195-1/ 
1LT7 >100 
45  
 
VU0469199-1/ 
1LU7 >100 
46  
 
VU0469198-1/ 
1LU6 >100 
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47  
 
VU0469197-1/ 
1LRW >100 
48  
 
VU0469196-1/ 
1LTT >100 
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We next assessed the effects of VU573 in adult female mosquitoes (Ae. aegypti).  VU573 
was dissolved in a phosphate-buffered saline (PBS) containing 15% DMSO and delivered 
directly to the hemolymph via intrathoracic microinjection (69 nL per mosquito).  The injection 
of VU573 renders mosquitoes incapacitated (flightless or dead) within 24 hours in a dose-
dependent manner (ED50 = 53.6 pmol; Fig. 3A).  Of the mosquitoes incapacitated by VU573, 
92.3% were flightless while 7.7% were dead.  Some of the incapacitated mosquitoes (3.6%) also 
exhibited greatly distended abdomens consistent with the retention of fluid in the absence of 
renal functions (‘bloated’ in Fig. 3B).  Parallel experiments in adult females of other important 
mosquito vectors (Anopheles gambiae, Aedes albopictus, Culex pipiens) show that injection of 
VU573 also incapacitates these mosquitoes (Fig. 4). 
To determine if the effects of VU573 on mosquitoes are associated with its inhibition of 
AeKir1, we compared the efficacy of VU573 to incapacitate mosquitoes (Ae. aegypti) with that 
of the inactive analog VU342. Figure 2C shows that nearly 100% of the mosquitoes injected 
with VU573, but less than 20% of those injected with the vehicle or VU342, are incapacitated 
within 24 hours. Furthermore, 10% of the mosquitoes injected with VU573 were bloated (e.g., 
Fig. 3B), while none of the vehicle or VU342-injected mosquitoes retained fluid. Thus, the 
incapacitation of mosquitoes by VU573 likely arises from the inhibition of Kir channels—
presumably those in the renal excretory system.  
To assess whether VU573 inhibits the production of urine by Malpighian tubules we used 
the method of Ramsay [201].  As shown in Fig. 3D, isolated Malpighian tubules bathed in a 
high-potassium Ringer solution (control) spontaneously secrete fluid at a rate of ~0.6 nL/min in 
the first 30 min. The addition of VU573 to the peritubular bath (10 µM final concentration) 
significantly inhibits the rate of fluid secretion to 0.26 nl/min after 2 hours (Fig. 3D), whereas 
160!!
the addition of the vehicle (0.05% DMSO) or VU342 (10 µM) has no effect on the rate of fluid 
secretion after 2 hours (Fig. 3D). Thus, VU573 inhibits the first step in urine formation at the 
level of the Malpighian tubules. 
To confirm the inhibition of Kir channels by VU573, we used two-electrode voltage 
clamping to measure the basolateral membrane voltage (Vbl) and input resistance (Rpc) of 
principal cells of isolated Malpighian tubules [202].  Peritubular application of VU573 (10 µM) 
significantly hyperpolarizes the Vbl by 7.0 mV while increasing the Rpc by 5.7 k& (Table 1); 
these changes are consistent with the blockade of Kir channels in the basolateral membrane of 
Malpighian tubules [202].  By comparison, peritubular application of barium at 5 mM, which is a 
generic blocker of potassium channels including Kir channels (e.g., Fig. 2), also significantly 
hyperpolarizes the Vbl while increasing the Rpc.  The channel block by Ba2+ is significantly 
greater than that of VU573, which is to be expected given that it is less selective than VU573 
(Table 2).   
 
Table 2. Effects of VU573 (10 µM) and barium (5 mM) on the basolateral membrane voltage 
(Vbl) and input resistance (Rpc) of principal cells in isolated Malpighian tubules.   
 
 Vbl (mV) Rpc (k%) 
Control (n = 5) -45.4 ± 3.6  249.6 ± 15.2  
VU573 (n = 5) -52.4 ± 4.5 b 255.3 ± 15.4 a 
Control (n = 6) -47.4 ± 4.2  199.2± 30.4  
Barium (n = 6) -59.3 ± 3.3 c 322.8 ± 31.0 d 
 
a,b,c,d indicate P < 0.02, 0.003, 0.008, and 0.0003, respectively (paired t-test). Values are means 
± SEM. 
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To determine whether the VU573-mediated inhibition of fluid secretion by isolated 
Malpighian tubules causes renal failure in intact mosquitoes, we measured urine excretion rates 
using a method modified from the laboratory of Hansen [203].  Mosquitoes fed on a sucrose 
solution ad libitum (control) excrete urine at a rate of 0.41 nL/min (Fig. 3E, top), whereas those 
injected with 900 nL of a Na+-HEPES-buffered saline (HBS)—a volume 30% less than that 
ingested with a blood meal [195]—excrete urine at a significantly higher rate of 5.64 nl/min 
(‘vehicle’ in Fig. 3E, top).  The rate of urine excretion is significantly dampened to 2.14 nL/min 
if the Na+-HBS contains VU573 (0.77 mM), whereas the rate is unaffected (5.7 nL/min) if the 
Na+-HBS contains VU342 (Fig. 3E, top). 
A more pronounced inhibition of urine excretion by VU573 is observed when 900 nl of a 
K+-HBS is injected (Fig. 3E, bottom).  Mosquitoes injected with the K+-HBS alone (vehicle) 
excrete urine at a significantly higher rate (3.54 nL/min) than the controls (Fig. 3E, bottom), but 
if the injected K+-HBS contains VU573 (0.77 mM) then the rate of urine excretion is markedly 
reduced to 0.73 nL/min (Fig. 3E, bottom).  Urine excretion is unaffected if the K+-HBS contains 
VU342 (Fig. 3E, bottom).  Thus, VU573 inhibits both the production of urine in Malpighian 
tubules in vitro (Fig. 3D) and the excretion of urine in vivo (Fig. 3E).  The more effective 
inhibition of urine excretion by VU573 in the presence of elevated hemolymph K+ is expected 
with the block of Kir channels in Malpighian tubules [74].  Taken together, the above findings 
suggest that VU573 incapacitates mosquitoes by interfering with K+ homeostasis.  
In view of the above results, we sought to determine if the incapacitating effects of 
VU573 are enhanced by K+ in Ae. aegypti.  In the control experiment, the injection of 900 nL of 
Na+-PBS with VU573 (0.77 mM) into the thoracic hemolymph of mosquitoes does not 
significantly increase mortality compared to those injected with the Na+-PBS vehicle alone (Fig. 
162!!
3F), but still renders them flightless within 24 hours.  In contrast, the injection of K+-PBS with 
VU573 (0.77 mM) significantly increases mortality compared to the vehicle (Fig. 3F).  This 
finding mirrors the more pronounced effects of VU573 on the urine excretion rates of 
mosquitoes injected with K+-HBS vs. Na+-HBS (Fig. 3E), suggesting that the lethal effects of 
VU573 stem from the disruption of hemolymph K+ homeostasis.  Accordingly, the above 
findings indicate that VU573 would be most toxic to female mosquitoes after feeding on 
vertebrate blood, which presents a K+ load to the hemolymph [195-197].  In Ae. aegypti, about 
30 min after feeding, the digestion of blood cells releases as much K+ for absorption into the 
hemolymph as that in the injection of K+-PBS [195].  Thus, soon after feeding on blood, a female 
mosquito is expected to succumb to the effects of VU573, which are amplified by elevated 
hemolymph K+ levels.   
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Figure 3. Effects of VU573 and VU342 on adult female mosquitoes (Aedes aegypti). (A) 
Dose-response curve of the incapacitating effects of VU573 on mosquitoes with an effective 
dose 50% (ED50) of 53.6 pmol. ‘% Incapacitated’ refers to the proportion of mosquitoes that are 
flightless or dead within 24 h after injection. Each mosquito was injected with 69 nL of 
PBS/15% DMSO containing an appropriate concentration of VU573 to deliver the dose indicated. 
The ED50 was determined by fitting a non-linear curve to the data (R2 = 0.95). n = 3-5 trials of 10 
mosquitoes per dose. (B) Representative images of Ae. aegypti exhibiting ‘Normal’ and ‘Bloated’ 
abdomens. (C) Incapacitating effects resulting 24 h after injecting mosquitoes (69 nL each) with 
PBS containing the vehicle (15% DMSO), VU573 (10 (M), or VU342 (10 (M). n = 6 trials of 
10 mosquitoes per treatment. Lower-case letters indicate statistical categorization of the means 
as determined by a one-way ANOVA and a Newman-Keuls posttest (P<0.05). (D) Effects of 
VU573 and VU342 on the in vitro secretion of fluid by isolated Malpighian tubules. Tubules 
were bathed in a peritubular Ringer solution (control) to which one of the following was added: 
vehicle (0.05% DMSO), VU573 (10 (M), or VU342 (10 (M). Secretion rates of the controls 
were calculated for the first 30 min, whereas those of the vehicle and small molecules were 
calculated 2 h after their addition. n = 7 tubules for control, vehicle, and VU342; n = 5 tubules 
for VU573. Lower-case letters indicate statistical categorization of the means as determined by a 
one-way ANOVA and a Newman-Keuls posttest (P<0.05). (E) Effects of VU573 and VU342 on 
the in vivo rates of urine excretion in intact mosquitoes. Mosquitoes were either uninjected 
(control) or injected with a Na+ or K+ HBS (900 nL) containing the vehicle (1.8% DMSO), 
VU573 (0.77 mM) or VU342 (0.77 mM). n = 8 trials of 3 mosquitoes for controls; n = 10 and n 
= 8 trials of 3 mosquitoes for Na+-HBS and K+-HBS, respectively. Lower-case letters indicate 
statistical categorization of the means as determined by a one-way ANOVA and a Newman-
Keuls posttest (P<0.05). (F) Effects of injecting a Na+ or K+ PBS (900 nL) with the vehicle 
(1.1% DMSO) or VU573 (0.77 mM) on mosquito mortality. n = 5 trials of 10 mosquitoes each. 
Statistical differences between the vehicle and VU573 are determined with a paired t-test for 
each PBS. Values shown in all panels are means ± SEM. 
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Figure 4. Incapacitating effects of VU573 in three species of mosquitoes. Adult female 
mosquitoes were injected with Na+- PBS (69 nL) containing the vehicle (15% DMSO) or VU573 
(10 mM). ‘% Incapacitated’ refers to the proportion of mosquitoes that are flightless or dead 
within 24 h after injection. Values are means ± SEM (n = 4 independent trials of 10 mosquitoes). 
Statistical differences between vehicle and VU573-treated mosquitoes were determined by a 
paired t-test for each species. Anopheles gambiae is the primary vector of malaria; Aedes 
albopictus is a vector of emerging arboviruses, such as dengue and Chikungunya fevers; Culex 
pipiens is a vector of West Nile virus and lymphatic filariasis. 
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In conclusion, we have demonstrated that a small-molecule inhibitor of Kir channels 
elicits renal failure in female mosquitoes, which would decrease their reproductive output and 
ability to transmit pathogens by limiting the number of vertebrate blood meals they could 
consume.  Therefore, such inhibitors could be considered as a potential new class of insecticides 
to be further developed for combatting the emerging problem of insecticide resistance in 
mosquitoes.  The challenges that lay ahead are the development of:  1) small molecules that 
inhibit Kir channels of mosquitoes with greater potency than those of humans and beneficial 
insects, and 2) an efficient and effective system to deliver the inhibitors to mosquitoes.  The 
high-throughput screening assay for AeKir1 established in the present study will expedite the 
former effort. 
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Chapter VII 
MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF ANOPHELES 
GAMBIAE INWARD RECTIFIER POTASSIUM (KIR1) CHANNELS: A NOVEL ROLE 
IN EGG PRODUCTION 
Abstract 
Inward rectifier potassium (Kir) channels play essential roles in regulating diverse 
physiological processes. Although Kir channels are encoded in mosquito genomes, their 
functions remain largely unknown. In this study, we identified the members of the Anopheles 
gambiae Kir gene family and began to investigate their function. Notably, we sequenced the A. 
gambiae Kir1 (AgKir1) gene and showed that it encodes all the canonical features of a Kir 
channel: an ion pore that is composed of a pore helix and a selectivity filter, two transmembrane 
domains that flank the ion pore, and the so-called G-loop.  Heterologous expression of AgKir1 in 
Xenopous oocytes revealed that this gene encodes a functional, barium-sensitive Kir channel. 
Quantitative RT-PCR experiments then showed that relative AgKir1 mRNA levels are highest in 
the pupal stage, and that AgKir1 mRNA is enriched in the adult ovaries. Gene silencing of 
AgKir1 by RNA interference did not affect the survival of female mosquitoes following a blood 
meal, but decreased their egg output. These data provide evidence for a new role of Kir channels 
in mosquito fecundity, and further validates them as promising molecular targets for the 
development of a new class of mosquitocides to be used in vector control. 
 
168!!
Introduction 
A reviewed of mammalian Kir channels is discussed in Chapter I. In comparison to 
mammals, relatively little is known about Kir channels in insects, with most of our understanding 
coming from the model insect, Drosophila melanogaster. The D. melanogaster genome encodes 
three members of the Kir gene family, which are named Kir1, Kir2, and Kir3 [205]. Experiments 
using heterologous expression systems have demonstrated that Kir1 and Kir2 encode functional 
inward rectifier K+ channels, whereas Kir3 does not [205]. In embryos, Kir2 and Kir3 are 
expressed in the hindgut and the Malpighian (renal) tubules, respectively [205], whereas in adult 
flies all Kir encoding genes are expressed in the Malpighian tubules [206]. Thus, given their 
spatial expression it has been hypothesized that Kir channels may play a role in osmoregulatory 
processes [205,206]. Kir channels also appear to be involved in development; a recent study by 
Dahal et al. (2012) showed that genetic disruption of Kir2 expression causes wing-patterning 
defects as a result of dysregulation of bone morphogenetic protein (BMP) signaling. 
The genome of the yellow-fever vector mosquito Aedes aegypti encodes five members of 
the Kir channel family, named Kir1, Kir2A, Kir2B, Kir2B’ and Kir3 [74]. Similar to the 
Drosophila Kir family, A. aegypti Kir1 and Kir2B, but not Kir3, encode functional channels 
when heterologously expressed [74]. Also similar to D. melanogaster, the expression of Kir1, 
Kir2B, and Kir3 is enriched in Malpighian tubules, consistent with the hypothesis that these 
genes play important roles in osmoregulation and urine production. Indeed, we recently reported 
that pharmacologically inhibiting A. aegypti Kir1 channels using a small-molecule antagonist 
reduces urine output, disrupts K+ homeostasis, and leads to a flightless or dead phenotype within 
24 hours of treatment. That study showed that Kir channels are essential for proper renal 
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physiology and suggests that inhibiting Kir channels could be a novel insecticidal mechanism for 
the control of mosquito disease vectors [207].   
The biology of Kir channels in the African malaria vector Anopheles gambiae remains 
unexplored.  Here, we identified the members of the A. gambiae Kir gene family and began to 
explore their expression, function, pharmacology, and integrative physiology. Most notably, we 
found that the expression of A. gambiae Kir1 (AgKir1) is enriched in the ovaries and that RNAi-
mediated knockdown of the channel decreases the number of eggs laid by female mosquitoes. 
 
Materials and Methods 
Mosquito rearing 
Anopheles gambiae Giles sensu stricto (G3 strain; Diptera: Culicidae) were reared and 
maintained in an environmental chamber set to 27°C and 75% humidity as previously described 
[208]. Briefly, eggs were hatched in distilled water and larvae were fed a mixture of koi food and 
yeast daily. Upon eclosion, adults were fed a 10% sucrose solution ad libitum. All experiments 
were carried out on adult female mosquitoes. 
 
Sequencing of Anopheles gambiae Kir1 from Malpighian tubule cDNA 
As described in previous studies [74,209,210], the GeneRacer Kit (Life Technologies, 
Carlsbad, CA) was used to generate two independent pools of single-stranded cDNA (designated 
as 5$-cDNA and 3$-cDNA) from Malpighian tubule total RNA (derived from !50 females).  The 
5$-cDNA was used as the template for 5$-rapid amplification of cDNA ends (RACE), whereas 
the 3$-cDNA was used as the template for 3$-RACE. 
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The 5$- and 3$-RACE reactions were assembled in volumes of 25 µl as recommended by 
the manufacturer.  Each reaction consisted of (1) a GeneRacer Kit primer (5$-Primer or 3$-
Primer), (2) a gene-specific primer (designed using the bioinformatic prediction of AgKir1), (3) 
5$- or 3$ RACE library cDNA, and (4) Platinum PCR Supermix HF (Life Technologies).  A 
“touchdown” thermocycling protocol was used for all RACE reactions as outlined by the 
GeneRacer Kit.  The amplification products of the RACE reactions were visualized by 1% 
agarose gel electrophoresis, TA-cloned (Life Technologies), and chemically transformed into 
Escherichia coli (Zymo Research, Irvine, CA), as described previously [74,209,210]. Plasmid 
DNA from the resulting E. coli colonies was sequenced at the Molecular and Cellular Imaging 
Center of the Ohio State University Ohio Agricultural Research and Development Center 
(Wooster, OH).  A consensus sequence for AgKir1 was generated after aligning the DNA 
sequences of the 5$-RACE, 3$-RACE, and full-length PCR products. After assembly, sequences 
were graphically visualized using Artemis software (Wellcome Trust Sanger Institute, 
Cambridge, UK). The primers used to determine the full-length sequence of AgKir1 are 
presented in Table 1 and the positions and lengths of AgKir1 exons and introns in the AgamP3 
assembly of the A. gambiae genome are shown in Table 2. 
The predicted AgKir1 protein mass was calculated using the Compute pI/Mw tool in the 
ExPASy Bioinformatics Resource Portal (http://web.expasy.org/ compute_pi/), and a search for a 
signal peptide was done using the SignalP 4.0 server [211].  The membrane-associated domains 
were predicted using the Eukaryotic Linear Motif server (http://www.elm.eu.org), and ExPASy 
ProtScale (http://web.expasy.org/protscale/) was used to plot hydrophobicity using the Rao and 
Argos scale [212].  Prediction of the selectivity filter was done by searching for the canonical T-
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X-G-Y(F)-G sequence [1], the pore helix was identified by alignment to AeKir1 [74], and 
alignment with human Kir sequences was used to predict the G-loop [213]. 
 
Table 1. Primers used for cloning and sequencing Anopheles gambiae Kir1 (AgKir1). 
Name Sequence (5$ -3$) PCR reaction 
1R GCCACTAGCCGGTTGATCTTTCATTCGT 5$-RACE (initial) 
2R CAGCTGACGAGCACTGCACAGAGGAGTA 5$-RACE (initial) 
3R      TAAATAGCTGCTGCGTGCTTGCGTGGT 5$-RACE (nested) 
4R CTCCATGGCTCAGGGCGATCAGGTA 5$-RACE (initial) 
5R ACTCGCTTCCGAATACGTCTGGAGCTGT 5$-RACE (nested) 
1F GTGGTGGAATCGACCGGTATGAC 3$-RACE (initial) 
2F TCCGATACCGATGAATCCGACACAT 3$-RACE (initial) 
3F CCCGTTCGTCGTCCAGTGCCAGTGGT 3$-RACE (nested) 
FL_3F CAGCAGCAGCAGACGACTT Full-length 
FL_4F GCGGTGTCGTTGGAAATAAG Full-length (nested) 
FL_1R TTCTGCAACCACTGGCACT Full-length 
FL_2R GAACTGAACGGGAGGATGTG Full-length (nested) !
 
Table 2. Positions and lengths of Anopheles gambiae Kir1 exons and introns in the Anopheles 
genome 
Exon Chromosome Start 
Position 
Stop 
Position 
Length of 
Exon 
Length of Following Intron 
1 2R 2,201,198 2,201,335 1,037 5,805  
2 2R 2,207,081 2,207,547 407 56,200 *Start codon (51-53) 
3      2R 2,263,718 2,263,834 115 282  
4 2R 2,264,117 2,264,258 142 68  
5 2R 2,264,327 2,264,410 84 75  
6 2R 2,264,486 2,264,760 275 77  
7 2R 2,264,838 2,264,838 190 69  
8 2R 2,265,097 2,265,221 125 66  
9 2R 2,265,288 2,265,396 109 67  
10 2R 2,265,464 2,265,758 295 2,745 *Stop codon (267-
269) 
11 2R 2,268,504 2,269,189 673 n/a   !
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Protein alignment and phylogenetic analysis 
Protein sequences of Kir channels from Aedes aegypti, Anopheles gambiae, Culex 
quinquefasciatus, Drosophila melanogaster and Microcoleus vaginatus were retrieved from the 
National Center for Biotechnology Information protein database website 
(http://www.ncbi.nlm.nih.gov/pubmed/) or VectorBase (https://www.vectorbase.org/), with 
accession IDs shown in Table 3. Protein sequences were aligned with the ClustalW algorithm 
using Geneious Pro v4.8.5 software (http://www.geneious.com; Biomatters, Auckland, New 
Zealand), and amino acid similarities were calculated using the Blosum62 score matrix 
(threshold = 0). The LG+I+G+F model of amino acid substitution according to the Akaike 
information criterion was then identified with ProtTest 2.4 [214], and used to construct a 
maximum likelihood tree (1000 replicates) in PhyML 3.0 [215], as implemented in the T-REX 
web server [216]. The phylogenetic tree was visualized and edited with FigTree v1.4.0 
(http://tree.bio.ed.ac.uk/software/figtree/). The amino acid sequence of Ion transport 2 domain 
protein (a putative Kir channel) from the cyanobacterium M. vaginatus was used as the outgroup.  
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Table 3. Accession numbers of A. aegypti, A. gambiae, C. quinquefasciatus, D. melanogaster 
and M. vaginatus Kir channel sequences. 
Protein 
name 
VectorBase ID 
AeKir1 AAEL008932 
AeKir2A AAEL008928 
AeKir2B AAEL008931 
AeKir2B’ AAEL013373 
AeKir3 AAEL001646 
AgKir1 AGAP001280 
AgKir2A AGAP001281 
AgKir2A’ AGAP001283 
AgKir2B AGAP001284 
AgKir3A AGAP007818 
AgKir3B AGAP028144 
CqKir1 CPIJ017135 
CqKir2A CPIJ017138 
CqKir2B CPIJ017140 
CqKir3A CPIJ000961 
CqKir3B CPIJ000962 !
Protein 
name 
GenBank ID 
DmKir1 NP_001262861.1 
DmKir2 ACL85253.1 
DmKir3 NP_001137835.1 
MvKir WP_006634522.1 !  
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Heterologous expression and electrophysiology in Xenopus oocytes  
To express AgKir1 in Xenopus oocytes, the open-reading frame of AgKir1 was sub-
cloned into a pGH19 plasmid and the synthesized complimentary RNA (cRNA) was injected 
into stage IV-V defolliculated Xenopus laevis oocytes as previously described [74]. The oocytes 
were injected with either 7.5 or 15 ng of cRNA to induce AgKir1 channel expression, and 
cultured for 3-7 days in OR3 media as described [74,209,217].  Oocytes that had been injected 
with nuclease-free H2O served as controls.   
Whole-cell AgKir1 currents were recorded using the two-electrode voltage clamp 
technique as previously described [74]. Current and voltage commands were generated with a 
Digidata 1440A Data Acquisition System (Molecular Devices, Sunnyvale, CA) and the Clampex 
module of pCLAMP software (version 10, Molecular Devices). For current recordings, an oocyte 
was transferred to the holding chamber under superfusion with a control solution and was 
impaled with two conventional-glass microelectrodes backfilled with 3M KCl (resistances of 
0.5–1.5 M&). The control solution (ND96) contained (in mM): 96 NaCl, 0 NMDG-Cl, 2 KCl, 1 
MgCl2, 1.8 CaCl2, and 5 HEPES, with pH adjusted to 7.5 with NMDG-OH. For some 
experiments, a low-K+ solution was used, which contained (in mM): 0.5 NaCl, 97.5 NMDG-Cl, 
0.5 KCl, 1 MgCl2, 1.8 CaCl2, and 5 HEPES. Alternately, a high-K+ solution was used, which 
contained (in mM): 0.5 NaCl, 48 NMDG-Cl, 50 KCl, 1 MgCl2, 1.8 CaCl2, and 5 HEPES.  
AgKir1 currents were inhibited with Ba2+ (1 mM), a non-specific K+ channel blocker 
[84,218,219]. For current-voltage (I-V) recordings, oocytes were voltage clamped near their 
spontaneous membrane potential (Vm) and stepped from -140 mV to + 40 mV in 20 mV 
increments for 100 ms each. All recordings were performed at room temperature, and the I-V 
plots were generated using the Clampfit module of pCLAMP. 
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RNA isolation, cDNA synthesis, and quantitative real-time PCR 
Total RNA was isolated from whole adult female mosquitoes as previously described 
[220]. Briefly, RNA extracted from 10 to 20 mosquitoes was isolated using TRIzol® Reagent 
(Life Technologies, Carlsbad, CA) and purified using the RNeasy kit (Qiagen, Valencia, CA). 
First-strand cDNA was synthesized from poly(A)+ RNA using the SuperScript® III First-Strand 
Synthesis System for RT-PCR (Life Technologies) according to manufacturer instructions. Real-
time quantitative PCR (qRT-PCR) was then done using Power SYBR® Green PCR Master Mix 
(Applied Biosystems, Foster City, CA) on an ABI 7300 Real-Time PCR System. Relative 
quantification was carried out using the 2#--CT method [221], and the ribosomal protein S7 
(rps7) was used as the reference gene [222,223]. 
AgKir1 mRNA levels, and the mRNA levels of other A. gambiae Kir genes, were 
measured by real-time quantitative PCR (qRT-PCR) essentially as described [208]. To quantify 
AgKir1 mRNA levels in different developmental stages, cDNA was synthesized from RNA 
purified from ~200 eggs, 50 second instar larvae, 40 third instar larvae, 30 fourth instar larvae, 
20 pupae (callow or black) or 15 adults (24 h, 5 days or 10 days old). Two biological replicates 
were conducted and each was analyzed in duplicate. The graphed output displays the average 
fold-change in mRNA levels relative to eggs. 
To quantify A. gambiae Kir gene expression in different body segments, cDNA was 
synthesized from RNA purified from 10 whole bodies, 20 heads, 20 thoraces or 20 abdomens 
from adult mosquitoes at 4 days post-eclosion. To quantify A. gambiae Kir gene expression in 
dissected tissues, cDNA was synthetized from RNA purified from midguts, Malpighian tubules, 
ovaries and fat bodies. Tissues were collected from %25 mosquitoes as previously described 
[208], except that in this study the Malpighian tubules were separated from the midgut and 
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processed separately. These are standard methods of tissue dissection, although the procedure for 
fat body collection suffers from the fact that other cell types are collected as well, including the 
dorsal vessel, other muscle, the ventral nerve cord, pericardial cells, and sessile hemocytes 
[224,225]. The body segment and tissue experiments were conducted in parallel, with three 
independent trials being performed and each being analyzed in duplicate. The graphed output of 
body segment and tissue analyses displays the average fold-difference in mRNA levels relative 
to whole bodies. The primers used for qRT-PCR are presented in Table 4. 
 
RNA interference (RNAi)-based gene silencing  
An RNAi-based strategy was used to silence gene expression. A 492 bp double stranded 
RNA (dsRNA) construct specific to A. gambiae Kir1 was synthesized using the MEGAscript® 
kit (Life Technologies, Carlsbad, CA) as described earlier [222]. As a control, a 214 bp dsRNA 
construct specific to bla(ApR), the ampicillin-resistant gene that is encoded in Novagen’s pET-46 
Ek/LIC vector (EMD Chemicals, Gibbstown, NJ), was synthesized from DNA purified from 
BL21(DE3) Escherichia coli cells containing the pET-46 plasmid.  
To knockdown mRNA levels, approximately 500 ng of AgKir1 dsRNA or bla(ApR) 
dsRNA was intrathoracically injected into 3-day-old female mosquitoes. To verify knockdown 
efficiencies, %10 mosquitoes were collected at days 4, 8, and 11 post-injection, total RNA was 
purified, cDNA was synthesized, and relative gene expression was quantified by qRT-PCR.  For 
each timepoint, 2-3 biological replicates were conducted, and each was assayed in duplicate. 
Gene silencing data are presented as mRNA levels relative to the bla(ApR) dsRNA-injected 
control groups.  The primers used for RNAi and gene expression are presented in Table 4. 
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Table 4. Primer sequences used for amplification of Kir channel genes for expression analyses and RNA interference. 
Gene  Vectorbase ID a 
(Application) 
Primer name Primer sequence (5’-3’) b Amplicon 
Length (bp) 
AgKir1 AGAP001280 (qRT-PCR) 
Ag_Kir1_02F TCCTCTGTGCAGTGCTCGTC 
168 
Ag_Kir1_02R TACACTGGCGTGAAGCGAAG 
AgKir1 AGAP001280 (dsRNA synthesis) 
Ag_Kir1_T702F TAATACGACTCACTATAGGGCGATGAAAGTCACAAAC 
519 c 
Ag_Kir1_T702R TAATACGACTCACTATAGGGCTATCCCGATCGATCTTG 
AgKir2A AGAP001281 (qRT-PCR) 
Ag_Kir2A_03F GAGACGCACTCCGTCGATAC 
153 
Ag_Kir2A_03R ACATACGCAAACGGTCAACA 
AgKir2A’ AGAP001283 (qRT-PCR) 
Ag_Kir2A’_02F GTTACATCTGCCCGATAACC 
217 
Ag_Kir2A’_02R CACTATGCCAACCATGAACG 
AgKir2B AGAP001284 (qRT-PCR) 
Ag_Kir2B_01F GTCAGGTGTATTGCTTACGC 
178 
Ag_Kir2B_01R GCGGGGTTTCTTGTACCCAG 
AgKir3A AGAP007818 (qRT-PCR) 
Ag_Kir3_01F CGTGTGGTGAACAAGATTGG 
193 
Ag_Kir3_01R GAATCAGATCACCGTGAGCG 
rpS7 AGAP010592 (qRT-PCR) 
rpS7_02F GACGGATCCCAGCTGATAAA 
132 
rpS7_02R GTTCTCTGGGAATTCGAACG 
bla(ApR) Bacterial gene (dsRNA synthesis) 
blaApr_T7_01F TAATACGACTCACTATAGGGCCGAGCGCAGAAGTGGT 214 c 
blaApr_T7_01R TAATACGACTCACTATAGGGAACCGGAGCTGAATGAA  
a Vectorbase IDs were obtained from the AgamP3 assembly in www.vectorbase.org. 
b Underlined sequences are specific to the T7 RNA polymerase promoter sites needed for dsRNA synthesis. 
c dsRNA amplicon length includes the T7 promoter sequence tags. 
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Antibody production 
An affinity purified, polyclonal rabbit antibody raised against a synthetic peptide 
(SRRIRKRVIFKQGDC) corresponding to a putative fragment of the cytosolic NH2-terminal 
domain of AgKir1 (S128-C142) was developed by 21st Century Biochemicals (Marlboro, MA). 
 
Western blotting 
To prepare protein lysates, whole mosquitoes were homogenized in a 10% Ringer 
solution.  After determining the protein concentration using the Bradford reagent, the lysates 
were diluted by addition of one volume of high-urea buffer that was composed of the following: 
6 M Urea, 15 mM TrisHCl, 0.3% SDS and 0.25 mM NaCl at pH 7.4 [209]. The high-urea lysates 
were mixed with an appropriate volume of a 5X Laemmli gel loading buffer (60 mM Tris-HCl, 
25% glycerol, 2% SDS, 0.5% !-mecaptoethanol, 0.1% bromophenol blue) and incubated at 
100°C for 5 minutes. Approximately 30 µg of protein was separated by SDS-PAGE on a 
denaturing 12% polyacrylamide resolving gel (with a 4% stacking gel; ProtoGel®Quick-Cast, 
National diagnostics, Atlanta, GA) using an XCell SureLock Mini Cell electrophoresis unit (Life 
Technologies). After electrophoresis, the stacking gel was discarded and the separated proteins 
were transferred to a polyvinylidene difluoride (PVDF) membrane (Thermo Scientific, Rockford, 
IL) using an XCell II blot module (Life Technologies) according to the manufacturer’s protocol. 
To detect AgKir1 immunoreactivity, the PVDF membrane was washed three times with 
Tris-buffered saline containing 0.01% Tween 20 (TBST; 10 mM TrisHCl, 150 mM NaCl, and 
0.01% Tween 20, pH 7.4), blocked for 30 min with 5% nonfat dry milk dissolved in TBST 
(blocking buffer), and incubated overnight at 4°C with the anti-AgKir1 antibody (1:1000 
dilution) in blocking buffer.  The following day, the PVDF membrane was washed three times (5 
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min each) with TBST, incubated for 1 h with a horseradish peroxidase (HRP)-conjugated goat 
anti-rabbit IgG (1:20,000 dilution; Pierce Biotechnology, Thermo Scientific, Rockford, IL) in 
blocking buffer, and washed three times (5 min each) with TBST. To visualize AgKir1 
immunoreactivity, a luminescent substrate of HRP (DuraWest Chemiluminescent, Pierce 
Biotechnology) was applied to the PVDF membrane, and the signal was detected with a 
ChemiDocVersatile Document Imager (Bio-Rad Laboratories, Hercules, CA). 
 
Survival assays 
For survival assays, 3-day-old adult female mosquitoes were intrathoracically injected 
with bla(ApR) dsRNA or AgKir1 dsRNA and then returned to the environmental chamber and 
provided with 10% sucrose. At day 8 following the dsRNA injections, the mosquitoes were 
allowed to blood-feed on mice anesthetized with a mixture of ketamine and xylazine for 
approximately 30 min, and subsequently maintained on 10% sucrose. Beginning with the time of 
blood feeding, mosquito survival was recorded daily for 19 days, and the graphed output 
represents the mean percent survival from the three biological replicates (24-27 mosquitoes per 
group in each trial). 
  
Fecundity assays 
For the fecundity assays, 3-day-old adult female mosquitoes were intrathoracically 
injected with bla(ApR) dsRNA or AgKir1 dsRNA and allowed to blood feed 8 days later. Forty-
eight hours after blood-feeding, fully engorged mosquitoes were individually transferred to 
Drosophila vials (Fisher Scientific, Pittsburgh, PA) containing 2-3 mL of distilled water and 
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capped with a cotton ball. Mosquitoes were monitored for the next 3 days, and eggs were 
counted once oviposition had taken place. A total of 5 biological replicates were performed. 
 
Results 
Anopheles gambiae Kir1 gene structure 
Reciprocal tblastn searches of the AgamP3 assembly of the A. gambiae genomic 
sequence and the AaegL2 assembly of the A. aegypti genomic sequence in www.vectorbase.org 
revealed that A. gambiae AGAP001280 and A. aegypti AAEL008932 are 1:1 orthologs 
(reciprocal E-values = 0.0).  Thus, because AAEL008932 is named AeKir1 [74], we named 
AGAP001280 AgKir1. 
To determine the complete mRNA sequence of AgKir1, the entire transcript was 
sequenced by 5" and 3" RACE.  Assembly of the RACE sequences revealed that the AgKir1 
mRNA is 3,452 nucleotides (base pairs; bp) in length, and is composed of a 1,085 bp 5" 
untranslated region (UTR), a 1,668 bp open reading frame (ORF) and a 669 bp 3" UTR (Fig. 1; 
GenBank ID: Pending).  Alignment of the mRNA sequence and the chromosome 2R genomic 
sequence revealed that the AgKir1 gene is composed of 11 exons that span 68,906 bp of genomic 
sequence.  Although initially predicted as AGAP001280, the mRNA sequence is significantly 
larger than the prediction.  Starting at the 5" end, AgKir1 spans the predictions of AGAP013159 
and AGAP001280.  Thus, these two VectorBase gene IDs should be merged into a single entry. 
Conceptual translation of the full-length mRNA revealed that AgKir1 encodes a 555 
amino acid (aa) protein with a predicted mass of 62.1 kDa.  As expected of an ion channel, the 
ORF does not encode a signal peptide.  The ORF, however, does encode all of the characteristic 
features of inward rectifier potassium channels (Kirs).  Specifically, ELM analysis predicts three 
181!!
membrane-associated domains, located in aa positions 171-193, 213-235, and 248-270.  The first 
and third predictions are the classical transmembrane domains seen in Kir channels [1].  The 
second prediction is the ion pore, which includes the pore helix (aa 219-230; 100% identity with 
the predicted pore helix in AeKir1; [74]) and the selectivity filter TIGYG (aa 232-236; [1]).  A 
hydrophobicity plot of the conceptual translation of AgKir1 supports the prediction of the two 
transmembrane domains and the ion pore (Fig. 2).  Finally, alignment of AgKir1 with human 
Kirs [213] predicts that aa 390-400 form the so-called G-loop. 
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Figure 1. Gene structure of Anopheles gambiae AgKir1. The open reading frame (ORF) is the 
gray boxes, the untranslated regions (UTRs) are the white boxes, and the introns are the 
horizontal lines. The locations that encode the transmembrane domains (TM1 and TM2), pore 
helix, selectivity filter and G-loop are marked, and the sizes (in bp) of the UTRs, ORF, exons 
and introns are provided. 
  
!"# !"$ %&'(()
*+,+-./0/.1&2/,.+34(3+&5+,/6
789
:#;<<=&>)?
@A&B!8
:#;C=@>)?
DA&B!8
:<EE&>)?
F
6(
G&
$&
:H
CI
&>
)?
F
6(
G&
D&
:#
#@
&>
)?
F
6(
G&
H&
:#
H$
&>
)?
F
6(
G&
@&
:=
H&
>)
?
F
6(
G&
<&
:$
I@
&>
)?
F
6(
G&
I&
:#
EC
&>
)?
F
6(
G&
=&
:#
$@
&>
)?
F
6(
G&
E&
:#
CE
&>
)?
F
6(
G&
#C
&:$
E@
&>
)?
F
6(
G&
##
&:<
ID
&>
)?
JG
.3(
G&
$&
:@
<;
$C
C&
>)
?
JG
.3(
G&
D&
:$
=$
&>
)?
JG
.3(
G&
I&
:<
E&
>)
?
JG
.3(
G&
<&
:I
I&
>)
?
JG
.3(
G&
@&
:I
@&
>)
?
JG
.3(
G&
H&
:<
=&
>)
?
JG
.3(
G&
=&
:<
<&
>)
?
JG
.3(
G&
E&
:<
I&
>)
?
JG
.3(
G&
#C
&:$
;I
H@
&>
)?
F
6(
G&
#&
:#
;C
DI
&>
)?
JG
.3(
G&
#&
:@
;=
C@
&>
)?
183!!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Hydrophobicity plot of AgKir1. Hydrophobicity plot showing the three major 
hydrophobic regions of AgKir1: the two transmembrane domains (TM1 and TM2) and the ion 
pore (composed of the pore helix and the selectivity filter).  Higher values indicate higher 
hydrophobicity. !  
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Phylogenetic analysis of AgKir channels  
A tblastn search of the AgamP3 assembly of the A. gambiae genomic sequence and the 
CpipJ1 assembly of the C. quinquefasciatus genomic sequence in www.vectorbase.org using 
AgKir1 as the query sequence, followed by the identification of characteristic features of Kir 
channels, identified five additional members of the A. gambiae Kir gene family (for a total of six 
Kir genes), and five members of the C. quinquefasciatus Kir gene family.  Based on sequence 
alignment and a phylogenetic analysis (see below), the A. gambiae genes were named AgKir2A, 
AgKir2A!, AgKir2B, AgKir3A and AgKir3B, and the C. quinquefasciatus genes were named 
CqKir1, CqKir2A, CqKir2B, CqKir3A and CqKir3B. 
For the A. gambiae Kir genes, alignment of the conceptual translation of AgKir1 with the 
putative amino acid sequences of AgKir2A, AgKir2A", AgKir2B, AgKir3A and AgKir3B 
revealed several characteristic features of Kir channels, including a pore-forming domain 
containing the signature “TIGYG” K+ selectivity filter (STGYG in the case of the two AgKir3 
genes), two transmembrane-spanning domains (TM1 and TM2), and the G-loop (Figs. 1-3) 
[1,213]. The core region (between filled circles in Fig. 3; [205]) of AgKir1 shares approximately 
60% amino acid sequence identity with AgKir2 subtypes, but only about 40% identity with 
AgKir3 subtypes. Finally, it is interesting that all mosquito (Anopheles, Aedes and Culex) Kir3 
genes encode a non-canonical form of the selectivity filter, whereas DmKir3 contains the 
canonical form. Given that AeKir3 and DmKir3 do not encode a functional channel [74,205], it is 
possible that the A. gambiae and C. quinquefasciatus Kir3 genes do not encode functional 
channels as well (for an alignment of the selectivity filters of dipteran and human Kir channels 
see Fig. 4). 
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A maximum likelihood tree of dipteran Kir channels using Ion transport 2 domain protein 
(a putative Kir channel) of M. vaginatus as the outgroup shows that Kir genes can be divided into 
two major clades: Kir1/Kir2 and Kir3 (Fig. 5). Consistent with the neighbor-joining analysis of 
Piermarini et al. [74], the Kir1/Kir2 clade can be subdivided into Kir1 and Kir2 groups, and the 
Kir2 group can be further subdivided into Kir2A and Kir2B subgroups. Interestingly, whereas D. 
melanogaster only encodes three Kir genes (Kir1, Kir2 and Kir3), the Kir gene family has 
expanded in the mosquito lineage. That is, the genomes of all three mosquito species encode at 
least two Kir2 genes, and the genomes of A. gambiae and C. quinquefasciatus encode two Kir3 
genes. 
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Figure 3. Amino acid sequence alignment of Anopheles gambiae Kir channels. ClustalW 
alignment of the conceptual translations of the RACE sequenced AgKir1 and the other predicted 
members of the A. gambiae Kir gene family. The transmembrane domains (TM1 and TM2), the 
pore-helix, the selectivity filter and the G-Loop are indicated. The core region is flanked by filled 
circles.!Shadings denote the amino acid similarity at a given position, with black highlight, dark 
grey highlight, light grey highlight, and no highlight indicating 100%, 80-99%, 60-79% and 
<60% similarity, respectively.  
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Figure 4. ClustalW protein sequence alignment of the K+-selectivity filter (TXGY[F]G) 
from Aedes aegypti, Anopheles gambiae, Culex quinqefasciatus, Drosophila melanogaster, 
Homo sapiens and Microcoleus vaginatus Kir channels.  The Kir3 genes of Aedes aegypti, 
Anopheles gambiae and Culex quinquefasciatus encode a non-canonical selectivity filter.! The 
GenBank accession numbers used in this analysis were the following: 
Homo sapiens (Hs): NP_000211.1; NP_000882.1; NP_066292.2; NP_690607.1; NP_037480.1; 
NP_001181887.2; NP_002230.1; NP_002231.1; NP_004974.2; NP_000881.3; NP_002232.2; 
NP_733932.1; NP_061128.1; NP_004973.1; NP_000516.3; NP_002233.2. Refer to Table S1 for 
VectorBase and GenBank accession numbers for dipteran Kir channels (Aedes aegypti, Ae; 
Anopheles gambiae, Ag; Culex quinquefasciatus, Cq; Drosophila melanogaster, Dm) and the 
cyanobacterium Microcoleus vaginatus, Mv.  
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Figure 5. Phylogenetic analysis of the Anopheles gambiae, Aedes aegypti, Culex 
quinquefasciatus, and Drosophila melanogaster Kir channel families. Proteins sequences were 
aligned by ClustalW and the maximum likelihood tree computed with PhyML 3.0. A putative 
Kir channel from the cyanobacterium M. vaginatus was used as the outgroup, and bootstrap 
support for the clades are shown for each node. The proportion of amino acid changes among the 
proteins is indicated by the branch length. The gene IDs are presented in Table 3.   
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Functional characterization of AgKir1 channels in Xenopus oocytes 
We have shown that a small molecule inhibitor of AeKir1 (VU573) (1) incapacitates 
adult females of several mosquito species (A. aegypti, A. albopictus, A. gambiae and C. pipiens) 
and (2) disrupts the excretory physiology of at least A. aegypti [207]. Thus, because of the 
important role that AeKir1 plays in renal physiology, our first assessment of Kir gene function in 
A. gambiae focused on AgKir1. As shown in Fig. 6A, when bathed in a control (ND96) solution, 
heterologous expression of AgKir1 channels in Xenopus oocytes gave rise to functional channels 
exhibiting spontaneous large inward and small outward currents between -140 mV and -80 mV.  
Moreover, the spontaneous resting membrane potential of the AgKir1-expressing oocytes (-96.9 
± 1.3 mV) was (1) hyperpolarized compared to the H2O-injected oocytes (-42.0 ± 2.5 mV), and 
(2) close to the estimated Nernst potential for K+ (-102 mV). As shown in Fig. 6B, the inward 
AgKir1 channel currents increase with increased extracellular K+ concentrations and are 
inhibited by barium.  These functional characteristics are canonical of most animal Kir channels, 
and very similar to those of AeKir1 [207].  Thus, AgKir1 functions as an inward rectifier K+ 
channel. 
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Figure 6. Current-voltage (I-V) relationships of AgKir1 channels in Xenopus oocytes. (A) 
The I-V relationship of AgKir1 channel-expressing oocytes (filled circles; n = 6) reveals robust 
inward rectifying currents when bathed in the control (ND96) solution, whereas those of H2O-
injected oocytes (open circles; n = 8) exhibit nominal currents. Data are mean ± SEM.  (B) 
Barium (1 mM) blocks inward-rectifying K+ currents in AgKir1 channel expressing oocytes. 
Oocytes were bathed consecutively in the following solutions: (1) low-K+ solution (open 
squares), (2) high-K+ solution (filled circles), (3) high-K+ solution with Ba2+ (open circles).  
Shown is a representative I-V plot from an oocyte. Vm, membrane voltage; Im, membrane current.  
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Developmental and tissue distribution of Kir1 in Anopheles gambiae  
To gain insight into the possible in vivo functions of AgKir1, we analyzed the expression 
patterns of AgKir1 at different life stages. Quantitative RT-PCR analyses revealed that AgKir1 is 
ubiquitously expressed in all mosquito life stages, with transcript levels being highest in the 
pupal stage and lowest in third instar larval stage (Fig. 7; ANOVA P = 0.0003). Specifically, 
relative to eggs, there is a trend for AgKir1 mRNA levels to decrease by half during the larval 
and then increase between 2- and 3-fold in the early (callow) and late (black) pupal stages. After 
eclosion, AgKir1 mRNA levels return to levels similar to those observed in eggs and remain 
unchanged through the 10th day following adult emergence (the last timepoint assayed).  
To determine the locations of AgKir1 transcription, we analyzed the expression pattern of 
AgKir1 in different body segments and tissues of 4-day-old adult female mosquitoes. 
Quantitative RT-PCR analyses revealed that AgKir1 mRNA levels are detectable in all body 
segments and in all tissues assayed (Fig. 8). Specifically, mRNA levels in the head, thorax, 
abdomen and Malpighian tubules are comparable to the levels detected in the mosquito whole 
body. AgKir1 mRNA levels trended to be lower in the midgut and fat body tissues when 
compared to the whole body, a finding that is in agreement with the Kir1 gene expression profile 
reported in MozAtlas [226]. However, of all the tissues examined, we observed the significant 
enrichment of AgKir1 mRNA in the ovaries: levels were almost 2.5-fold higher than those found 
in the whole body (ANOVA P = 0.0008). Furthermore, when compared to other Anopheles Kir 
genes, enrichment of Kir mRNA in the ovaries was only observed for AgKir1 (Fig. 9). This 
finding suggested a potentially novel role of Kir channels in mosquito fecundity.  
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Figure 7. Quantitative RT-PCR analysis of the expression of A. gambiae AgKir1 in different 
developmental stages. Transcript levels were measured in eggs, developing first instar larvae, 
second through fourth instar larvae, callow (early) and black (late) pupae, and adults at 24 h, 5 
days and 10 days after eclosion. Data are mean ± SEM fold-difference (two biological replicates) 
in mRNA levels relative to eggs, using RPS7 as the reference gene. ANOVA P = 0.0003, and the 
asterisk indicates P<0.05 when compared to eggs (Tukey’s test). 
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Figure 8. Quantitative RT-PCR analysis of the expression of A. gambiae AgKir1 in different 
body segments and tissues. Transcript levels were measured in the whole body, head, thorax, 
abdomen, Malpighian tubules, midgut, fat body and ovaries. Data are mean ± SEM fold-
difference (three biological replicates) in mRNA levels relative to the whole body, using RPS7 as 
the reference gene. ANOVA P = 0.0008, and the asterisk indicates P<0.05 when compared to 
whole body (Tukey’s test).  
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Figure 9. Quantitative RT-PCR analysis of the expression of A. gambiae Kir genes in 
different body segments and tissues. Transcript levels were measured in the whole body, head, 
thorax, abdomen, Malpighian tubules, midgut, fat body and ovaries. Data are mean ± SEM fold-
difference (three biological replicates) in mRNA levels relative to the whole body, using RPS7 as 
the reference gene.!  
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AgKir1 knockdown does not affect survival 
We have shown that injection of a small-molecule inhibitor of AeKir1 (VU573) into the 
hemocoel of adult female mosquitoes (A. aegypti, A. albopictus, A. gambiae, C. pipens) induces 
incapacitation and/or death [207]. Moreover, VU573 disrupts renal excretory physiology and 
hemolymph K+ homeostasis in at least A. aegypti [207]. These findings suggest that Kir channels 
are essential regulators of physiological events affecting osmoregulation. Thus, we sought to 
determine whether AgKir1 is important for mosquito survival following a blood meal, which is a 
period when mosquitoes face extreme stresses to hemolymph Na+, K+, Cl-, and water 
homeostasis [69,70] 
Toward this goal, we developed methods for knocking down AgKir1 mRNA levels by 
RNA interference. Relative to the bla(ApR) dsRNA controls, injection of AgKir1 dsRNA 
significantly reduced AgKir1 mRNA levels by 24%!(P = 0.3487) and 58%!(P = 0.0108) at 4 and 
8 days post-treatment, respectively (Fig. 10A). To determine if AgKir1 knockdown affects 
survival following blood feeding, we blood fed mosquitoes 8 days after injecting AgKir1 dsRNA 
or bla(ApR) dsRNA, discarded the mosquitoes that were not fully engorged, and monitored their 
survival over the next 19 days. Surprisingly, in three independent trials, knockdown of AgKir1 
had no effect on mosquito survival as compared to the control bla(ApR) group (Logrank P values 
= 0.6500, 0.8523 and 0.9288; Fig. 11).  In fact, the slopes and R-square values of the survival 
curves of the AgKir1 dsRNA (y = -3.43; R2 = 0.985) and bla(ApR) dsRNA (y = -3.17; R2 = 
0.941) groups were nearly identical. 
Engorged mosquitoes usually take 2-3 days to digest their meal.  To ensure that AgKir1 
remained suppressed at that time, we measured AgKir1 mRNA and protein levels at 72 hrs post-
blood feeding, which also represented 11 days post-injection of dsRNA.  As shown in Fig. 10, 
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AgKir1 mRNA levels were decreased by >95% (P = 0.0014) relative to the bla(ApR) dsRNA 
control group, and AgKir1 protein was reduced considerably, but not completely. These findings 
suggest that a partial knockdown of AgKir1 (1) might not be sufficient to affect mosquito 
survival following a single naïve blood meal, (2) that the function of AgKir1 may be redundant 
with other Kir channels, or (3) that the functional role(s) of Kir1 may differ between the 
anopheline and culicine lineages. 
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Figure 10. Quantitative RT-PCR and western blot analyses showing AgKir1 RNAi-based 
knockdown efficiencies. (A) Quantitative RT-PCR analysis demonstrating the efficiency of 
AgKir1 RNAi-based knockdown at 4, 8 and 11 days post-dsRNA injection. Data are mean ± 
SEM fold-difference (two or three biological replicates) in mRNA levels relative to the bla(ApR) 
dsRNA control group. ANOVA P = 0.0023, and asterisks (*, **) indicate P<0.05 or P<0.01 
respectively when compared to the bla(ApR) dsRNA group (Tukey’s test). (B) Western blot 
analysis demonstrating the partial knockdown of AgKir1 protein levels in A. gambiae 
mosquitoes at 11 days post bla(ApR) dsRNA or AgKir1 dsRNA injection. 
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Figure 11. AgKir1 knockdown does not affect mosquito survival after a blood meal. Paired 
cohorts composed of 24-27 A. gambiae each were injected with bla(ApR) dsRNA or AgKir1 
dsRNA, provided a blood meal 8 days later, and the survival was tracked for the next 19 days. 
Data are mean ± SEM of 3 biological replicates.   
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AgKir1 knockdown decreases fecundity 
Because AgKir1 is enriched in the ovaries (Fig. 8), we hypothesized that it could be 
involved in fecundity. Therefore, we investigated the effect of AgKir1 RNAi-based knockdown 
on egg production using a similar protocol to that used for survival experiments, except that the 
mosquitoes were placed in an oviposition environment at 48 hrs post-blood feeding, and egg 
laying was monitored for up to three days thereafter. As shown in Fig. 12, mosquitoes that were 
treated with AgKir1 dsRNA oviposited an average of 21.41 eggs whereas the mosquitoes that 
were treated with bla(ApR) dsRNA oviposited an average of 30.11 eggs (n = 151 for both groups; 
Mann-Whitney P = 0.0485).  Furthermore, the number of mosquitoes that laid any eggs in the 
AgKir1 dsRNA and bla(ApR) dsRNA was 32% and 42%, respectively. Together, these data 
indicate that silencing of AgKir1 significantly impairs a mosquito’s ability to produce and 
oviposit eggs.  
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Figure 12. AgKir1 knockdown decreases mosquito fecundity. Paired cohorts of A. gambiae 
were injected with bla(ApR) dsRNA or AgKir1 dsRNA, provided a blood meal 8 days later, and 
allowed to oviposit. The circles represent the number of eggs laid by each female (n = 151), the 
horizontal line marks the mean, and the whiskers the SEM. The two groups were statistically 
different (*, Mann–Whitney P = 0.0485).  
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Discussion 
The large volume of blood that is commonly ingested by mosquitoes represents a major 
physiological challenge, thereby necessitating an efficient excretory system that rapidly off-loads 
excessive weight, water, and solutes [69,70]. In a previous study, we showed that 
pharmacological inhibition of Kir1 (1) incapacitates adult female mosquitoes of several species 
(A. aegypti, A. albopictus, A. gambiae, C. pipiens) and (2) reduces urine production/excretion 
and disrupts the maintenance of hemolymph K+ homeostasis in at least A. aegypti [207]. That 
study, besides showing that Kir channels are essential for proper renal excretory physiology in 
mosquitoes, suggested that inhibiting Kir channels could be used to control mosquito populations, 
and by extension, mosquito-borne diseases. However, the two major mosquito lineages, the 
Culicinae (e.g., Aedes sp., Culex sp.) and the Anophelinae (e.g., Anopheles sp.), diverged 
approximately 200 million years ago [227], and many physiological differences are known to 
exist between these two groups [223,228-230].  In the present study, we began the 
characterization of the Kir gene family in the African malaria mosquito, Anopheles gambiae.  
Among other things, we identify the members of the A. gambiae Kir gene family, describe their 
developmental and tissue expression, and show that silencing AgKir1 reduces mosquito 
fecundity. 
Whereas the genome of Drosophila melanogaster encodes three Kir genes, the genomes of 
A. aegypti, A. gambiae and C. quinquefasciatus encode between five and six Kir genes. This 
gene expansion in mosquitoes may reflect an increase in the molecular complexity of homomeric 
or heteromeric Kir channel complexes that are required to regulate unique physiological 
processes. Indeed, the importance of functional complexity was demonstrated in Drosophila, 
where disruption of Kir channel heteromerization results in the dysregulation of BMP signaling, 
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which causes major developmental defects [231]. Thus, by encoding six Kir genes, A. gambiae 
have potentially increased the diversity of heteromeric and homomeric complexes available to 
carry out a multitude of diverse physiological processes. 
Using heterologous expression in Xenopus oocytes, we show that AgKir1 encodes a 
canonical inward-rectifying K+ channel with similar properties as AeKir1 [74].  That is, the 
channel mediates strong inward K+ currents that are blocked by barium.  Moreover, the 
electrophysiological properties of AgKir1-expressing oocytes in ND96 solution (i.e., resting 
membrane potentials and I-V relationships) closely resemble those of AeKir1-expressing oocytes 
[74]. 
AgKir1 is transcribed in all developmental stages. Peak expression of AgKir1 occurs in 
pupae, which suggests a role for AgKir1 during post-embryonic development, and more 
specifically, metamorphosis. Interestingly, a reciprocal pattern of expression for at least Kir2A 
occurs in the development of A. aegypti, where Kir2A abundance is elevated in larvae and adults 
but is decreased in pupae [232]. The reorganizations associated with metamorphosis are known 
to result in changes in membrane excitability. As pertains to Kirs, earlier studies have implicated 
a role for K+ channels in regulating membrane potential during post-embryonic development of 
motor neurons in the fruit fly, Drosophila melanogaster [233], and the tobacco hornworm, 
Manduca sexta [234,235]. Further supporting a role for Kirs in development, a recent study 
showed that D. melanogaster DmKir2 is required for normal wing development, and that Kir 
channel involvement occurs through the regulation of BMP signaling [231]. 
AgKir1 is expressed in all adult tissues and body segments. Interestingly, AgKir1 expression 
was enriched in the ovaries. This enrichment suggested that Kir channels could be involved in 
fecundity. Previous studies have demonstrated a role for ionic currents in the maturation of 
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oocytes.  For example, ionic currents such as inward rectifying K+ currents undergo dynamic 
modulation (i.e., K+ current amplitude decreases with oocyte maturation) upon in vitro hormone-
stimulation in maturing starfish oocytes [236]. Moreover, ion channel currents (e.g. calcium 
currents) are involved in oocyte maturation and fertilization in vertebrate and invertebrate 
animals [237,238]. Therefore, given that AgKir1 expression is enriched in the ovaries and that 
AgKir1 gene silencing reduces fecundity, it is possible that AgKir1 may participate in the 
regulation of mosquito oocyte maturation by modulating membrane excitability in these tissues. 
In insects, oocyte maturation is generally arrested during meiotic cell division and resumes in a 
fertilization independent manner that requires a mechanical stimulus, such as oviduct passage or 
rehydration [239,240]. Thus, future studies should investigate whether AgKir1 plays a role in 
oogenesis. 
Although we detected a role for AgKir1 in fecundity, we originally anticipated that, based 
on our previous findings in A. aegypti and A. gambiae [207], gene silencing of AgKir1 would 
result in a dead or flightless phenotype following blood feeding. However, no significant 
increase in post-blood feeding mortality was observed between AgKir1 dsRNA and bla(ApR) 
dsRNA-treated groups, and the flightless phenotype was not observed either. The fact that we did 
not observe an obvious phenotype following gene silencing may reflect the difference in 
efficiency between pharmacologic and reverse-genetic approaches. For example, acute 
pharmacological inhibition of protein function is expected to yield an extreme phenotype (e.g., 
death or bloating), whereas partial gene silencing by RNAi may not sufficiently reduce protein 
levels to produce an obvious effect. Alternatively, it is possible that (1) other Kir channels 
expressed in the Malpighian tubules of A. gambiae can compensate for the reduced levels of 
AgKir1, (2) Kir1 performs different functions in the Malpighian tubules of A. gambiae and A. 
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aegypti, or (3) RNAi efficiency is markedly different between tissues [241]. Nevertheless, our 
survival experiment is consistent with studies in D. melanogaster, where there is no apparent 
lethal effect following Kir1 knockdown, but rather a sub-lethal effect on immune function [242]. 
In conclusion, here we present the first evidence that Kir channels play a role in mosquito 
fecundity, which together with their important roles in mosquito renal physiology [207], further 
validates them as promising molecular targets for the development of a new class of 
mosquitocides to be used in vector control. 
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Chapter VIII 
DISCOVER AND CHARACTERIZATION OF A POTENT AND SELECTIVE 
INHIBITOR OF AEDES AEGYPTI INWARD RECTIFIER POTASSIUM CHANNELS 
Abstract 
Vector-borne diseases such as dengue fever and malaria, which are transmitted by 
infected female mosquitoes, affect nearly half of the world’s population. The emergence of 
insecticide-resistant mosquito populations is reducing the effectiveness of conventional 
insecticides and threatening current vector control strategies, which has created an urgent need to 
identify new molecular targets against which novel classes of insecticides can be developed. We 
previously demonstrated that small molecule inhibitors of mammalian Kir channels are 
promising chemicals for new mosquitocide development. In this study, high-throughput 
screening of approximately 30,000 chemically diverse small-molecules was employed to 
discover potent and selective inhibitors of Aedes aegypti Kir1 (AeKir1) channels heterologously 
expressed in HEK293 cells. Of 283 confirmed screening ‘hits’, the small-molecule inhibitor 
VU625 was selected for lead optimization and in vivo studies based on its potency and 
selectivity toward AeKir1, and tractability for medicinal chemistry. In patch clamp 
electrophysiology experiments of HEK293 cells, VU625 inhibits AeKir1 with an IC50 value of 
96.8 nM, making VU625 the most potent inhibitor of AeKir1 described to date.  Furthermore, 
electrophysiology experiments in Xenopus oocytes revealed that VU625 is a weak inhibitor of 
AeKir2B. Surprisingly, injection of VU625 failed to elicit significant effects on mosquito 
behavior, urine excretion, or survival. However, when co-injected with probenecid, VU625 
inhibited the excretory capacity of mosquitoes and was toxic, suggesting that the compound is 
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detoxified and/or excreted by organic anion and ATP-binding cassette (ABC) transporters. 
Interestingly, the dose-toxicity relationship of VU625 (when co-injected with probenecid) is 
biphasic, which is consistent with the molecule inhibiting both AeKir1 and AeKir2B with 
different potencies. This study demonstrates proof-of-concept that potent and highly selective 
inhibitors of mosquito Kir channels can be developed using conventional drug discovery 
approaches. Furthermore, it reinforces the notion that the physical and chemical properties that 
determine a compound’s bioavailability in vivo will be critical in determining the efficacy of Kir 
channel inhibitors as insecticides. 
 
Introduction 
Mosquitoes are vectors of protozoan, filarial nematode, and viral pathogens that cause 
numerous human diseases, including malaria, lymphatic filariasis, and dengue fever. These 
diseases impose an enormous burden on global health and profoundly impair socioeconomic 
advancement in developing countries [243].  The overuse of pyrethroid insecticides targeting 
mosquito voltage-gated sodium channels in nerve cells has led to the emergence of insecticide-
resistant populations of mosquitoes, which is hampering the effectiveness of vector control 
strategies [190,244].  Consequently, there is an urgent need to identify new molecular targets 
against which insecticides can be developed and deployed.    
An emerging body of evidence from our group supports the idea that inward rectifier 
potassium (Kir) channels represent viable targets for insecticide development.  Kir channels are 
tetrameric proteins that conduct K+ ions across the cell membrane and thereby generate an ionic 
current that underlies various cellular functions. In mammals, for example, Kir channels regulate 
the electrical excitability of neurons and cardiac cells, hormone secretion, and transport of K+ 
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ions across epithelial tissues of the kidney and gut [1]. Missense mutations that perturb the 
activity of Kir channels cause human diseases of the heart, nervous system, pancreas, and kidney 
[2,3,245].    
The functions of Kir channels in mosquitoes and other insects is less clear, although several 
recent studies have begun to shed light on the molecular physiology of this important gene 
family. Dipterans possess three major Kir channel subtypes, denoted Kir1, Kir2 and Kir3. In 
Drosophila melanogaster, Kir channels are known to play important physiological roles in 
osmoregulation, immunity, and development [205,206,231,242]. 
The genome of Aedes aegypti encodes five Kir channel genes (AeKir1, AeKir2A, AeKir2B, 
AeKir2B’ and AeKir3), which are expressed in various body segments and tissues such as the 
carcass (thorax and abdomen), head, Malpighian tubules, midgut and hindgut [74,232].  We 
showed previously in vitro that the A. aegypti Kir1 (AeKir1) channel mediates strong inward 
rectifying K+ currents that are blocked by barium and the small molecule inhibitor, VU573 
(companion paper) [74,207]. Furthermore, we demonstrated in vivo that VU573 induces a 
reduction in urine production and excretion in isolated Malpighian tubules and intact mosquitoes, 
respectively, and incapacitates and/or kills mosquitoes within 24 h [207]. In the companion paper, 
we show that VU590, a small molecule inhibitor of AeKir1 that is structurally distinct from 
VU573, also inhibits urine excretion and kills mosquitoes.  Taken together, these studies indicate 
that Kir channels represent promising molecular targets for insecticides.  
Although the above ‘tool’ compounds allowed us to establish proof-of-concept, they are not 
suitable for insecticide development, in part, because they inhibit mammalian Kir channels with 
greater potency than AeKir1.  Here, we aim to discover new chemical probes of AeKir1 channels 
that exhibit improved potency and selectivity compared to the tool compounds by optimizing and 
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validating an existing fluorescent thallium (Tl+) flux-based assay of AeKir1 function [207] for 
high-throughput screening (HTS) of small molecule libraries. Screening approximately 30,000 
small molecules from the chemical library of the Vanderbilt Institute of Chemical Biology 
(VICB) resulted in the identification of 283 compounds with activity against AeKir1 channels. 
We focus on the in vitro and in vivo activity of one of these compounds, N-(3-methoxyphenyl)-
2-methyl-1-propionylindoline-5-sulfonamide (VU625), which exhibits nanomolar affinity and 
selectivity for AeKir1 over mammalian Kir channels. 
 
Materials and Methods 
 Tl+ flux assays 
Tl+ flux assays were performed essentially as described previously [137,246,247]. Briefly, 
stably transfected T-Rex-HEK-293 cells expressing AeKir1 channels were cultured overnight in 
384-well plates (20,000 cells/20 µL/well black-walled, clear-bottomed BD PureCoat amine-
coated plates (BD, Bedford, MA) with a plating media containing DMEM, 10% dialyzed FBS 
and 1µg/mL tetracycline. The next day, the cell culture medium was replaced with a dye-loading 
solution containing assay buffer (Hanks Balanced Salt Solution with 20 mM HEPES, pH 7.3), 
0.01% (w/v) Pluronic F-127 (Life Technologies, Carlsbad, CA), and 1.2 µM of the thallium-
sensitive dye Thallos-AM (TEFlabs, Austin, TX). Following 1 hr incubation at room temperature, 
the dye-loading solution was washed from the plates and replaced with 20 µL/well of assay 
buffer.  
The plates were transferred to a Hamamatsu Functional Drug Screening System 6000 
(FDSS6000; Hamamatsu, Hamamatsu (or Bridgewater, NJ), Japan) where 20 µL/well of test 
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compounds in assay buffer (as prepared below) were added and allowed to incubate with the 
cells for 20 min. After the incubation period, a baseline recording was collected at 1 Hz for 10 s 
(excitation 470 ± 20 nm, emission 540 ± 30 nm) followed by a thallium stimulus buffer addition 
(10 µL/well) and data collection for an additional 4 min. The Tl+ stimulus buffer contains in 
(mM) 125 NaHCO3, 1.8 CaSO4, 1 MgSO4, 5 glucose, 12 Tl2SO4, 10 HEPES, pH 7.4. For Tl+ 
flux assays on Kir2.x, Kir4.1 and Kir6.2/SUR1 expressing cells, the Tl+ stimulus buffer 
contained 1.8 mM Tl2SO4. Also, Tl+ flux assays on Kir3.1/3.2/mGlu8 expressing cell, required 
addition of an EC80 concentration of glutamate (Sigma-Aldrich, St. Louis, MO) with the thallium 
stimulus buffer [64]. 
The test compounds were transferred to daughter polypropylene 384-well plates (Greiner 
Bio-One, Monroe, NC) using an Echo555 liquid handler (Labcyte, Sunnyvale, CA), and then 
diluted into assay buffer to generate a 2X stock in 0.6% DMSO (0.3% final). For Tl+ flux assays 
on Kir6.2/SUR1 expressing cells, test compounds were diluted in assay buffer containing 
diazoxide (250 µM final) to induce channel activation. Concentration-response curves (CRCs) 
were generated by screening compounds at 3-fold dilution series in 4-point (1 µM - 30 µM) or 
11-point (1 nM - 30 µM) CRCs.  
Tl+ flux data were analyzed as previously described [65,83,137,246] using a combination 
of Excel (Microsoft Corp, Redmond, WA) with XLfit add-in (IDBS, Guildford, Surrey, UK) and 
OriginPro (OriginLab, Northampton, MA) software.  Raw data were opened in Excel and each 
data point in a given trace was divided by the first data point from that trace (static ratio) 
followed by subtraction of data points from control traces generated in presence of vehicle 
controls.  The slope of the fluorescence increase beginning 5 s after Tl+ addition and ending 15 s 
after Tl+ addition was calculated. 
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Compound synthesis  
 
 
2,2,2-trifluoro-1-(2-methylindolin-1-yl)ethan-1-one: To a round bottom flask equipped with a 
magnetic stir bar 2-methylindoline (4.8 mL, 37 mmol, 1 eq.) and pyridine (46 mL) were added. 
The reaction mixture was cooled to 0°C and trifluoroacetic anhydride (6.3 mL, 44 mmol, 1.2 eq.) 
was added dropwise. The reaction mixture was allowed to warm to room temperature and was 
stirred an additional 2 hours. The reaction was quenched with water (50 mL) and diluted with 
DCM (100 mL). The organic layer was separated and washed subsequently with water (50 ml) 
and brine (50 mL), dried over Na2SO4, and concentrated under reduced pressure. The crude 
material (8.33g, 98%) was used without purification.  LCMS:  RT = 0.785 min, [M + H] + = 
229.6; >98%. 
2-methyl-1-(2,2,2-trifluoroacetyl)indoline-5-sulfonyl chloride: Chlorosulfonic acid (22 mL, 
330 mmol, 9 equiv.) was added to a 100 mL round bottom flask equipped with a reflux 
condensor, cooled to 0°C. To this, 2,2,2-trifluoro-1-(2-methylindolin-1-yl)ethan-1-one, (8.5 g, 37 
mmol, 1 eq.) was added dropwise. The reaction mixture was removed from the ice bath. The vial 
was heated to 40 °C for 1 hour. The reaction was subsequently cooled to room temperature and 
PCl5  (7.7 g, 37 mmol, 1 equiv.) was added slowly. After gas evolution ceased, the reaction 
mixture was heated to 80°C for 1 hour. The reaction mixture was cooled to room temperature 
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and then placed in an ice bath. Water was added very slowly to the reaction mixture. 
Subsequently, DCM was added and the reaction was filtered through a phase separator. The 
organic layer was concentrated under reduced pressure and used without subsequent purification 
(6.46 g, 53%). 
 N-(3-methoxyphenyl)-2-methylindoline-5-sulfonamide:    2-methyl-1-
(2,2,2-trifluoroacetyl)indoline-5-sulfonyl chloride (2.5 g, 7.6 mmol, 1 eq.) was diluted with 
DCM (10 mL). 3-methoxyaniline (1.71 mL, 15.2 mmol, 2 eq.) followed by N,N-
Diisopropylethylamine (5.3 mL, 31 mmol, 4 eq.) was added to the reaction. Reaction progress 
was monitored by LCMS. Once the reaction was deemed complete, it was diluted with DCM (40 
mL) and washed with water (2x, 50 mL) and brine (50 mL). The organic layer was dried over 
Na2SO4 and concentrated under reduced pressure. Purification by flash chromatography (0%-
100% EtOAc in Hexanes) afforded the desired product (2.66 g, 85%).  LCMS:  RT = 0.800 min.,  
[M + H]+ = 414.7; >98% @ 220 and @ 254 nm. The trifluoroacetate was removed by stirring in 
a 1:1:1 mixture of MeOH, THF, and 10% NaOH affording the title compound (782 mg, 38%). 
LCMS:  RT = 0.665 min., [M + H]+ = 318.8; >98% @ 220 and @ 254 nm. 
N-(3-methoxyphenyl)-2-methyl-1-propionylindoline-5-sulfonamide (VU0077625): N-(3-
methoxyphenyl)-2-methylindoline-5-sulfonamide (11 mg, 0.035 mmol, 1 eq.) was diluted with 
DCM (0.3 mL). To this reaction, pyridine was added (0.011 mL, 0.14 mmol, 4 eq.) followed by 
priopionyl chloride (0.003 mL, 0.05 mmol, 1.5 eq.). Reaction progress was monitored by LCMS. 
Once the reaction was deemed complete it was concentrated under forced air and heat and was 
subsequently purified on preparative HPLC (3 mg, 26%). 1H NMR (400.1 MHz, CDCl3) d 
(ppm): 8.17 (bs, 1 H); 7.67 (dd, J = 1.69, 8.72 Hz, 1 H); 7.58 (s, 1 H); 7.16 (t, J = 8.25 Hz, 1 H); 
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6.69-6.57 (m, 4 H); 4.58 (bs, 1 H); 3.74 (s, 3 H); 3.38-3.32 (m, 1 H); 2.66-2.47 (m, 4 H); 1.29-
1.22 (m, 5 H). HRMS (TOF, ES+) C19H23N2O4S [M + H] + calc’d for 375.1379, found 375.1381. 
 
Patch clamp electrophysiology 
T-REx-HEK293-AeKir1 cells were voltage clamped in the whole-cell configuration of 
the patch clamp technique after overnight induction with tetracycline (1 mg/ml) essentially as 
described earlier [207].  Briefly, patch electrodes were pulled from silanized 1.5 mm outer 
diameter borosilicate microhematocrit tubes using a Narishige PC-10 two-stage puller.  Electrode 
resistance ranged from 3.5 to 5.5 M# when filled with the following intracellular solution (in 
mM):  135 KCl, 2 MgCl2, 1 EGTA, 10 HEPES free acid, 2 Na2ATP (Roche, Indianapolis, IN), 
pH 7.3, 275 mOsm. The standard bath solution contained (in mM): 135 NaCl, 5 KCl, 2 CaCl2, 1 
MgCl2, 5 glucose, 10 HEPES free acid, pH 7.4, 290 mOsm. Whole-cell currents were recorded 
under voltage-clamp conditions using an Axopatch 200B amplifier (Molecular Devices, 
Sunnyvale, CA). Electrical connections to the amplifier were made using Ag/AgCl wires and 3 M 
KCl/agar bridges. Electrophysiological data were collected at 5 kHz and filtered at 1 kHz.  Data 
acquisition and analysis were performed using pClamp 9.2 software (Axon Instruments).  All 
recordings were made at room temperature (20–23°C). 
 
Heterologous expression of AeKir1 and AeKir2B in Xenopus oocytes 
AeKir1 and AeKir2B proteins were expressed heterologously in Xenopus laevis oocytes 
as described previously [74]. In brief, defolliculated Xenopus oocytes (Ecocyte Bioscience, 
Austin, TX) were injected with 10 ng (0.35 ng/nL) of either AeKir1 or AeKir2B cDNA and 
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cultured for 3–7 days in OR3 media at 18°C.  Oocytes injected with 28 nl of nuclease-free H2O 
served as controls.  
  
Electrophysiology of Xenopus oocytes  
All electrophysiological experiments on Xenopus oocytes were performed at room 
temperature.  The compositions of the solutions used in these experiments are shown in Table 1. 
When present, VU625 was dissolved in solution III to a final concentration of 0.1, 1, 5, 15, or 50 
$M (0.05% DMSO). All solutions were delivered by gravity to a RC-3Z oocyte chamber 
(Warner Instruments, Hamden, CT) via polyethylene tubing at a flow rate of ~2 ml/min.  
Solution changes were made with a Rheodyne Teflon 8-way Rotary valve (Model 5012, 
Rheodyne, Rohnert Park, CA).  
 
Table 1. Compositions (in mM) of solutions used in Xenopus oocyte electrophysiology.  
Solution # I II III 
NaCl 96 88.5 88.5 
NMDG-Cl 0 9.5 0 
KCl 2 0.5 10 
MgCl2 1.0 1.0 1.0 
 
pH = 7.5 adjusted with NMDG-OH (NMDG = N-methyl-D-glucamine). 
Osmolality = 190 mOsm kg-1 H2O (± 5 mOsm kg-1 H2O)  
 
 
In brief, each oocyte was transferred to the holding chamber under superfusion with 
solution I and impaled with two conventional-glass microelectrodes backfilled with 3 M KCl 
(resistances of 0.5–1.5 M#) to measure membrane potential (Vm) and whole-cell membrane 
current (Im), respectively.  Current-voltage (I-V) relationships of oocytes were acquired as 
described in the companion paper.  In brief, the oocytes were subject to a voltage-stepping 
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protocol consisting of 20 mV steps from -140 mV to +40 mV (100 ms each).  After the 
conclusion of the voltage-stepping protocol, the clamp was turned off and a new solution was 
superfused through the chamber for ~90 s before acquiring another I-V relationship.  All Vm and 
Im values were recorded by a Digidata 1440A Data Acquisition System (Molecular Devices) and 
the Clampex module of pCLAMP.  The I-V plots were generated using the Clampfit module of 
pCLAMP.  
To evaluate the inhibition of Kir1 and Kir2B activity by VU625, we focused on the 
maximal inward currents elicited by the voltage-stepping protocol, which occur at a voltage of -
140 mV.  The background, inward currents in solution II (i.e., low K+) were subtracted from 
those in 1) solution III (i.e., elevated K+) to calculate the total inward current for an oocyte 
before exposure to VU625 (IA), and 2) solution III with VU625 to calculate the inward current 
after exposure to the small molecule (IB). The percent inhibition of the inward current was 
calculated by subtracting IB from IA and then dividing by IA. 
 
Mosquito colony 
The Aedes aegypti eggs were obtained through the MR4 as part of the BEI Resources 
Repository, NIAID, NIH: Aedes aegypti LVPIB12, MRA-735, deposited by M.Q. Benedict. The 
eggs were raised to adults as described previously [210], and all experiments described were 
conducted with adult females 3–10 days post-emergence. 
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Mosquito toxicology experiments 
Mosquitoes for injection were anesthetized on ice and impaled through the metapleuron 
using a pulled-glass capillary attached to a nanoliter injector (Nanoject II, Drummond Scientific 
Company, Broomall, PA). A single injection delivered 69 nL of solution. The injection solution 
consisted of a potassium-rich phosphate buffered saline (K+-PBS), 15% DMSO, 1% !-
cyclodextrin, 0.1% Solutol, and various concentrations of VU625 to deliver the desired doses. 
When needed, water-soluble probenecid (Biotium, Hayward CA) was present at 50 mM. The K+-
PBS solution consisted of the following in mM: 92.2 NaCl, 47.5 KCl, 10 Na2HPO4, and 2 
KH2PO4 (pH 7.5).  After injection, the mosquitoes were placed into small cages (10 females per 
cage) within a rearing chamber (28°C, 80% relative humidity, 12:12 light:dark) and allowed free 
access to a solution of 10% sucrose.  The mosquitoes were observed at 2 h or 24 hr after 
injection. 
 
Mosquito excretion experiments 
Urine excretion rates were measured as described in the companion paper.  In brief, after 
anesthetizing mosquitoes on ice, they were injected as described above with 900 nL of a K+-PBS 
vehicle containing 1.15% DMSO, 0.077% !-cyclodextrin, and 0.008% Solutol, or the vehicle 
containing VU625 (0.77 mM). When needed, the vehicle was supplemented with water soluble 
probenecid (3.08 mM).  After injection, the mosquitoes were placed immediately in a graduated, 
packed-cell volume tube (MidSci, St. Louis, MO; 5 mosquitoes per tube) and held at 28%C.  In a 
previous study [207], the mosquitoes remained in a single tube for 2 h and were then removed 
from the tubes with forceps.  The excreted urine was centrifuged into the graduated column of 
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the tube for measurement and the total excreted volume after 2 h was measured.  In the present 
study, preliminary experiments were conducted to better resolve the time-course of urine 
excretion.  That is, mosquitoes were transferred to a new tube every 30 minutes and the amount 
of urine excreted was measured.  We found that ~95% of the total volume excreted by the 
mosquitoes in 120 min is voided within the first 60 min.  Thus, we used a 60 min end point for 
the excretion measurements in the present study. 
 
Statistical analyses 
Tl+ flux assay. The Z’ value was calculated as described earlier [137], using the following 
formula:  
Z’ = 1- (3SDp + 3SDn)/|meanp + meann| 
 
where SD is standard deviation, p and n are vehicle control and compound inhibited flux values 
respectively. 
To compare the effect of DMSO on AeKir1-mediated Tl+ flux, a one-way ANOVA was 
performed with a Tukey’s multiple comparison test. Prism software (GraphPad Software) was 
used to generate CRC from Tl+ flux.  Half-inhibition concentration (IC50) values were calculated 
from fits using a four parameter logistic equation. 
Mosquito toxicology and urine excretion.  Prism (Graphpad Software) was used to generate a 
dose-response curve for the toxicity of VU625; the doses (x-axis) were first log transformed and 
then the mortality data was fitted using a ‘biphasic’ algorithm (<100 constraint) to calculate 
potencies (ED25 and ED75 values).  To compare the toxic effects among the vehicle, probenecid, 
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VU625, and VU625 + probenecid treatments, and the excretory capacity among the vehicle, 
probenecid, VU625, and VU625 + probenecid treatments, one-way ANOVAs were performed 
with Newman-Keuls posttests. 
 
Results 
Discovery of novel AeKir1 inhibitors via high-throughput screening 
In an effort to discover mosquito-specific inhibitors of AeKir1, we optimized a Tl+ flux 
assay for high-throughput screening (HTS) of large libraries of chemically diverse small 
molecules. The assay utilizes a monoclonal T-REx-HEK293 cell line that expresses AeKir1 from 
a tetracycline-inducible promoter [207]. The fluorescent dye, Thallos, is used to report the 
inward flux of Tl+ through the AeKir1 channel pore in a population of cells plated in individual 
wells of a 384-well plate. As shown in Fig. 1A, overnight induction of AeKir1 expression with 
tetracycline leads to a robust Tl+ flux compared to control cells that were not treated with 
tetracycline. This assay enables more than 300 compounds to be tested simultaneously in a single 
plate, and thousands of compounds to be tested daily, for effects on AeKir1 activity. 
The assay was validated for HTS by meeting a series of performance benchmarks.  First, 
the assay was tested for its tolerance to the small-molecule vehicle DMSO at screening 
concentrations up to 0.3% v/v.  As shown in Fig. 1B, the Tl+-flux mediated by AeKir1 is 
unaffected by DMSO concentrations up to 1.3% v/v as compared to the 0% DMSO control (one-
way ANOVA, P <0.0001).  Next, the assay was tested for uniformity and reproducibility of HTS 
performance. As shown in Fig. 1C, the average Z’ statistic for these experiments was 0.69 ± 0.05 
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(Z’ & 0.5 is suitable for HTS), indicating that the assay is robust and will enable modulators of 
AeKir1 to be identified in HTS with a low false-positive rate.  
Approximately 30,000 compounds from the VICB library were screened at a nominal 
concentration of 10 µM for inhibition of AeKir1. From this primary screen and following 
confirmation testing in tetracycline-induced and uninduced T-REx-HEK293-AeKir1 cells (see 
Methods), 283 authentic channel-dependent modulators were selected for further study. Because 
our ultimate goal is to develop Kir channel inhibitors that are active against mosquitoes and not 
humans, these ‘hits’ were subsequently tested for dose-dependent activity against a panel of 
mammalian Kir channels, including Kir1.1, Kir2.1, Kir2.2, Kir2.3, Kir3.1/3.2, Kir4.1, 
Kir7.1(M125R), and Kir6.2/SUR1 [20,64,137]. Four-point concentration response curves 
(CRCs) were generated for the 283 compounds, resulting in 17 inhibitors with 11 unique 
chemical scaffolds that exhibited dose-dependent inhibition of AeKir1 with IC50 values below 5 
µM and little to no activity (IC50 & 30 µM) against mammalian Kir channels (data not shown). 
These compounds were purchased from commercial vendors, freshly dissolved in DMSO, and 
assayed in 11-point CRCs against AeKir1. In Tl+ flux assays, one compound—N-(3-
methoxyphenyl)-2-methyl-1-propionylindoline-5-sulfonamide, termed VU625—was found to 
inhibit AeKir1 in 11-point CRCs with an IC50 of 0.32 µM (95% CI: 0.25 – 0.39 µM) and a Hill 
coefficient value of 0.98 (95% CI: 0.8 – 1.2) (Figs. 2A-C). 
 !  
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Figure 1. Tl+ flux assay of AeKir1 channel activity for high-throughput screening. (A) 
Representative Tl+-induced changes in Thallos fluorescence in T-Rex-HEK293-AeKir1 cells 
cultured overnight with (+Tet) or without (-Tet) tetracycline. The shaded box indicates the cell 
exposure to Tl+. (B) DMSO concentrations up to 1.3% v/v DMSO have no effect on Tl+ flux 
through AeKir1. Data are means ± SEM (n = 3). One-way ANOVA P < 0.0001, and asterisks (**, 
***) indicate P<0.01 or P<0.001 respectively, when compared to 0% DMSO (Tukey’s test). (C) 
Representative checkerboard analysis using 100 µM VU573 or 0.1% v/v DMSO as the vehicle 
control. The mean peak fluorescence amplitude of each sample population is indicated with a 
solid line and alternating samples for DMSO (top) and VU573 (bottom) are graphed as 
individual points. The mean ± SD Z’ calculated over 6 plates on 3 separate days was 0.69 ± 0.05. !  
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Figure 2. VU625 is a potent inhibitor of AeKir1 in Tl+ flux assays. (A) Chemical structure of 
VU625. (B) Dose-dependent inhibition of the AeKir1-mediated Tl+ flux by VU625 with 
concentrations ranging from ' 0.12 to 30 µM.  The arrow indicates when Tl+ was added to the 
extracellular bath.  (C) Concentration-response curves of VU625 derived from Tl+ flux assays. 
The IC50 and Hill-coefficient (nH) values are 315 nM (95% CI: 254.4 - 390.2 nM) and 0.98 
respectively. Data are mean ± SEM. n = 4 independent experiments performed in triplicate. !  
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VU625 is a potent and preferential inhibitor of AeKir1 
From Tl+ flux experiments, we found that VU625 had no significant effects on the 
mammalian Kir channels assayed with the exception of G-protein coupled Kir channels 
comprised of Kir3.1/3.2 subunits (IC50 = 8.6 µM; Table 2). Furthermore, in radioligand 
displacement assays against 68 mammalian GPCR’s, ion channels, and transporters, 10 µM 
VU625 was active (>50% displacement) against only three targets: adenosine A1 receptor (76% 
displacement), melatonin MT1 receptor (56% displacement) and 5-HT2B receptor (69% 
displacement) (Table 3).  
 
 
Table 2. Selectivity of VU625 against human Kir channels assessed in Tl+ flux assays. n= 2 
independent experiments in triplicate 
 
 
 
 
 
 
  
Kir channel Inhibition of Tl+ flux 
(IC50, µM) 
Kir1.1 >30 
Kir2.1 >30 
Kir2.2 >30 
Kir2.3 >30 
Kir3.1/3.2 8.6 
Kir4.1 >30 
Kir6.2/SUR1 >30 
Kir7.1(M125R) >30 
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Table 3. Summary of results obtained from the activity of the VU625 compound in radioligand 
binding assays. The significant results are highlighted in grey. 
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To further confirm the activity of VU625 obtained from Tl+-flux assays, we used patch-
clamp electrophysiology to assay the inhibition of AeKir1. In whole-cell patch clamp recordings, 
VU625 inhibited AeKir1 channel activity with an IC50 of 96.8 nM (95% CI: 75.4 - 124.2 nM) 
and a Hill coefficient value of 1.02 (95% CI: 0.8 – 1.3) (Figs. 3A, B).  In Appendix A, we 
demonstrated that VU573 and VU590 have distinct pharmacological effects on AeKir1 and 
AeKir2B channel functions.  Thus, we sought to determine the effects of VU625 on AeKir2B. 
We evaluated VU625 activity on Xenopus oocytes heterologously expressing AeKir2B, using 
AeKir1 expressing oocytes as positive controls.  As shown in Fig. 3C, VU625 inhibits AeKir1- 
and AeKir2B-mediated K+currents with IC50 values of 3.8 µM (95% CI: 2.3 – 6.3 µM), and 45.1 
µM (95% CI: 31.7 – 64.2 µM), respectively. Thus, VU625 inhibits both AeKir1 and AeKir2B 
channels, albeit with greater affinity for AeKir1. Because of its potency, relatively clean ancillary 
pharmacology and chemical tractability, VU625 was selected for lead optimization. !!  
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Figure 3. VU625 is preferential inhibitor of AeKir1 over AeKir2B in whole-cell 
electrophysiology. (A) Normalized AeKir1 current-voltage relationships obtained from 
heterologous expression in T-Rex-HEK293 cells, illustrating VU625-dependent inhibition before 
(control) and after addition of 0.9 µM VU625. Residual AeKir1 currents were inhibited with 2 
mM barium. Cells were voltage clamped at -75 mV and ramped between -120 mV and +60 mV. 
(B) Concentration-response curve of VU625 derived from patch clamp experiments (n = 4-6).  
The IC50 of VU625 is 96.8 nM (95% CI: 75.4 - 124.2 nM). (C) Concentration-response curves of 
current inhibition mediated by heterologous expression in Xenopus oocytes of AeKir1 (filled 
circles) and AeKir2B (open circles) channels after bath application of VU625. n = 4-5 oocytes 
per concentration.  The calculated IC50 values of VU625 for AeKir1 and AeKir2B current 
inhibition are 3.8 µM (95% CI: 2.3 – 6.3 µM) and 45.1 µM (95% CI: 31.7 – 64.2 µM), 
respectively.!  
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Chemical lead optimization and structure-activity relationships 
For the lead optimization of VU625 (3a, Table 4), we partitioned the compound into 
three areas for SAR exploration denoted as the sulfonamide, central core, and southern amide 
portions (Fig. 4A).  The first generation libraries held the sulfonamide and the central core 
sections constant and diversified the southern amide portion (Table 4).  The synthetic scheme 
(Fig. 4B) for this portion was straightforward and started with protection of the amine with 
trifluoracetamide (TFAA, pyridine) followed by sulfonyl chloride formation (ClSO3, PCl5). Next, 
the sulfonamide was formed, the protecting group was removed, and either the amide or 
sulfonamide was formed (see Methods for details). Little tolerance for steric bulk was seen in 
this portion of the molecule.  That is, the trifluoroacetamide (VU0477197, 3b, Table 4) retained 
potency (0.58 $M), however, larger aromatic amides were much less active (3c-g, Table 4).  The 
same trend was observed for the sulfonamide compounds, with smaller sulfonamides retaining 
nanomolar activity (VU0477691, 3k, 0.76 $M; VU0477692, 3l, 0.82 $M) and the larger 
aromatic group leading to less activity (3h, Table 4). 
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Figure 4.  Design and chemical lead optimization strategy for VU625.  (A) Modular approach 
to assess three areas of diversification of VU625: sulfonamide (red shading), central core (green 
shading), and southern amide (blue shading) portions. (B) General synthetic approach to access 
VU625 and analogs around the amide and sulfonamide portions.  
Design and chemical lead optimization performed by Corey R. Hopkins.  
Figure 4 
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Table 4. Structure-activity relationships and lead optimization summary of VU0077625 scaffold 
(n=2 independent experiments performed in triplicate)!
!
Cmpd R VU# IC50 ± SEM (!M) 
3a  VU0077625 0.36 ± 0.02 
3b  VU0477197 0.58 ± 0.04 
3c 
 
VU0477684 5.20 ± 0.40 
3d 
 
VU0477693 4.41 ± 1.11 
3e 
 
VU0477694 3.87 ± 1.97 
3f 
 
VU0477688 > 30 
3g  VU0477685 4.40 ± 0.50 
3h  VU0477686 3.29 ± 0.89 
3i  VU0477687 2.09 ± 0.49 
3j  VU0477690 2.82 ± 0.48 
3k  VU0477691 0.76 ± 0.00 
3l  VU0477692 0.82 ± 0.48 
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Next, we evaluated the left-hand sulfonamide portion of the molecule, however, all 
efforts to change the 3-methoxyaryl moiety led to significant reductions in potency (see Table 5).  
Finally, we explored the central core with the intent of establishing the minimal pharmacophore 
needed for activity against AeKir1.  To this end, the indoline core was replaced with simple aryl, 
heteroaryl or biaryl groups which all led to compounds with much reduced activity (>10-fold 
loss of potency).  However, an interesting SAR was seen with very closely related 6,6- or 6,5-
indole or dihydroquinolinone-like structures (4a-f, Table 6).  The simple N-methyl indole 
(VU0481807, 4a, 0.55 µM, Table 6) retained most of the activity as VU625 and addition of a 2-
methyl (VU0486620, 4b, 0.97 µM, Table 3) led to a further minor reduction in activity. 
Expanding the ring system and addition of a lactam (4c-e, Table 6) was not productive.  Lastly, 
removal of the methyl group in the indoline system of VU625, led to a ~3-fold loss of potency 
(VU0483404, 4f, 1.15 µM, Table 6). 
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Table 5.  SAR around the left-hand sulfonamide. 
!
Cmpd VU R R1 R2 IC50 (µM) 
5a VU0111100 Me H 
 
3.27 
5b VU0111077 Me H 
 
3.44 
3a VU0111158 Me H 
 
0.856 
5c VU0077625 Me H 
 
0.338 
5d VU0111108 Me H 
 
1.42 
5e VU0472705 Me H 
 
1.15 
5f VU0111168 Me Me 
 
2.16 
5g VU0472699 Me H 
 
2.36 
5h VU0472694 Me H 
 
3.49 
5i VU0472696 Me H 
 
3.25 
5j VU0472695 Me H 
 
1.36 
5k VU0084675 Me H 
 
1.12 
5l VU0111098 Me H 
 
4.94 
5m VU0472698 Me H 
 
5.24 
5n VU0472697 Me H 
 
3.54 
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5o VU0472702 Me H 
 
5.25 
5p VU0472700 Me H 
 
1.55 
5q VU0472703 Me H 
 
1.87 
5r VU0472701 Me H 
 
1.97 
5s VU0472704 Me H 
 
1.62 
5t VU0110817 H H ! >30 
5u VU0110920 H H ! >30 
5v VU0485659 H H ! >30 
5w VU0144119 H H ! >30 
5x VU0485660 H H ! 7.50  
5y VU0485652 H H ! >30 
5z VU0485653 H H ! >30 
5aa VU0485654 H H ! >30 
5bb VU0485655 H H ! >30 
5cc VU0077420 H H ! >30 
5dd VU0166512 H H ! >30 
5ee VU0486113 H H ! >30 
5ff VU0486114 H H ! 3.47  
5gg VU0486115 H H ! 1.40  
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5hh VU0486121 H H ! >30 
5ii VU0486122 H H ! >30 
5jj VU0486123 H H ! >30 
5kk VU0486124 H H ! >30 
5ll VU0486125 H H ! >30 
5mm VU0486126 H H ! 1.93  
5nn VU0486136 H H ! >30 
5oo VU0486137 H H ! >30 
5pp VU0486116 H Me ! >30 
5qq VU0486127 H Me ! >30 
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Table 6. Structure-activity relationships and lead optimization summary for the central core 
portion of VU0077625 scaffold (n=2 independent experiments performed in triplicate) 
 
!
Cmpd R VU# IC50 ± SEM (!M) 
4a 
 
VU0481807 0.55 ± 0.08 
4b 
 
VU0486620 0.97 ± 0.10 
4c 
 
VU0481811 > 30 
4d 
 
VU0483082 > 30 
4e 
 
VU0483402 > 30 
4f 
 
VU0483404 1.15 ± 0.05 
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Figure 5 summarizes the SAR observed for the VU625 scaffold.  The left-hand 
sulfonamide portion offered the least amount of SAR traction as only the 3-methoxyphenyl (and 
weaker 2-methoxyphenyl) sulfonamide provided activity.  Replacement with an amide, or 
substituting the 3-methoxyphenyl for other aryl groups all led to less potent compounds.  
Replacement of the proponamide in the southern fraction was tolerated as long as the substituent 
was small and aliphatic.  Sulfonamides could be exchanged, although there was an observed ~2-
3-fold loss of activity.  Lastly, the central core was also important for potency. Only very similar 
compounds such as indole and des-methyl indoline were tolerated. !!  
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Figure 5.  Summary of structure-activity relationship (SAR). Summary of observed SAR of 
over 100 analogs synthesized exploring all three regions of VU625.  
SAR summary provided by Corey R. Hopkins.!  
Figure 5 
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VU625-induced toxicity is increased by probenecid 
Injection of the AeKir1 channel inhibitors VU573 or VU590 into the hemolymph of adult 
female A. aegypti mosquitoes leads to their incapacitation and/or death within 24 h (Appendix 
A; [207]). Surprisingly, injection of a high dose of VU625 (690 pmol), which is a more potent 
inhibitor of AeKir1 than VU573 and VU590, into the hemolymph of mosquitoes had no 
significant effects on mosquito behavior or survival within 24 h (Fig. 6). Thus, we hypothesized 
that the lack of in vivo effects could be due to poor bioavailability of VU625 as a result of 
metabolic detoxification and/or excretion by the mosquito.  
We therefore tested probenecid, which is a broad-spectrum inhibitor of organic anion 
transporters (OATs) and ATP-binding cassette (ABC) transporters [248-250]. Interestingly, both 
probenecid and VU625 have a sulfonamide moiety in their chemical structure (Fig. 7). As shown 
in Fig. 6, injection of probenecid (3.4 nmol per mosquito) along with VU625 (690 pmol) 
significantly increases the toxicity of VU625 within 24 h compared to injection of VU625 or 
probenecid alone.  The abdomens of these mosquitoes were not severely bloated and obvious 
sub-lethal effects (e.g., loss of flight) were not apparent. Preliminary experiments in which 
mosquitoes were treated with piperonyl butoxide (PBO; 100 ng per mosquito), which is a 
commonly used synergist in insecticide formulations that inhibits the activity of cytochrome 
P450 enzymes [251-253], did not improve the efficacy of VU625 (data not shown).  
We next sought to characterize the dose-response relationship of VU625 in mosquitoes 
following co-injection with a constant dose of probenecid (3.4 nmol).  As shown in Fig. 8, co-
injection of VU625 with probenecid induces mortality in mosquitoes within 24 h in a biphasic 
manner with 25% and 75% efficacious doses (ED25 and ED75) of 9.9 pmol and 502 pmol, 
respectively. This biphasic dose-response relationship suggests the inhibition of at least two 
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distinct molecular targets, for which VU625 has different affinities. This result is consistent with 
the inhibition of AeKir1 and AeKir2B channels as shown in Fig. 3C. 
 !  
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Figure 6. Effects of probenecid and VU625 on survival of adult female mosquitoes (A. 
aegypti). Percent mortality of mosquitoes at 24 h post-injection. Each mosquito was injected 
with 69 nL of the vehicle containing either VU625 (690 pmol), probenecid (3.4 nmol), or 
probenecid and VU625. n = 6-7 trials of 10 mosquitoes each per treatment.  Lower-case letters 
indicate statistical categorization of the means as determined by a one-way ANOVA with a 
Newman-Keuls post-test (P < 0.05).  
 
Data collected by Matthew Rouhier and Peter Piermarini. !! !
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Figure 7. VU625 and probenecid share a sulfonamide moiety. The sulfonamide moiety 
contained in the chemical structure of VU625 and probenecid is shaded in blue. !  
Supplementary Figure S1 
!!
!!
Probenecid VU625 
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Figure 8. The dose-response curve of the toxic effects of VU625 on adult mosquitoes (A. 
aegypti) is bi-phasic. Percent mortality of mosquitoes at 24 h post-injection.  Each mosquito was 
injected with 69 nL of the vehicle containing probenecid (3.4 nmol) and an appropriate 
concentration of VU625 to deliver the dose indicated.  The ED25 and ED75 were determined by 
fitting a non-linear curve to the data.  n = 3-4 trials of 10 mosquitoes each per dose. 
Data collected by Matthew Rouhier and Peter Piermarini. !  
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VU625-induced reduction of urine excretion is enhanced by probenecid 
We showed previously [207] and in Appendix A that pharmacological inhibition of 
AeKir1 with the small molecule inhibitors VU573 and VU590 leads to a decrease in the 
excretory capacity of A. aegypti mosquitoes. Therefore, we sought to determine the effects of 
VU625 on urine excretion. Consistent with the toxicity studies, we found that VU625 injections 
alone did not significantly decrease the excretory capacity (583.3 ± 29.52 nL/female) compared 
to the vehicle controls (644 ± 24.18 nL/female) (Fig. 9). Interestingly, injection of probenecid 
alone significantly reduces the urine output to 467.8 ± 33.53 nL/female, suggesting a potential 
role of probenecid-sensitive transporters in urine excretion.  However, the injection of both 
VU625 (690 pmol) and probenecid (3.4 nmol) significantly decreases the excretory capacity 
further to 236.7 ± 24.53 nL/female. 
 !  
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Figure 9. Effects of probenecid and VU625 on the in vivo excretory capacity of adult female 
mosquitoes (A. aegypti). Amount of urine excreted by mosquitoes 1 h after injection with 900 
nL of the vehicle (K+-PBS50 containing 1.8% DMSO, 0.077% !-cyclodextrin, and 0.008% 
Solutol), the vehicle containing either VU625 (690 pmol), probenecid (3.4nmol), or probenecid 
and VU625. Values are means ± SEM; n = 6-18 trials of 5 mosquitoes per treatment.  Lower-
case letters indicate statistical categorization of the means as determined by a one-way ANOVA 
with a Newman-Keuls posttest (P < 0.05).  
Data collected by Matthew Rouhier and Peter Piermarini.!  
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Discussion 
Here, we report the discovery of VU625, the first sub-micromolar inhibitor of a mosquito 
Kir channel.  VU625 is one of 283 confirmed AeKir1 inhibitors identified in a HTS of 
approximately 30,000 compounds from the VICB library.  It was chosen for lead optimization 
based on its potency (IC50 = 96.8 nM), greater than 80-fold selectivity for the AeKir1 channel 
over 8 mammalian Kir channels, and clean ancillary pharmacology among a panel of 68 critical 
mammalian off-targets comprised of voltage-gated ion channels, ion transporters, and receptors 
(i.e., neurotransmitter, peptide, and G-protein coupled). With the exception of one class of 
single-nanomolar inhibitors of mammalian Kir1.1 developed by Merck Research Laboratories 
[22], VU625 is the most potent and selective Kir channel inhibitor reported to date.  
This study provides proof-of-concept that conventional drug discovery approaches can be 
employed successfully to identify small-molecule tools for probing the physiology of insect Kir 
channels and potential lead compounds for insecticide development.  A similar approach has 
been used recently in insecticide discovery efforts targeting mosquito G-protein coupled 
receptors [254]. 
While VU625 is the most potent and selective mosquito Kir channel inhibitor reported to 
date, it exhibits inhibitory activity against both AeKir1 and AeKir2B, albeit with greater affinity 
for AeKir1. To date, we have reported the activity of two other small-molecule inhibitors of 
mosquito Kir channels that exhibit differential pharmacology. VU590 is a selective inhibitor of 
AeKir1 over AeKir2B, whereas VU573 inhibits AeKir1 and activates AeKir2B (companion 
paper). Thus, VU625 potentially represents a broad-spectrum small-molecule blocker of 
mosquito Kir channels, pending the characterization of its effects on the other mosquito Kir 
channels (AeKir2A, AeKir2B’ and AeKir3 channels), which to date have not yet been expressed 
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functionally in a heterologous system ([74]; Denton and Piermarini, personal observations).  
Furthermore, the distinguishing pharmacological properties of each of these Kir channel 
inhibitors can potentially be employed to determine the relative contributions of Kir channel 
subtypes in the physiology of various mosquito tissues.  
Given the superior in vitro potency of VU625 compared to the AeKir1 inhibitors VU573 
[207] and VU590 (companion paper), we expected VU625 to elicit superior in vivo efficacy.  
However, we were surprised that high doses of VU625 elicited no observable effects on 
mosquito survival or excretory capacity when injected directly into the hemolymph. Mosquitoes 
have evolved robust protective mechanisms for detoxifying and excreting xenobiotics that would 
harm them otherwise [255,256]. Thus, we investigated whether the molecule may be detoxified 
and/or excreted.   
Preliminary experiments with PBO did not improve the efficacy of VU625, suggesting 
that detoxification of the compound by cytochrome P450s is unlikely to contribute to its poor in 
vivo efficacy.  However, the co-injection of VU625 with probenecid rescued not only its toxicity, 
but also its effects on excretory capacity, which suggests that VU625 is likely excreted by OATs 
and/or ABC transporters in the mosquitoes and thereby rendered ineffective in vivo. The toxicity 
of VU625 when co-injected with probenecid may be due to the ability of VU625 to inhibit at 
least two Kir channels, some of which are expressed in the central and peripheral nervous 
systems, such as Kir1 and Kir2B’ [74,75,205,226], and/or a synergistic effect of probenecid that 
enhances VU625 efficacy to inhibit Kir channels by preventing its renal excretion. Indeed, it is 
conceivable that the sulfonamide moiety in the structures of VU625 and probenecid causes them 
to be substrates for OATs and/or ABC transporters. Taken together, these findings highlight 
efficient xenobiotic transport mechanisms in mosquitoes that render a nanomolar inhibitor of 
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AeKir1 (VU625) ineffective when introduced directly to the hemolymph. The tissues that 
contribute to the excretion of VU625 remain to be determined, but presumably involve the 
Malpighian tubules and/or gut [257,258].   
The medicinal chemistry efforts put forth in the present study may be a valuable first step 
in determining which structural moieties are important for the excretion of VU625 by xenobiotic 
transporters in mosquitoes.  Future studies should assess the in vivo efficacy and probenecid-
mediated clearance of the VU625 analog series we generated to determine if any of these 
compounds exhibit potent in vivo activity without probenecid. 
 
Perspectives   
Here, we show a direct relationship between in vitro pharmacology and in vivo toxicity 
of VU625, which is consistent with our previous studies ([207]; Appendix A) suggesting that 
Kir channels inhibitors are promising chemicals for insecticide development. To date, none of 
the Kir channel inhibitors we have reported (i.e. VU573, VU590, VU625) exhibit toxicity when 
applied to the cuticle (Piermarini, unpublished observations), which is a waxy, lipophilic 
structure that creates a physical barrier to insecticide permeation into the hemocoel of 
mosquitoes. This lack of topical activity severely limits the potential use of the present Kir 
channel inhibitors as active compounds for incorporation into insecticide-treated bed nets and 
indoor-residual sprays. The efficacy of common insecticides, such as permethrin, is dependent in 
part on their lipophilic nature [259,260]. Thus, future chemistry efforts will focus on lipophilic 
inhibitors of Kir channels.  Furthermore, exploring SAR and tolerance of analogs to lipophilic 
substitutions may reveal more suitable small-molecules compounds for insecticide development.  
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Chapter IX 
SUMMARY AND FUTURE DIRECTIONS 
Summary 
Inward rectifier potassium (Kir) channels represent an important family of K+ channels, 
which contribute to essential physiological functions in various organisms. While physiological, 
genetic and pharmacological evidences suggest that Kir channels represent promising drug 
targets for the development of new therapeutics, there is a need for improved (potent and 
selective) modulators of this K+ ion channel family to assess their integrative physiology and 
druggability. Indeed, the molecular pharmacology of Kir channels has only seen major expansion 
in the past five years [261]. In insects, Kir channels are also known to play important 
physiological functions. In particular, over the past decade, emerging evidence has revealed that 
Kir channels are involved in physiological functions ranging from osmoregulation, development 
and immunity [205,206,231,242] as assessed in the fruit fly, Drosophila melanogaster. Their 
roles in mosquitoes have only recently begun to be addressed [72,74], and their potential as 
insecticidal targets remains largely unexplored. More importantly, the small-molecule 
pharmacology around mosquito Kir channels was virtually nonexistent, which precluded any 
efforts to assess their druggability for insecticide development. The projects presented in this 
dissertation highlight our efforts to fill a major gap in the molecular pharmacology of both 
mammalian and insect Kir channels, which include the discovery, optimization and 
characterization of new subtype-specific small molecule modulators. 
More specifically, we have 1) implemented fluorescent-based high-throughput (HTS) 
assays to discover new small-molecule modulators of human and mosquito (A. aegypti) Kir 
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channels, 2) employed medicinal chemistry to optimize and determine the structure-activity 
relationships of these small molecules to improve on their potency and selectivity, and 3) begun 
to investigate new roles of Kir channel functions in mosquitoes. In this dissertation, we describe 
how various new modulators of human (VU573, Chapter III; VU717, Chapter IV; VU0071063, 
Chapter V) and mosquito  (VU625, Chapter VIII) Kir channels were discovered from HTS 
assays. These new pharmacological probes were further characterized in various 
electrophysiology experiments to confirm their activity and selectivity. In the case of some 
modulators (i.e. VU573 and VU625), iterative rounds of medicinal chemistry for compound 
optimization and structure-activity relationships were assayed. Furthermore, the effects of these 
compounds were determined in native astrocytes  (VU717), pancreatic !-cells (VU0071063), and 
whole-mosquitoes (VU573, VU625).  
In summary, the work accomplished in this dissertation supports modern drug discovery 
efforts to identify new modulators or lead compounds of Kir channels. These new small-
moelcules modulators can be improved upon to explore the integrative physiology and identify 
novel functions of Kir channels for new therapeutic and insecticide development. 
 
Future Directions 
The results of the projects presented in this dissertation provide us with proof-of-concept 
studies from targeting various Kir channel subtypes, new lead compounds for modulation of Kir 
channel activity, and new insights into the physiological roles of Kir channels. All of these 
findings are critical to expand the small-molecule pharmacology for Kir channels and further 
explore their biology.  Importantly, several new questions have emerged, which warrant further 
investigations into the mechanisms of action of Kir channels modulators and their in vivo 
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potential for drug and insecticide development. Moreover, in mosquitoes the diversity of Kir 
channels and their differential developmental and tissue expression suggest potentially new roles 
in regulating essential biological processes.  The first area of future research that we will focus 
on is the limitations of the pharmacological tools discussed in this dissertation and potential 
optimization for in vivo studies. Next, we will address the importance of determining new Kir 
channel functions in mosquitoes.  
One major limitation encountered with these new compounds discovered in this work is 
their weak potency and relatively poor selectivity in targeting human Kir channels.  As discussed 
in Chapter III, VU537 is a low micromolar inhibitor of Kir2.3, Kir3.x and Kir7.1. Although not 
discussed in that chapter, we have preliminary evidences suggesting that VU573 inhibits other 
Kir channels albeit with lower potency, which include Kir2.2 and Kir6.2/SUR1. Therefore, 
determining the contribution of Kir2.3, Kir3.x and Kir7.1 in native tissues where one ore more of 
these subtypes is expressed (e.g. brain, kidney) might prove to be difficult. This issue can be 
overcome partially by generating through medicinal chemistry, various analogs that will exhibit 
a decrease in Kir channel activity in a subtype-specific manner. Differently stated, the substype-
specificity of these analogs will help uncover more precisely the contribution of Kir channels in 
various tissues. Initial lead compounds exhibiting subtype-specific activity against Kir channels 
can be identified through counterscreens of small molecule libraries (from established focused or 
primary libraries). Indeed, while employing HTS counterscreening assays against various Kir 
channel panels to mine a focused library of modulators (as discussed in Chapter V), we 
identified new compounds with subtype-specificity. These initial lead compounds will then be 
optimized via medicinal chemistry to improve upon their potency and selectivity. The discovery 
and optimization of such lead compounds will provide useful probes to initially investigate the 
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contribution of these channels in various biological paradigms, with the goal to develop novel 
therapeutics.  
While we demonstrated in Chapter V that VU0071063 is a selective opener for SUR1-
containing KATP channels, its mechanisms of action remain unknown. The importance of 
determining the mechanism of action of small-molecule modulators is crucial to predict their 
behaviors in vivo. KATP channel openers represent the largest class of small-molecule modulators 
of Kir channels [262,263]. However, their mechanisms of action have for the most part been 
identified to involve SUR subunits [264]. Therefore, it will be interesting to determine whether 
VU0071063 modulates KATP activity through its interaction with SUR1 subunits (similarly to 
diazoxide) and/or interacts directly with Kir6.x subunits. To begin to answer this question, a 
combination of molecular biology—through mutagenesis of SUR1 subunits—and 
electrophysiology experiments can be used to test whether the nucleotide binding domains of 
SUR1 subunits are involved in channel modulation by VU0071063. A similar approach was 
employed previously to determine the modulatory mechanism of KATP channels by diazoxide 
[265]. Next, it will be important to determine whether VU0071063 modulation of KATP channels 
is at all depending upon SUR1 subunits. Therefore, we need to test if VU0071063 can open KATP 
channels independently of SUR1 subunits. We have already generated a truncated form of the 
Kir6.2 subunits (Kir6.2(C36, truncation of last 36 amino acid residues), which is known to form 
functional channels without SUR1 subunits [266].  Using such molecular tools will contribute to 
identifying the mechanisms by which VU0071063 modulates SUR1-containing KATP channels. 
These approaches will ultimately guide efforts to develop optimized analogs of VU0071063 for 
in vivo testing, and thus determine their therapeutic potential for the treatment of 
hyperinsulinemia.  
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The discovery of VU625, first potent and selective inhibitor of Aedes aegypti Kir1 
channels, via HTS is a significant improvement for the development of mosquito specific Kir 
channel modulators. However, as discussed in Chapter VIII, we found that VU625 was 
ineffective in vivo unless co-administered with probenecid. Therefore, it would be interesting to 
determine whether the lack of in vivo effect of VU625 is the resut of its excretion through efflux 
mechanisms. Although not discussed in Chapter VIII, we have some preliminary data from 
isolated Malpighian tubule experiments, which suggest that VU625 is indeed effluxed through 
this epithelial tissue (Klaus Bayenbach, personal communication). To specifically address this 
question, we can employ in vitro transport assays [267,268] Determining whether VU625 is a 
substrate for efflux transport mechanisms will inform our medicinal chemistry efforts for the 
design of small-molecule compounds without structural determinants for efflux liability.      
A next line for future research is to determine the role of Kir channels in mosquito 
development. As discussed in Chapter VII, we have shown for the first time that AgKir1 
transcript levels are enriched during the pupal developmental stage. This result suggests a 
possible role for this gene during mosquito development. One immediate question that could be 
investigated is to determine the level of expression of the other Anopheles Kir genes (i.e. 
AgKir2A, AgKir2A’, AgKir2B, AgKir3A and AgKir3B) during development. Furthermore, 
exploring the roles of these genes during various developmental stages will be critical to 
identifying novel biological regulatory processes and targets for vector control. To achieve this 
goal, employing strategies that will disrupt gene/protein functions via genetic or pharmacological 
approaches during development (i.e. larval stage) should be explored. A major drawback for 
assessing gene functions in mosquito larval stage through gene silencing remains the delivery 
method. Current strategies involve dsRNA injections, which are technically difficult when 
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performed in larvae [269]. The recent development of chitosan nanoparticles-based delivery 
method for gene silencing via larval feeding has proven successful in knocking-down both 
Anopheles and Aedes specific genes [269,270] and could represent a useful tool to address these 
questions. Hence, by adapting this technique to silence gene expression of Kir channels in vector 
mosquitoes such as Anopheles gambiae, we can begin to identify developmental or behavioral 
defects that will be associated with one or more of these genes. Futhermore, the various small-
molecule compounds (inhibitors and activators) discovered and discussed in this dissertation 
could be used to further test the functions of these channels during development, by employing 
this same nanoparticle-feeding method. 
In summary, the work discussed in this dissertation has contributed to the discovery of 
novel small-molecule probes with which to investigate Kir channel functions in humans and 
mosquitoes. Furthermore, by our efforts to characterize these various compounds, we are 
expanding on the pharmacology of Kir channel modulators. While these small-molecule probes 
remain to be optimized for use as therapeutics or insecticides, we hope that they will represent 
important research tools to map the contribution of Kir channels in various tissues and organ 
system, and uncover novel physiological roles. In addition, the physiological functions of Kir 
channels in mosquitoes needs to be further investigated, as they could reveal important and 
unknown signalling mechanisms for insecticide target and lead to the development of new vector 
control strategies. 
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APPENDIX A 
PHARMACOLOGICAL VALIDATION OF AN INWARD-RECTIFIER POTASSIUM 
(KIR) CHANNELS AS AN INSECTICIDE TARGET IN THE YELLOW FEVER 
MOSQUITO AEDES AEGYPTI 
This work is under review and is a collaborative effort between the laboratories of Peter 
Piermarini and Jerod S. Denton 
My contribution to this work was performing the thallium flux assay on AeKir1 expressing 
T-Rex-HEK293 cells to determine the inhibitory effects of VU590 and VU608 compounds 
on AeKir1-mediated fluorescence. 
Briefly, we demonstrated in a previous study (see Chapter VI) that pharmacological 
inhibition of mosquito inward rectifier potassium (Kir) channels with VU573 represents a novel 
mechanism for killing mosquitoes and could represent promising targets for insecticide 
development. To further validate Aedes aegypti Kir 1 (AeKir1) channels as insecticidal targets, 
we sought to determine the effects of another inhibitor, VU590, on mosquito survival and 
excretory capacity. VU590 is a mammalian Kir1.1 and Kir7.1 inhibitor, which we found to 
inhibit AeKir1 activity in thallium flux assays. VU590 is structurally unrelated to VU573. In this 
study, we report that VU590, but not its inactive analog VU608, decreases urinary excretion 
when injected in the hemolymph and causes mortality in adults Aedes aegypti mosquitoes after 
24 h. Furthermore, we determined in electrophysiology experiments that VU590 and VU573 
exhibit differential pharmacology against AeKir1 and AeKir2B subtypes expressed in Xenopus 
oocytes. Indeed, while VU590 only inhibits AeKir1 channel activity, VU573 acts as both an 
inhibitor of AeKir1 and potentiator of AeKir2B. Importaantly, this result suggests that the toxic 
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effects of VU590 observed in vivo are caused by inhibition of AeKir1 channel functions. 
Therefore, we further confirm in this study that targeting AeKir1 channels is a viable approach 
for insecticide development, and thus mosquito control. 
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Figure A-1.  Effects of VU590 and VU573 on AeKir1 and AeKir2B channels expressed 
heterologously in Xenopus oocytes. Summary of the percent changes of inward currents at -140 
mV in AeKir1 and AeKir2B elicited by 50 µMVU590 and 50 µM VU573.  Positive and negative 
percent changes indicate activation and inhibition, respectively.  P values indicate significant 
inhibition or activation as determined by a one sample t test.  Values are means ± SEM.  For 
VU590 experiments, n = 3 oocytes each for AeKir1 and AeKir2B.  For VU573 experiments; n = 
5 and 8 oocytes each for AeKir1 and AeKir2B, respectively.  Lower-case letters indicate 
statistical categorization of the means as determined by a one-way ANOVA with a Newman-
Keuls posttest (P < 0.05).  
Assay performed by Matthew Rouhier and Peter Piermarini. ! !
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Figure A-2.  Effects of VU590 on the urine excretion and survival of adult A. aegypti female 
mosquitoes. (A) Amount of urine excreted by mosquitoes 1 h after injection with 900 nL of the 
vehicle (K+-PBS50 containing 1.8% DMSO, 0.077% !-cyclodextrane, and 0.008% Solutol), the 
vehicle containing VU590 (0.77 mM), or the vehicle containing VU608 (0.77 mM).  Values are 
means ± SEM; n = 11 trials of 5 mosquitoes per treatment. (B) Comparison of the toxic effects of 
the vehicle, VU590, and VU608.  Mortality was assessed 24 h after injecting the hemolymph 
with the vehicle (K+-PBS75 with 15% DMSO, 1% !-cyclodextrin, and 0.1% Solutol) or the 
vehicle containing VU590 or VU608 (2.8 nmol). Values are means ± SEM; n = 4 trials of 10 
mosquitoes.  Lower-case letters indicate statistical categorization of the means as determined by 
a one-way ANOVA with a Newman-Keuls posttest (P < 0.05).  
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APPENDIX B 
LIST OF PUBLICATIONS 
1. Raphemot R, Rouhier MF, Swale DR, Days E, Weaver CD, Lovell KM, Konkel LC, 
Engers DW, Bollinger SF, Hopkins C, Piermarini PM, Denton JS. Discovery and 
characterization of a potent and selective inhibitor of Aedes aegypti inward rectifier 
potassium channels. In preparation.  
2. Rouhier MF, Raphemot R, Denton JS, Piermarini PM (2014). Pharmacological 
validation of an inward-rectifying potassium (Kir) channel as an insecticide target in the 
yellow fever mosquito Aedes aegypti. In revision. 
3. Raphemot R, Estévez-Lao TY, Rouhier MF, Piermarini PM, Denton JS, Hillyer JH 
(2014). Molecular and functional characterization of Anopheles gambiae inward rectifier 
potassium (Kir1) channels: A novel role in egg production. Insect Biochem Mol Biol. In 
press. 
4. Rouhier M, Hine R, Park S, Raphemot R, Denton J, Piermarini P, Beyenbach K (2014). 
The excretion of NaCl and KCl loads in mosquitoes: 2. Effects of the small molecule Kir 
channel inhibitor VU573 and its inactive analog VU342. In revision. 
5. Raphemot R, Swale DR, Dadi PK, Jacobson DA, Cooper P, Wojtovich AP, Banerjee S, 
Nichols C, Denton JS (2014) Direct activation of !-cell KATP channels with a novel 
xanthine derivative. Mol Pharmacol. doi:10.1124/mol.114.091884. 
6. Raphemot R, Kadakia R, Olsen ML, Banerjee S, Days E, Smith SS, Weaver CD, and 
Denton JS (2013) Development and validation of fluorescence- and automated patch 
clamp-based functional assays for the inward rectifier potassium channel Kir4.1. Assay 
Drug Dev Technol. 11(9-10): 532-543. doi:10.1089/adt.2013.544. Journal cover. 
7. Raphemot R, Rouhier MF, Hopkins CR, Gogliotti RD, Lovell KM, Hine RM, Ghosalkar 
D, Longo A, Beyenbach KW, Denton JS, Piermarini PM (2013) Eliciting Renal Failure in 
Mosquitoes with a Small-Molecule Inhibitor of Inward-Rectifying Potassium Channels. 
PLoS ONE 8(5): e64905. doi:10.1371/journal.pone.0064905. 
8. Raphemot R, Weaver CD, Denton JS (2013) High-throughput Screening for Small-
molecule Modulators of Inward Rectifier Potassium Channels. J. Vis. Exp. (71), e4209, 
doi: 10.3791/4209.  
9. Raphemot R, Lonergan DF, Nguyen TT, Utley T, Lewis LM, Kadakia R, Weaver CD, 
Gogliotti R, Hopkins C, Lindsley CW and Denton JS (2011) Discovery, characterization, 
and structure–activity relationships of an inhibitor of inward rectifier potassium (Kir) 
channels with preference for Kir2.3, Kir3.X, and Kir7.1. Front. Pharmacol. 2:75. doi: 
10.3389/fphar.2011.00075.  
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